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Recent   advances   in   genomic   sequencing   technology   have   facilitated   relatively  
inexpensive,   high-­fidelity   sequencing   of   microbial   genomes.   Increased   genome  
sequencing  capacity  has  been  accompanied  by  developments   in  bioinformatics,  which  
enable  rapid  homology  searching  to  predict  gene  products,  such  as  enzymes  involved  in  
the  production  of  small-­molecules.  The  recent  surge  in  genomic  information  revealed  that  
only  a  small  percentage  of  genes  involved  in  small-­molecule  biosynthesis  had  previously  
been   characterized.   In   fact,   it   appears   that   we   have   only   scratched   the   surface   in  
understanding  the  full  biosynthetic  potential  of  microorganisms.  The  current  void  in  small-­
molecule   discovery   is   in   part   because   of   the   particular   challenges   associated   with  
identifying  new  compounds  and  in  part  because  of  the  nature  of  microbial  small-­molecule  
production.    
   Perhaps  the  largest  obstacle  in  the  path  to  characterizing  new  small-­molecules  is  
the  absence  of  a  templated  structure.  For  instance,  in  genomics,  the  number  of  building  
blocks  is  extremely  limited,  just  four  different  bases,  which  fit  together  predictably  through  
phosphodiester  bonds.  Moving  up   in  complexity   to  proteomics,   the  number  of  building  
blocks  increases  to  roughly  twenty  amino  acids,  however  still  assembled  in  a  predictable  
manner,  through  peptide  bonds.  Additionally,  protein  primary  sequence  can  be  derived  
directly   from   the   corresponding   genetic   sequence,   which   coupled   with   homology  
 searching  enables  quick   judgments  as   to  whether  or  not  a  detailed  characterization   is  
warranted.  The  situation  in  metabolomics  is  starkly  more  complicated  as  the  number  of  
building  blocks  increases  to  over  one-­hundred  chemical  entities  that  can  be  assembled  
in   virtually   any   imaginable   way   that   obeys   the   laws   of   chemistry.   Moreover,   small-­
molecule  structural  insights  simply  cannot  be  attained  from  the  genetic  sequence  alone,  
meaning  every  compound  must  be  individually  characterized.    
   In  addition  to  the  challenges  of  small-­molecule  characterization,  the  very  nature  of  
microbial   biosynthesis   has   significantly   hindered   more   thorough   annotation   of   the  
metabolome.  Expression  of  genes  encoding  biosynthetic  enzymes  is  tightly  regulated  and  
responsive   to   various   natural   environments.   Simple   laboratory   culturing   conditions  
usually  fail  to  reproduce  the  necessary  cues  to  promote  small-­molecule  production.  While  
media  screening  methods  or  so  called  fermentation  optimization  is  an  option  to  overcome  
this  barrier,  the  power  of  genetic  engineering  offers  a  far  more  straightforward  solution  
and  has  the  added  benefit  of  precision.  The  production  of  small-­molecules  can  be  turned  
on  or  eliminated  in  a  controlled  manner  by  creating  over-­expression  or  knock-­out  mutant  
microbial  strains.  Comparison  of  mutant  and  wild-­type  strains  using  differential  analysis  
by  2D-­NMR  spectroscopy  (DANS)  and  LC-­MS-­based  comparative  metabolomics  enables  
a  systems  biology  prospective  of  metabolic  changes  resulting  from  genetic  engineering.    
   Described   herein   is   the   utilization   of   DANS   and   LC-­MS-­based   comparative  
metabolomics   to   discover   novel   metabolites   from   orphan  microbial   biosynthetic   gene  
clusters.  Applied   to   the  has  gene  cluster   in  Aspergillus   fumigatus  DANS   revealed   the  
biosynthesis   of   a   novel   iron(III)-­complex,   which  was   shown   to   increase  A.   fumigatus’  
virulence.  Results  from  the  has  study  led  to  an  investigation  of  diketopiperazine  formation  
 in  the  notorious  gliotoxin  biosynthetic  pathway.  Gliotoxin  biosynthesis  was  shown  to  be  
dependent  on  a  cluster-­encoded  cyclization  domain,  which  ultimately  functioned  to  cyclize  
a  modified  dipeptide  into  the  diketopiperazine  core  of  the  gliotoxin  structure.  In  another  
A.   fumigatus   gene   cluster,   called   fsq,   DANS   and   LC-­MS-­based   comparative  
metabolomics  revealed  the  elusive  fungal  isoquinoline  formation  pathway,  which  despite  
having  been  described  in  plants  more  than  twenty  years  ago,  remained  unknown  in  fungi  
until   now.   The   fungal   isoquinoline   pathway   was   shown   to   be   conserved   through   the  
characterization  of  another  isoquinoline  producing  gene  cluster   in  the  plant  pathogenic  
fungus  A.  flavus.  Lastly,  the  identification  and  characterization  of  an  additional  set  of  fsq-­
dependent  metabolites,  called  the  fumizinones,  is  described.  The  fumizinones  derive  from  
an   alternative   biosynthetic   mechanism,   resulting   in   pyrazinone   formation,   rather   than  
isoquinoline  formation,  as  observed  for  the  main  products  of  the  fsq  pathway.    
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PREFACE  
  
The   purpose   of   this   preface   is   to   describe   the   overarching   rationale   for   the   research  
conducted  towards  this  dissertation,  to  detail  important  background  that  pertains  to  all  of  
the  remaining  chapters,  and  to  provide  clarity  for  field  specific  language  used  recurrently  
throughout   each   chapter.   The   general   theme   of   this   dissertation   is   using   analytical  
chemistry  tools  to  investigate  and  characterize  metabolic  pathways  in  filamentous  fungi.  
While  the  work  described  here  represents  investigations  specifically  in  fungal  metabolism,  
the  results  are  more  broadly  applicable   to  microorganisms,  as   fungi  and  bacteria  (and  
other  microbes)  share  related  metabolic  pathways1.    
The   word   metabolism   refers   to   the   broad   set   of   chemical   reactions   that   are  
necessary   to   sustain   life2.   Introduction   of   the   qualifier   “secondary”   (metabolism),   is   to  
describe  a   subset   of   chemical   reactions   that   are  not   essential   for   survival3.  However,  
secondary  metabolism   is   only   unessential   for   survival   in   laboratory   conditions,   which  
represent  unchallenging,  nutrient  rich  conditions  that  would  very  rarely  or  altogether  not  
occur  in  the  wild4.  Primary  metabolism  is  then  of  course  the  set  of  chemical  reactions  that  
represent   the   bare-­minimum  necessary   for   survival   in   laboratory   conditions5.   The   line  
between   primary   and   secondary   metabolism   is   blurred   and   as   our   understanding  
increases,  the  line  becomes  increasingly  transparent.  Eventually  the  community  will  likely  
not  distinguish  between  primary  and  secondary  metabolism  at  all,  since,  as  has  already  
been   established   to   some   extent,   secondary   metabolic   pathways   are   in   almost   all  
circumstances  necessary  for  survival  in  the  wild6.  The  percentage  of  microbial  genomes  
dedicated  towards  secondary  metabolism  is  in  itself  a  strong  argument  for  the  essential  
role  of  these  complex  chemical  species7.  For  the  sake  of  clarity,  secondary  metabolism  
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in   reference   to   the   research   described   in   this   dissertation   pertains   strictly   to   anabolic  
pathways  that  build  larger  molecules  from  the  smallest  possible  building  blocks,  such  as  
amino  acids  or  acetyl-­CoA’s8.  These  anabolic  pathways  will  henceforth  be  described  as  
biosynthetic  pathways  or  the  biogenesis  for  a  compound  or  a  class  of  compounds.    
  
Importance  of  studying  secondary  metabolism  in  filamentous  fungi:  Throughout  our  
daily  lives  humans  are  continually  in  close-­contact  with  fungi9.  In  particular,  the  fungus  
Aspergillus  fumigatus,  the  focus  of  the  work  in  this  dissertation,  is  ubiquitously  distributed  
in  nature  and  its  spores  are  regularly  inhaled  by  humans  (roughly  100-­300  daily)10.  The  
spores  of  A.  fumigatus  have  evolved  to  be  the  perfect  size  such  that  they  are  inhaled  and  
not  exhaled  out  of  the  lungs10,11.  Once  inside  the  lungs,  spores  are  normally  engulfed  by  
immune   cells   and   destroyed,   as   is   the   case   for   a   healthy   individual,   however,   in   an  
immunocompromised  person,  the  immune  system  may  fail  to  rid  the  lungs  of  all  spores  
and   the   fungus  will   begin   to   grow11.   The   pulmonary   fungal   growth   is   then   capable   of  
spreading  to  other  parts  of  the  body,  such  as  the  brain,  resulting  in  tissue  necrosis  and  
eventually  death11.  This  infection,  known  as  aspergillosis  is  extremely  difficult  to  treat  and  
accordingly  is  one  of  the  leading  causes  of  death  for  immunocompromised  individuals  in  
the   United   States12.   In   2004   the   Keller   Lab   at   the   University   of   Wisconsin-­Madison  
showed   that   disruption   of   a   global   regulator   of   secondary   metabolism,   called   LaeA,  
resulted  in  a  loss  of  A.  fumigatus’  virulence  in  a  mouse  model,  clearly  demonstrating  the  
importance   of   secondary   metabolism   for   fungal   survival   during   an   infection13.   In   this  
dissertation  unexplored  LaeA  regulated  secondary  metabolic  pathways  were  targeted  for  
characterization  because  of  their  potential  importance  for  virulence.  In  addition  to  being  
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an  important  human  pathogen,  filamentous  fungi  also  play  a  big  role  in  the  agricultural  
industry14.    
   Parallel  to  the  continuous  direct  interaction  between  A.  fumigatus  and  humans  is  
the  interaction  of  plants  and  another  related  fungus,  A.  flavus,  which  thrives  hand  in  hand  
with  agricultural  production14.  A.  flavus  grows  on  a  variety  of  different  crops,  such  as  corn,  
wheat,   sorghum,   and   peanuts   under   high-­humidity   or   stressful   drought   conditions.  A.  
flavus  became  well  known  in  the  1960’s  as  the  producer  of  Aflatoxin,  which  are  potent  
carcinogens  that  poison  feedstocks  of  nearly  all  types  of  livestock  and  some  aquatic  food  
sources,  such  as  trout,   in  addition  to  food  directly  consumed  by  humans15.  Across  the  
globe  losses  due  to  Aflatoxin  contamination  are  estimated  to  be  upwards  of  $1-­1.5  billion,  
which  doesn’t  include  the  human  health  impact  or  crop  yield  losses15.  A.  flavus  is  just  one  
of  many  plant  pathogenic  fungi  that  have  the  potential  to  cause  high-­value  crop  loss  and  
health   problems   if   not   managed   properly.   Understanding   secondary   metabolism   is  
essential  to  addressing  both  agricultural  and  health  problems  caused  by  fungi  because  
of   the   direct   implications   of   small-­molecules   (SMs)   in   their   fitness   and   virulence.  
Additionally,  annotation  of   the   fungal  metabolome  will   likely  uncover  new   fundamental  
fungal  biology.    
   While   detrimental   associations   of   filamentous   fungi   are   notable,   the   contrary   is  
equally   as   significant.   Understanding   SM   production   has   the   potential   to   yield   new  
complex   molecular   architectures   with   unforeseen   bioactivity.   Historically   speaking,   a  
considerable  percentage  of   therapeutics  are  derived   from  SMs  of  microbial  origin16.  A  
noteworthy  class  of  drugs  that  are  fungal  natural  products  or  derivatives  thereof   is   the  
Statins,  which  have  been  used  extensively  to  lower  cholesterol17.  The  research  described  
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in   this   dissertation   is   not   specifically   targeted   at   discovering   or   understanding   the  
bioactivity  of  fungal  metabolites.  However,  annotating  a  larger  percentage  of  the  currently  
scant   metabolome   inherently   increases   the   chances   of   finding   new   molecules   with  
medicinal   importance.  Furthermore,   the  central  approach   in   this  body  of  work   (DANS-­
based  comparative  metabolomics)  is  directed  toward  the  discovery  of  thermodynamically  
unstabile   molecules,   which   arguably   have   the   greatest   potential   for   bioactivity,   since  
potency  and  life  time  are  inversely  related  in  the  context  of  SM  interactions.    
  
Natural  history  of  microorganisms:  A  less  widely  discussed  aspect  of  the  rationale  for  
studying  microbial  metabolism   is   its   role   in   ecology.   To   draw   an   analogy   to   animals,  
metabolic  products  are  microbial  language.  The  production,  transport,  and  break  down  of  
SMs  represents  the  major  form  of  communication  between  different  species  of  microbes  
and  between  host-­microbe  interactions18.   It  would  be  difficult   to  understand  the  written  
English  language  without  first  having  a  grasp  of  the  alphabet.  This  is  exactly  analogous  
to   the  situation  with  our  understanding  of  microorganisms,   in  order   to  understand  how  
they  behave  we  must  first  understand  the  molecules  they  make,  break,  and  trade.  In  the  
past  it  was  often  enough  to  “grind  and  find”  or  simply  randomly  extract  a  bacterial,  fungal,  
or  plant  growth,  or  perhaps  an  animal.  A  host  of  important  discoveries  were  made  by  this  
method,  and   this   laid   the   foundation   for   the  natural   products   chemists  of   today.  Now,  
however,   with   the   power   of   genetic   engineering  we   have   the   ability   to   probe   specific  
metabolic  pathways.  This  serves  not  only  to  “trick”  an  organism  into  producing  enough  
material  for  isolation  and  characterization,  but  also  aids  in  the  identification  of  regulatory  
elements   and   cross-­pathway   communication.   Determining   the   underlying   regulatory  
mechanisms  for  SM  biosynthesis  will  be  essential  towards  combating  microbe-­associated  
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diseases.    
  
Microbial   small-­molecule  chemistry:  There   is   no   strict   definition   for   the   term   “small  
molecule”,  however  to  the  author  of  this  dissertation  it  refers  to  any  chemical  species  that  
has  a  molecular  weight   that   is  roughly  1500  amu  or   less.  Of  course,  exceptions  occur  
where  a  molecule  of  larger  molecular  weight  still  meets  most  criteria  and  would  in  fact  be  
described  as  a  SM.  Microorganisms  are   the  most  prominent  producers  of  SMs  on   the  
earth  and  are  capable  of  assembling  extremely  complex  molecular  architectures,  which  
has  driven  the  field  of  synthetic  organic  chemistry  and  provided  us  with  the  vast  majority  
of  antibiotics16.    
Genes  encoding  enzymes   responsible   for   the  assembly  of  microbial   secondary  
metabolites   usually   exist   in   proximity   to   each   other   in   the   genome,   comprising   a  
biosynthetic  gene  cluster  (BGC)19.  Gene  clustering  has  been  exploited  as  a  mechanism  
to   enable   facile   upregulation   or   deletion   of   entire   biosynthetic   pathways   by   a   single  
promoter   switch8.   In   bacteria   gene   clustering   seems   to   be   the   absolute   rule   for  
biosynthesis  (there  may  be  exceptions),   in   fungi  and  other  eukaryotes,  however,   there  
are  occasionally  genes  in  other  locations  of  the  genome  that  are  still  genuine  components  
of   the   BGC-­encoded   biosynthetic   pathway20.  Gene   clustering   has   also   enabled  more  
rapid   compound   discovery   and   helped   eliminate   rediscovery   via   bioinformatics  
analyses20.  Algorithms  have  been  designed   to  use  homology  searching   to  predict   the  
locations  of  BGCs  in  the  genome  and  to  characterize  the  corresponding  gene  products.  
Overall,  homology-­based  methods  have  been  incredibly  useful  but  occasionally  they  are  
misleading   because   despite   sharing   high   homology,   a   pair   of   BGCs   may   produce  
completely  different  SM  products.  The  simple  definition  of  what  constitutes  a  BGCs  is  the  
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existence  of  a  gene  encoding  a  core  enzyme  surrounded  by  one  or  many  genes  encoding  
tailoring  enzymes  (see  following  section)21.  
  
Microbial  biosynthetic  gene  cluster  composition:  Most  characterized  microbial  BGCs  
encode  for  core  enzymes  that  fall  into  one  of  three  major  families,  the  terpene  cyclases  
(TCs),   the   polyketide   synthases   (PKSs),   and   the   non-­ribosomal   peptide   synthetases  
(NRPSs)19,22.  TCs  function  through  the  catalysis  of  cationic  cyclization  reactions  of  linear  
isoprene  oligomers22.  PKSs  closely  resemble  standard  fatty  acid  biosynthesis  enzymes  
and  function  by  promoting  Claisen  condensations  between  successive  malonyl-­CoA’s19.  
NRPSs   function   through   the   assembly-­line   style   of   loading   amino   acids,   catalyzing  
peptide   bond   formation,   and   then   releasing   peptide   products19,23.   Beyond   the   core  
enzyme,   BGCs   across   the   three   major   biosynthetic   families   include   similar   tailoring  
enzymes,  which  serve  to  modify  the  scaffold  produced  by  the  core  enzyme.  Some  of  the  
common   tailoring   enzymes   include   cytochrome   p450   oxidases,   N-­   and   O-­
methyltransferases,   and   prenyltransferases24.   BGCs   also   often   include   transporter  
proteins,  such  as  the  hallmark  multi-­drug  resistant  ABC-­transporters25.  Importantly,  many  
BGCs  have  one  or  more  transcription  factors  that  regulate  the  expression  of  all  cluster  
genes  (the  usual  target  for  genetic  engineering  to  facilitate  whole-­cluster  upregulation).  
Nearly  all  of  the  research  described  in  this  dissertation  is  about  NRPS-­based  BGCs.    
While   it   is   outside   the   scope   of   this   preface   to   exhaustively   cover   NRPS  
background  it  is  useful  to  describe  some  of  the  fundamentals  aspects  of  NRPS  chemistry.  
The  first  step  in  NRPS  biosynthesis  is  the  activation  of  the  free  carboxy  group  of  an  amino  
acid  by  the  adenylation  (A)  domain.  Following  A  domain-­dependent  activation  the  amino-­
adenylate  ester  is  captured  by  a  free  thiol  of  the  phosphopantetheinyl  arm  on  the  thiolation  
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(T)   domain.   Then,   a   condensation   (C)   domain   catalyzes   the   peptide   bond   formation  
between  two  T  domain  bound  thioesters,  resulting  in  a  nonribosomal  peptide  (NRP).  The  
NRP  can  be  modified  further  by  additional  domains  present  in  the  NRPS,  or  by  tailoring  
enzymes,   or   can   be   simply   released   from   the   NRPS   as   an   unmodified   peptide.   The  
mechanism  and  timing  of  release  dictates  the  biosynthetic  scheme  for  a  particular  BGC.  
For  example,   if  an  NRP   is   released   largely  unmodified,   then  ensuing  modifications  by  
tailoring  enzymes  will  occur  by  shuttling  around  the  NRP  from  one  enzyme  to  the  next  
until   it   has  been  completely  elaborated.   If,   on   the  other  hand,   the  modifications  occur  
while  the  peptide  is  still  bound  to  the  NRPS,  then  the  released  NRPS  product  is  the  final  
pathway   product   and   the   substrate   of   each   tailoring   enzyme   is   an   NRPS-­tethered  
intermediate.  Distinguishing  between  these  two  modes  of  NRPS  biosynthesis  is  important  
for  understanding  the  true  biosynthetic  pathway  of  many  microbial  metabolites.    
  
2D-­NMR   and   LC-­MS-­based   comparative   metabolomics   powered   by   genetic  
engineering:   Previous   methods   for   the   detailed   analysis   of   BGCs   involved   in   vitro  
reconstitution   of   individual   cluster   enzymes   to   determine   their   function26.   This   was  
however,  hopelessly  laborious,  as  many  enzymes  are  extremely  difficult  to  express  and  
purify  in  functional  form  in  vitro.  A  recent  and  major  advance,  and  the  foundation  of  the  
research  described  in  this  dissertation  was  the  development  of  differential  analysis  by  2D-­
NMR  spectroscopy  (DANS)-­based  comparative  metabolomics27.  The  principle  of  DANS-­
based  comparative  metabolomics   is   to  overlay  2D-­NMR  spectra  of  whole-­metabolome  
extracts  from  two  different  mutant  microbial  strains27.  The  two  mutants  differ  in  that  one  
is  an  overexpression  (OE)  strain  and  the  other  is  a  knock-­out  (KO)  strain  for  the  same  
BGC28.  Thus,  features  present  in  the  2D-­NMR  spectrum  of  the  metabolome  from  the  OE  
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strain  and  absent   in  the  corresponding  KO  spectrum  are  BGC-­associated  metabolites.  
Furthermore,  structural  features  can  be  determined  directly  from  the  OE  spectrum,  which  
means  in  one  step  the  identification  of  cluster  associated  metabolites  as  well  as  partial  
(occasionally  full)  structures  can  be  attained29,30.  Coupling  the  DANS-­based  approach  to  
liquid  chromatography-­mass  spectrometry  (LC-­MS)  based  comparison  of  mutant  strains  
provides  another  dimension   to  determine  differential   features  corresponding   to  cluster  
associated  metabolites  and  is  necessary  to  determine  molecular  formulae.  Utilizing  this  
approach   for   the   analysis   of  mutant   strains   for   individual   cluster   genes   allows   for   the  
determination  of  a  “snap-­shot”  of   the  biosynthetic  pathway.  The  work  described   in   this  
dissertation,   utilizing   this   comparative   metabolomics   approach   provides   detailed  
information  about  the  biosynthetic  function  of  entire  BGCs  and  individual  enzymes  with  
previously  unachievable  expediency  and  thoroughness.  
  
Preview  of  chapters:  Each  chapter  in  this  dissertation  represents  a  separate  but  related  
exploration  of  secondary  metabolic  gene  clusters  in  the  pathogenic  fungi,  A.  fumigatus  or  
A.   flavus.  Chapters  1  and  3  are  composed  of   reformatted  and  updated  co-­first  author  
manuscripts  written  by   the  author  of   this  dissertation.  Additional   text  and   figures  have  
been  included  where  appropriate  to  provide  more  details  pertaining  to  data  acquisition  
and  analysis,  hypothesis  formation,  and  open  questions.  Chapters  2  and  4-­5  consist  of  
separate,  unpublished  research  projects  that  have  been  summarized  specifically  for  this  
dissertation.  Supporting  information  for  Chapters  1-­5  can  be  found  in  Appendices  A-­E.  
Importantly,   all   of   the   projects   represented   in   this   dissertation   were   performed   in  
collaboration   with   several   other   labs.   Author   contributions   for   each   chapter   will   be  
described  here  and  not  within  each  chapter.    
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Chapter  1,  A  Nonribosomal  Peptide  Synthetase-­Derived  Iron(III)  Complex  from  the  
Pathogenic  Fungus  Aspergillus  fumigatus28:  Chapter  1  describes  the  characterization  
of   a   previously   orphan   gene   cluster,   which   we   called   the   has   cluster.  We   choose   to  
explore  the  has  cluster  because  it  was  both  positively  regulated  by  host-­exposure  and  the  
global  regulator  essential  for  virulence,  LaeA.  Comparison  of  overexpression  and  knock-­
out   strains   of   hasA,   the   cluster   transcription   factor,   using   DANS   and   LC-­MS-­based  
comparative  metabolomics  revealed  the  final  product  of   the  pathway  to  be  an   iron(III)-­
complex,  hexadehydroastechrome  (HAS,  Figure  P1).  Additional  DANS-­based  analyses  
of  double  mutant  strains  where   tailoring  genes  were  deleted   in  cluster  overexpression  
background  revealed  several  novel   intermediates  in  the  biosynthetic  pathway,  allowing  
us  to  propose  a  model  for  HAS  biosynthesis.  Deletion  of  the  has  cluster  NRPS,  HasD,  
led  to  a  significant  upregulation  in  the  fumitremorgin  gene  cluster,  revealing  cluster  cross-­
talk  within  A.  fumigatus.  
Figure  P1.  Overview  of  Chapter  1.  Microarray  sleuthing  revealed  has  cluster  expression  
increased  under  virulence  conditions,  which  upon  targeted  overexpression  and  deletion  
enabled  DANS-­based  discovery  and  characterization  of   the   final  product  as   the  novel  
iron(III)-­complex.  Overexpression  of  the  has  cluster  created  a  super  pathogenic  strain  of  
A  fumigatus  that  increased  mortality  in  mice  with  pulmonary  infections.   
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Authors’   contributions:   Joshua   A.   Baccile   isolated   and   characterized   all   compounds,  
constructed  the  figures,  and  wrote  the  manuscript.  Wen-­Bing  Yin  created  and  cultured  all  
A.  fumigatus  strains  and  wrote  the  manuscript.  Jin  Woo  Bok  and  Yiming  Chen  performed  
microarray  sleuthing  experiments.  Nancy  P.  Keller  and  Frank  C.  Schroeder  designed  the  
research  and  wrote  the  manuscript.    
  
Chapter   2,   Second   condensation-­like   domain   in   GliP   is   essential   for  
diketopiperazine   cyclization   in  gliotoxin  biosynthesis:  Chapter   2   revisits   the  well-­
studied  and  notorious  gliotoxin  biosynthetic  pathway  in  A.  fumigatus.  The  core  enzyme  in  
the  gli  cluster,  GliP,  consist  of  seven  domains,  A1-­T1-­C1-­A2-­T2-­C2-­T3.  The  terminal  C2-­T3  
domains   have   long   been   thought   not   to   participate   in   the   biosynthesis   of   gliotoxin.  
However,   LC-­MS-­based   comparative   metabolomics   of   GliP   truncation   mutant   A.  
fumigatus  strains  revealed  the  C2  domain  is  necessary  for  gliotoxin  production  in  vivo  and  























Figure  P2.  Overview  of  Chapter  2.  The  gli  cluster  NRPS,  GliP,  was  previously  annotated  
as  having  two  condensation  domains.  We  show  the  second  condensation-­like  domain  is  
actually  a  cyclization  domain  (CT).    
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In   vitro   reconstitution   of   the   GliP   truncation   mutant   proteins   and   the   terminal   C2-­T3  
standalone   domains   confirmed   the   cyclization   function   of   the   C2   domain.   The   results  
presented   in   Chapter   2   support   a   gli   pathway   biosynthetic   model   where   tailoring  
modifications  occur  on  a  T3-­tethered  linear  dipeptide,  which  is  then  cyclized  off  by  the  C2  
(now  CT)  domain.    
Authors’  contributions:  Joshua  A.  Baccile  designed  the  research,  performed  LC-­MS  data  
collection  and  analysis,  and  wrote  the  manuscript.  Henry  H.  Le  performed   in  vitro  GliP  
assays.  Brandon  Phannenstiel  and  Jin  Woo  Bok  created  mutant  A.   fumigatus   strains.  
Christian  Gomez  assisted  with  LC-­MS  data  collection.  Eileen  Brandenburger  and  Dirk  
Hoffmeister   conducted   A   domain   activation   assays.   Nancy   P.   Keller   and   Frank   C.  
Schroeder  helped  design  the  research.    
  
Chapter   3,   Plant-­like   biosynthesis   of   isoquinoline   alkaloids   in   Aspergillus  
fumigatus31:  Chapter  3  focuses  on  one  member  of  a  large  but  neglected  family  of  orphan  
BGCs   featuring   truncated   non-­ribosomal   peptide   synthetases,   that,   because   of   their  
truncated  nature,  cannot  produce  canonical  peptides.  Such  non-­canonical  NRPSs  are  
widespread  among  fungi,  however,  their  biosynthetic  roles  have  remained  obscure.  We  
show  that  the  fsq  biosynthetic  pathway  produces  a  novel  family  of  isoquinoline  alkaloids,  
the  fumisoquins,  which  are  produced  via  a  multi-­step  enzymatic  cascade  that  is  entirely  
analogous   to   the   biosynthesis   of   an   important   class   of   plant   alkaloids,   e.g.   in   poppy  
(Figure  P3)  Additionally,  the  fumisoquin  pathway  provided  evidence  for  a  new  carbon-­
carbon  bond  formation  mechanism  via  cooperative  action  of  the  truncated  NRPS  and  an  
ATP-­grasp  enzyme.    
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Authors’   contributions:   Joshua   A.   Baccile   and   Frank   C.   Schroeder   identified   and  
characterized  metabolites  and  biosynthetic  pathways.  Joseph  E.  Spraker  and  Jin  Woo  
Bok  created  A.  fumigatus  mutants.  Joshua  A.  Baccile  and  Christian  Gomez  performed  
stable-­isotope   labeling   experiments.   Henry   H.   Le,   Eileen   Brandenburger,   and   Dirk  
Hoffmeister  contributed  biochemical  assays.  Juliane  Macheleidt  and  Axel  A.  Brakhage  
contributed  to  the  identification  of  new  metabolites.  Joshua  A.  Baccile,  Joseph  E.  Spraker,  
Dirk  Hoffmeister,  Nancy  P.  Keller  and  Frank  C.  Schroeder  wrote  the  manuscript.    
  
Chapter  4,  Biosynthesis  of  the  structurally  unprecedented  imizoquins  in  the  plant  
pathogenic  fungus  Aspergillus  flavus:  In  connection  with  Chapter  3,  Chapter  4  is  the  
exploration  of  another  isoquinoline  producing  BGC,  called  the  imq  cluster,  however,  in  A.  
flavus  instead  of  A.  fumigatus.  LC-­MS  comparative  metabolomics  followed  by  detailed  2D  
NMR  spectroscopic  analysis  of  overexpression  strains  of   the   transcription   factor   ImqK  
revealed   imq-­dependent   production   of   a   class   of   tripeptide-­derived   alkaloids,   the  
imizoquins  (Figure  P4).  These  compound  include  the  expected  isoquinoline  moiety  as  
Figure  P3.  Overview  of  Chapter  3.  Fungi  and  plants  separately  evolved  analogous  sets  
of  enzyme  to   incorporate  methylene  group  (red)   that   forms  the   isoquinoline  present   in  
Fumisoquins  and  Scoulerine.  
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part   of   a   tricyclic   imidazo[2,1-­a]isoquinoline   ring   system,   for  which   there   are   no   other  
examples   among   known   natural   products.   As   in   the   case   of   the   fumisoquins,   the  
isoquinoline   portion   of   the   imizoquins   appears   to   be   derived   from   hydroxylation,   N-­
methylation  and  subsequent  oxidative  cyclization  of  tyrosine.    
  
Authors’   contributions:   Joshua   A.   Baccile   identified   and   characterized   metabolites.  
Joseph   E.   Spraker   created   A.   flavus   mutant   strains.   Saima   Khalid   performed   total  
antioxidant  capacity  assays.  Christian  Gomez  cultures  A.  flavus  and  helped  in  preparative  
compound  isolation.  Nancy  P.  Keller  and  Frank  C.  Schroeder  helped  design  the  research.  
  
Chapter  5,  Biosynthesis  of  the  fumizinones:  secondary  products  of  the  fsq  cluster  
in  Aspergillus   fumigatus:  During   the   characterization  of   the   fsq   cluster   described   in  
detail   in   Chapter   3,   we   discovered   that   an   additional   set   of   metabolites   was   fsq-­































L-Trp Imizoquin A:  R = H
Imizoquin B:  R = OH
Figure  P4.  Overview  of  Chapter  4.  The  imq  cluster  incorporates  L-­Leu,  L-­Tyr,  and  L-­
Trp  to  produce  the  Imizoquins,  novel  tricyclic  imidazo[2,1-­a]isoquinolin  alkaloids  from  
the  plant  pathogenic  fungus  A.  flavus.  
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fsq-­dependent  metabolites  were  instead  found  to  be  of  the  pyrazinone  class  of  natural  
products,   so  we   called   them   the   fumizinones   (Figure   P5).   Stable-­isotope   amino   acid  
feeding  experiments  allowed  us  to  determine  that  the  fumizinones  were  derived  from  L-­
leucine   and   L-­serine,   and   their   formation   was   likely   dependent   on   a   unique   carbon-­ 
carbon  bond  forming  reaction  catalyzed  by  the  NRPS-­like  enzyme  FsqF.    
Authors’   contributions:   Joshua   A.   Baccile   and   Frank   C.   Schroeder   identified   and  
characterized  metabolites  and  biosynthetic  pathways.  Joseph  E.  Spraker  and  Jin  Woo  
Bok  created  A.  fumigatus  mutants.  Joshua  A.  Baccile  and  Christian  Gomez  performed  
stable-­isotope   labeling   experiments.   Nancy   P.   Keller   and   Frank  C.   Schroeder   helped  
design  the  research.  
  
     
Figure  P5.  Overview  of  Chapter  5.  The  fsq  cluster  in  A.  fumigatus  produces  two  distinct  
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CHAPTER  1  
  
A  NONRIBOSOMAL  PEPTIDE  SYNTHETASE-­DERIVED  IRON(III)  COMPLEX  
FROM  THE  PATHOGENIC  FUNGUS  ASPERGILLUS  FUMIGATUS  
  
Abstract:  Small  molecules  (SMs)  play  central   roles  as  virulence  factors  of  pathogenic  
fungi  and  bacteria;;  however,  genomic  analyses  suggest  that  the  majority  of  microbial  SMs  
have  remained  uncharacterized.  Based  on  microarray  analysis  followed  by  comparative  
metabolomics   of   overexpression/knockout   mutants   we   identified   a   tryptophan-­derived  
iron(III)-­complex,  hexadehydro-­astechrome  (HAS),  as  the  major  product  of  the  cryptic  has  
non-­ribosomal   peptide   synthetase   (NRPS)   gene   cluster   in   the   human   pathogen  
Aspergillus  fumigatus.  Activation  of  the  has  cluster  created  a  highly  virulent  A.  fumigatus  
strain   that   increased  mortality  of   infected  mice.  Comparative  metabolomics  of  different  
mutant  strains  allowed  to  propose  a  pathway  for  HAS  biosynthesis  and  further  revealed  
cross-­talk  with  another  NRPS  pathway  producing  the  anti-­cancer  fumitremorgins.  
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Introduction:  Aspergillus   fumigatus   is   a   ubiquitous   filamentous   fungus  and   causative  
agent   of   invasive   aspergillosis   (IA),   a   life-­threatening   disease.   IA   associated  mortality  
ranges  from  50%  to  90%.1  One  of  the  few  proteins  that  have  been  shown  to  be  required  
for  A.  fumigatus'  pathogenicity  is  LaeA,  a  conserved  virulence  factor  in  filamentous  fungi.2-­
5  LaeA  is  a  global  regulator  of  secondary  metabolism  in  fungi  and  effects  virulence,   in  
part,  by  positive  regulation  of  multiple  small-­molecule  gene  clusters.3-­6  For  example,  LaeA  
controls  the  biosynthesis  of  the  epidithiodiketopiperazine  gliotoxin,7-­10  which  contributes  
to  A.  fumigatus’  success  as  a  pathogen.11  We  reasoned  that  SMs  most  likely  to  have  a  
role   in   virulence   would   be   positively   regulated   by   both   laeA   and   exposure   to   host  
environments  (host  exposure  itself  or  hypoxic  environments).    
  
Identification  of  the  has  biosynthetic  gene  cluster  and  predicted  gene  products:  By  
comparing  microarrays  of  genes  down-­regulated   in   laeA  deletants  but  up-­regulated  by  
host  exposure/hypoxia,6,12-­14  we  identified  an  eight-­gene  SM  cluster  named  has  meeting  
the   aforementioned   criteria.   The   eight   cluster   genes   encode   putative  C6   transcription  
factors  (HasA  and  HasF),  one  transporter  (HasB),  one  O-­methyltransferase  (HasC),  one  
non-­ribosomal  peptide   synthetase   (NRPS,  HasD,  previously  denoted  as  Nrps  515   and  
PesF16),  one  7-­dimethylallyltryptophan  synthase   (DMATS)17   (HasE),  one  putative  FAD  
binding  protein  (HasG)  and  one  cytochrome  P450  (HasH)  (Figure  1.1a  and  Tables  A1-­
3).  Often  SM  clusters  are  regulated  by  C6  transcription  factors.  Because  hasA  was  the  
3rd  most  down-­regulated  gene  in  the  DlaeA  array  and  strongly  induced  in  conidia  during  
neutrophil  exposure,6,12-­14  we  chose  to  overexpress  (OE)  this  gene  to  facilitate  chemical  
characterization  of  has-­associated  metabolites.18,19  Replacement  of  the  hasA  promoter  
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with  the  constitutive  gpdA  promoter  (OE::hasA)  resulted  in  induction  of  the  other  seven  
genes   (Figure  1.1b)  and  yielded  a  pink  pigmented  strain   (Figure  A1a).  Three  cluster  
flanking   genes,   (AFUB_036320,   AFUB_036310,   and   AFUB_036220,   Figure   1.1a,   b)  
were  not  regulated  by  hasA  and  thus  likely  defined  the  boundaries  of  the  cluster.    
  
Genetic  engineering  and  comparative  metabolomics  reveal  has  products:  To  probe  
the  functions  of  the  individual  has  genes,  we  additionally  constructed  knock-­out  mutants  
for   hasB-­hasH   in   the   OE::hasA   background   (Figure   A2).   Previous   biochemical  
characterization  of   the  DMATS  HasE  had  proven   its  capacity   to  prenylate  a  variety  of  
indole  derivatives  in  position  7,  with  L-­tryptophan  as  a  preferred  substrate;;17  however,  no  
cluster-­associated  metabolites  were   identified.  We  employed  HPLC-­MS   (Figure   1.1c)  
and  NMR-­based  comparative  metabolomics8,19,20  to  probe  for  has-­dependent  metabolites  
in   the  OE::hasA   strain.   Analysis   of   the   1H  NMR   spectrum   from   the  OE::hasA   extract  
revealed  signals  indicative  of  a  3-­substituted  indole  moiety  that  were  absent  in  the  WT  
extract   spectrum   (Figure  A3).  All   signals  of   this   compound  suffered   from   intense   line  
broadening,  suggestive  of  a  paramagnetic  species  such  as  an  iron  complex.  Comparison  
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of  high-­resolution   (HR)-­HPLC-­MS  data   from   the  OE::hasA  and  WT  extracts  showed  a  
OE::hasA-­specific   ion   cluster   eluting   at   46.8   min   whose   m/z   values   and   isotopic  
distribution  suggested  a  molecular  formula  of  C60H60FeN9NaO9  (m/z  calcd.  1129.3761;;  
obsvd.  1129.3751),  suggesting  an  Fe(III)  complex.  Supporting  the  requirement  of  iron  for  
production  of  this  metabolite,  OE::hasA  cultures  in  iron-­deficient  medium  did  not  produce  
the  peak  at  46.8  min  or  the  pink  color  (Figure.  A1b).  Because  extreme  line-­broadening  
prevented   full   spectroscopic   characterization   of   the   has-­dependent   iron   complex,   we  
Figure  1.1:  hasA  controls  has  cluster  gene  expression  and  metabolite  production.  (a)  
Schematic  of  has  gene  cluster  and  putative  assignments.  hasA  and  hasF:  C6  transcription  
factors;;  Trs:  transporter;;  MT:  methyltransferase;;  NRPS:  non-­ribosomal  peptide  synthetase;;  
DMATS:   dimethylallyltryptophan   synthase;;   FAD:   FAD   binding   domain   protein;;   P450:  
cytochrome  P450.  Flanking  genes  are  shown  in  white.  (b)  Northern  analysis  of  has  cluster  
gene   expression   in   the   WT   and   OE::hasA   strains.   (c)   HPLC   UV   chromatograms   for   A.  
fumigatus  mutant   strains   and   structures   of  has-­dependent  metabolites;;   (*)   denotes  HAS  
decomposition  products.  Ergosterol  amounts  were  highly  variable  between  replicates  and  
are  not  has-­dependent.  
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treated   the   isolated   starkly  pink   compound  with   strong  base   to  precipitate   iron  as   the  
hydroxide.   Following   iron   removal   we   obtained   the   O-­methylated   diketopiperazine  
derivative  9a,  whose  structure  was  determined  using  a  routine  set  of  2D  NMR  spectra  
and   HR-­MS   (Figure   1.1c).   Based   on   the   combined   spectroscopic   data,   the   iron-­
containing  metabolite  was  identified  as  a  trimeric  complex  of  9  with  Fe(III),  similar  to  the  
previously  described  A.  terreus  metabolite,  astechrome  (1113.1,  [M+H]+).21  Accordingly,  
we   named   the   has-­dependent   metabolite   we   identified   from   A.   fumigatus  
hexadehydroastechrome  "HAS"  (1;;  Figure  1.1c).    
   To  gain  insight  into  HAS  biosynthesis,  we  examined  the  metabolomes  of  the  seven  
double   mutants   carrying   deletions   of   the   other   has   genes   in   OE::hasA   background  
(Figure  A2)  by  2D  NMR  and  HPLC-­UV-­MS  for  the  presence  of  pathway  intermediates  or  
shunt   metabolites,   focusing   on   compounds   whose   UV   and   NMR   spectra   suggested  
incorporation  of  tryptophan.  Putative  pathway-­related  metabolites  were  characterized  by  
HR-­MS  and  purified  as  needed   to  complete  NMR-­spectroscopic  assignments   (Tables  
A4-­9).   Loss   of   the   second   transcription   factor   (OE::hasADhasF)   did   not   result   in   any  
detectable  metabolomic  change  compared  to  the  OE::hasA  strain,  indicating  that  under  
the  growth  conditions  used  in  this  study  HasF  does  not  affect  the  has  pathway  (Figure  
1.1c   and   Figure   A2).   In   contrast,   deletion   of   the   transporter   (HasB)   led   to   complete  
abolishment  of  HAS  production  and  no  intermediates  or  shunt  metabolites  were  observed  
(Figure  1.1c),  which   is   not   unexpected  given   that   deletions   of  SM  cluster   transporter  
genes  have  previously  been  shown  to  inhibit  SM  production.22,23  
   The  metabolite  profiles  of  several  other  double  mutant  strains  provided  important  
clues   for   the   HAS   biosynthetic   pathway.   Deletion   of   the   cytochrome   P450  
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(OE::hasADhasH)   abolished  HAS  production  and   instead   yielded   large  quantities  of   a  
single  shunt  metabolite,  the  prenylated  Trp-­Ala  diketopiperazine,  terezine  D  (7),24  small  
amounts   of  which  were  also  detected   in   the  parent  OE::hasA   strain.   In   the  OE::hasA  
strain,  but  not  the  P450  knock  out,  terezine  D  was  accompanied  by  its  hydroxy  derivative,  
8.24  Deletion  of  the  putative  O-­methyltransferase  (OE::hasADhasC)  unexpectedly  led  to  
production  of  large  quantities  of  L-­7-­dimethylallyltryptophan  (3),  as  well  as  the  cis-­  and  
trans-­  isomers  of  L-­7-­(3-­methylbutadienyl)tryptophan  (4a,  4b),  whereas  production  of  all  
diketopiperazine  derivatives  was  completely  abolished.  L-­configuration  of  compounds  3,  
and   4a/b   was   confirmed   by   converting   them   to   their   corresponding   Mosher   amides  
(Figure   A4).25   In   contrast,   the   NRPS   deletant   (OE::hasADhasD)   did   not   accumulate  
prenylated   tryptophan   derivatives   such   as   3   or   4a/b,   suggesting   that   prenylation   of  
tryptophan  may   not   precede   formation   of  NRPS-­tethered   tryptophan.   Lastly,   the   FAD  
deletant   (OE::hasADhasG)   yielded   the   previously   described   A.   terreus   metabolite,  
astechrome   (2)   instead   of   HAS   (Figure   1.2b   and   Table   A4),   suggesting   that   HasG  
converts  the  prenyl  to  a  methylbutadienyl  sidechain.  Bioinformatic  examination  of  the  A.  
terreus  genome   revealed  a  gene  cluster  with  close  homology   to   the  A.   fumigatus  has  
cluster;;  however,   the  A.   terreus   cluster   lacks  a  gene  encoding  a  homolog  of   the  FAD  
HasG  (Figure  A5),  supporting  that  HasG  is  required  for  introducing  the  diene  moiety  in  
the  side  chain  (Figure  1.2a).  We  further  noted  that  isolated  samples  of  the  cis-­isomer  4b  
slowly  isomerized  to  4a,  suggesting  that  HasG  produces  cis-­7-­(3-­methylbutadienyl)indole  
derivatives,  which  then  slowly  convert  to  the  corresponding  trans-­isomers  such  as  4a  and  
9a  during  extraction  and  isolation.  Therefore,  hexadehydroastechrome  (1)   is  shown  as  
cis  in  Figure  1.1.    
	   7	  
  
Model  for  HAS  biosynthesis:  These  results  are  consistent  with  a  biogenesis  model  in  
which   the  NRPS   is   loaded  with  alanine  and   tryptophan,   followed  by  prenylation  of   the  
tethered  tryptophan  or  the  resulting  tethered  Trp-­Ala-­dipeptide  (Figure  1.2a).  Deletion  of  
the  P450  hasH  appears  to  stall  further  processing  of  the  tethered  dipeptide,  which  then  
undergoes  spontaneous  cyclization  to  form  the  diketopiperazine,  terezine  D,  the  only  has  
pathway   metabolite   detected   in   the   OE::hasADhasH   strain.   Our   observation   that   the  
OE::hasA∆hasC  (MT)  mutant  strain  does  not  accumulate  diketopiperazines,  but  instead  
yields  large  quantities  of  prenylated  tryptophan  derivatives,  suggests  a  model   in  which  
HAS   biosynthesis   continues   via   tethered   intermediates   as   shown   in   Figure   1.2a,   as  
opposed   to  an  alternative  pathway   involving   further  modification  of   terezine  D-­derived  
diketopiperazines.  In  this  model,  the  presence  of  prenylated  tryptophan  derivatives  3  and  
4a/b  could  result  from  enzymatic  hydrolysis  of  a  tethered,  partially  oxidized  dipeptide,  for  
Figure  1.2:  Model  for  HAS  biogenesis  and  crosstalk  with  the  ftm  gene  cluster.  (a)  
Putative  has  biosynthetic  pathway  (A  =  adenylation,  T  =  thiolation,  C  =  condensation  
domains16,17),  (*)  order  of  enzyme  activity  unclear.  (b)  ftm  gene  cluster  expression  in  two  
has  mutants.  
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example  by  the  DMATS  HasE,  which  has  previously  been  reported  to  hydrolyze  linear  
dipeptides   such   as   of   H-­L-­Trp-­L-­Ala-­OH,   but   not   diketopiperazines.26   Deletion   of   the  
prenyltransferase  (DMATS,  HasE)  led  to  complete  abolishment  of  HAS  production  and  
no  intermediates  or  shunt  metabolites  were  observed.    
Surprisingly,   we   found   that   the   NRPS   deletant   (OE::hasADhasD),   although  
producing  no  HAS  intermediates,  yielded  large  amounts  of  metabolites  derived  from  the  
partially   characterized   ftm   (fumitremorgin)   NRPS   cluster,   including   brevianamide   F,  
fumitremorgin  C  and  demethoxy-­fumitremorgin  C  (5a,  5b,  6,  Figure  1c).  Fumitremorgin  
biosynthesis   also   involves   prenylation   of   tryptophan   derivatives,18   however,   the   ftm  
cluster  does  not  contain  a  pathway-­specific  transcription  factor.  Examination  of  ftm  gene  
expression   in   wild   type   (WT),  OE::hasA,  and  OE::hasADhasD   strains   showed   greatly  
increased  ftm  cluster  gene  expression  in  the  latter  strain  (Figure  2b),  consistent  with  the  
observation   of   increased   ftm-­metabolite   production   in  OE::hasA hasD.   These   results  
suggest   that   tryptophan   and   prenylation   activity   is   shunted   toward   fumitremorgin  
biosynthesis  when  the  has  pathway  is  shut  down  in  OE::hasA  background.  Interestingly,  
fumitremorgin  production  was  also  increased  in  NRPS  deletants  of  the  fumigaclavine  C  
pathway,27  possibly  due  to  a  similar  mechanism.  
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Invasive  aspergillosis  and  the  has  biosynthetic  gene  cluster,  a  mouse  model:  To  
gain  initial  insight  into  the  possibility  that  HAS  might  contribute  to  virulence,  WT,  OE::hasA  
and  OE::hasA∆hasD  strains  were  compared  in  a  neutropenic  murine  pulmonary  model.  
Infection  with  the  OE::hasA  strain  resulted  in  significantly  higher  mortality  than  infection  
with  WT  and  OE::hasA∆hasD  (Figure  1.3a).  Murine  lung  tissue  from  all  treatments  were  
examined   for   the   presence   of   has   metabolites.   Whereas   none   of   the   identified   has-­
dependent   metabolites   could   be   detected   in   the   WT-­   and   OE::hasA∆hasD-­infected  
samples,   tissue   samples   from   OE::hasA-­inoculated   mice   revealed   the   presence   of  
terezine  D  (Figure  1.3b)24.  HAS  was  not  detected  in  the  OE::hasA  lung  extracts,  however,  
based  on  our  experience  with  isolating  the  iron(III)  complex  from  fungal  cultures,  this  main  
product  of  the  has  pathway  is  likely  too  unstable  to  permit  isolation  from  animal  tissue.  
Figure  1.3:	  The  has  pathway  affects  survival  in  a  mouse  model  of  IA.  (a)  Mantel-­
Cox   survival   analysis   of   mice   infected   with   WT,   OE::hasA,   or   OE::hasA∆hasD   A.  
fumigatus  in  a  neutropenic  pulmonary  mouse  model  of  IA.  OE::hasA  is  significantly  more  
virulent  than  WT  or  OE::hasA∆hasD  (P<0.05,  Log-­Rank  Test).  There  was  no  significant  
difference   between   WT   or   OE::hasA∆hasD   strains.      (b)   MS   ion   chromatograms   for  
Terezine  D   (7)   standard   and   lung  extracts   from  mice   infected  with  WT,  OE::hasA,   or  
OE::hasA∆hasD.	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Our  observation   that   in   laboratory  culture  OE::hasADhasD  produces   large  amounts  of  
fumitremorgins  suggests  the  possibility  that  crosstalk  with  other  metabolic  pathways  may  
in   part   be   responsible   for   the   increased   virulence   of   OE::hasA   in   mice.      However,  
fumitremorgins   could   not   be   detected   in   any   of   the  mouse   lung   tissue   samples,   and  
production  of  gliotoxin,  another  metabolite  contributing  to  A.  fumigatus  virulence,11  was  
not  increased  in  either  the  OE::hasA  or  OE::hasA∆hasD  samples  relative  to  WT  (Figure  
A6).  
  
Conclusions:  We  show  that  microarray  analysis  coupled  with  comparative  metabolomics  
using  knockout  (KO)  and  overexpression  A.  fumigatus  mutants  enables  identification  of  
potential  virulence  factors  of  a  pathogenic  fungus  and  proposing  a  tentative  biosynthetic  
pathway.   Examination   of   available   fungal   genomes   indicates   that   has-­related   gene  
clusters  are  found  only   in  a  few  opportunistic  human  pathogenic  Aspergilli  and  related  
dermatophytic  fungi  of  the  Trichophyton  and  Arthroderma  genera  (Figure  A5),  providing  
additional  motivation  to  further  investigate  the  impact  of  HAS  and  related  metabolites  on  
virulence.  Because  of   its   iron-­binding  properties,  we  considered   the  possibility   that  9b  
could  be  acting  as  a  siderophore,  as  siderophores  are  well  known  virulence  factors  in  A.  
fumigatus  and   other   fungi.28  However,   for   entropic   reasons   it   seems   unlikely   that   the  
hydroxamic  acid  9b   is  able   to  compete  with  potent  multidentate  siderophores  such  as  
triacetylfusarinine  C  (TAFC)  or  ferricrocin.28  Correspondingly,  we  found  that  neither  9b  or  
1  were  produced  by  OE::hasA  cultures  grown  in  iron-­deficient  medium,  whereas  TAFC  
production  was  strongly  upregulated  (Figure  A7).  Nevertheless,  the  iron  requirement  for  
HAS   biosynthesis   suggests   that   the   has   pathway   and   siderophore   production   may  
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interact.   In  addition,   the  highly   lipophilic   trimer  HAS  may   function  as  a  vehicle   for   the  
delivery  of  its  much  more  polar  monomer  9  and/or  serve  to  inflict  oxidative  damage.  
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CHAPTER  2  
  
SECOND  CONDENSATION-­LIKE  DOMAIN  IN  GLIP  IS  ESSENTIAL  FOR  
DIKETOPIPERAZINE  CYCLIZATION  IN  GLIOTOXIN  BIOSYNTHESIS  
  
Abstract:  One  of  the  most  well-­studied  metabolites  and  virulence  factors  from  the  human  
pathogen  Aspergillus   fumigatus   is   gliotoxin,   an   epidithiodiketopiperazine   (ETP)   toxin.  
Despite   extensive   research   on   gliotoxin’s   biosynthesis,   bioactivity   and   ecology,   the  
enzymatic  activity  responsible  for  diketopiperazine  (DKP)  formation  en  route  to  gliotoxin  
has  remained  uncharacterized.  Here  we  show  that  the  second  condensation  (C)  domain  
in   the   non-­ribosomal   peptide   synthetase   (NRPS)   GliP   functions   as   a   cyclization   (CT)  
domain,  which  is  essential  for  DKP  formation  and  ultimately  gliotoxin  biosynthesis.  In  vivo  
truncation   of   GliP   to   remove   the   CT   domain   resulted   in   a   complete   loss   of   gliotoxin  
production,  as  well  as  all  intermediates  and  shunt  metabolites  in  the  gli  pathway.  In  vitro  
reconstitution  of   the  CT  domain   confirmed   its   essential   role   in   cyclization  of   dipeptidyl  
substrates.  We  further  show  that  a  single  point  mutation  of  a  conserved  catalytic  histidine  
eliminated  cyclization  activity  of   the  CT  domain  both   in  vitro  and   in  vivo.  These  results  
indicate  gliotoxin  biosynthesis  proceeds  via  tailoring  modifications  that  occur  on  a  linear  
dipeptide  scaffold  attached  to  GliP,  rather  than  on  the  released  cyclo(L-­Phe-­L-­Ser).  The  
GliP   CT   domain   belongs   to   the   same   class   of   cyclization   domains   involved   in  
fumiquinazoline   biosynthesis,   however   had   not   previously   been   annotated   as   such.  
Lastly,   this   work   highlights   a   general   strategy   for   the   biosynthesis   of   modified   DKPs  
derived  from  NRPSs  with  similar  domain  architecture  to  GliP.     
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Introduction:  Gliotoxin  was  discovered   in  1936  by  Weindling  and  Emerson  and  since  
then   has   been   the   subject   of   several   hundred   publications1,2.   After   some   debate   the  
correct   structure  was  elucidated   in  1958  by  Johnson  and  Woodward,  which  was   later  
confirmed  by  X-­ray  crystallography  (1,  Figure  2.1b)3,4.  Throughout  the  later  part  of  the  
20th  century  many  total  syntheses  of  1  were  undertaken,  as  well  as  isolations  from  several  
fungal  species  and  widespread  biological  activity  testing5-­8.  Suspected  of  playing  a  key  
role  in  Aspergillus  fumigatus’  pathogenicity  towards  humans  and  livestock,  understanding  
the  biogenesis  of  gliotoxin  became  an  important  goal  for  natural  product  chemists  and  
fungal  biologists  alike9,10.   Immediately  after  A.   fumigatus  was   first  sequenced   in  2005,  
Gardiner  and  Howlett  discovered  the  genetic  basis  of  1  by  using  bioinformatics  analyses  
of  gene  expression  data  to  correctly  predict  its  biosynthetic  gene  cluster  (BGC),  the  gli  
cluster11.   Because   of   the   availability   of   sequencing   data   and   the   human   health  
implications,   nearly   all   of   the  work   on   the  gli   cluster   has   since   been   conducted   in  A.  
fumigatus12.    
   The  core  enzyme   in   the  gli   cluster,  GliP,   is  a  nonribosomal  peptide  synthetase  
(NRPS)   comprised   of   seven   domains,   namely   two   adenylation   (A)   domains,   two  
condensation  (C)  domains,  and  three  thiolation  (T)  domains,  previously  annotated  and  
ordered  as  A1-­T1-­C1-­A2-­T2-­C2-­T3  (Figure  2.1a)13.  The  early  steps   in  gliotoxin   formation  
are  as  follows:  A1  activates  phenylalanine  and  A2  activates  serine,  which  are  tethered  to  
T1  and  T2,  respectively,  then  condensed  by  the  C1  domain,  forming  T2  attached  L-­Phe-­L-­
Ser  dipeptide  (Figure  2.1a).  While  the  mechanism  and  role  of  A1-­T1-­C1-­A2-­T2  domains  in  
the   formation   of   T2-­tethered   L-­Phe-­L-­Ser   is   straightforward,   the   ensuing   modification  
steps  and  release  from  GliP  are  not  well  defined  and  cannot  be  predicted  simply  from  the  
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annotation  of  GliP  and  gli  cluster  tailoring  genes.  In  terms  of  GliP,  the  C2  and  T3  domains  
in  particular  have  no  obvious  function,  since  an  additional  amino  acid  is  not  present  in  the  
structure  of  gliotoxin  and  the  absence  of  a  third  A  domain  would  mean  involvement  of  a  
stand-­alone  A  domain,  for  which  there  are  no  candidate  genes  in  or  around  the  gli  cluster.  
In  an  attempt  to  clarify  the  biosynthetic  function  of  each  domain  in  GliP,  Balibar  and  Walsh  
recombinantly  expressed  GliP  in  Escherichia  coli  in  200613.  They  confirmed  the  canonical  
function  of  A1-­C1-­T1-­A2-­T2  towards  the  formation  of  L-­Phe-­L-­Ser  through  the  observation  
of   cyclo(L-­Phe-­L-­Ser)   (2),   which   they   hypothesized   resulted   from   the   spontaneous  
cyclization  of  L-­Phe-­L-­Ser  from  the  T2  domain  (Figure  2.1c).  They  were  unable  to  discern  
the  function  of  C2  and  T3,  as  mutational  inactivation  of  these  domains  did  not  impact  the  
rate  of  formation  of  2  and  no  new  L-­Phe-­L-­Ser  related  products  were  observed.  Shortly  
after   the   in  vitro   reconstitution  of  GliP  several  efforts  were  undertaken  by   this   lab  and  
others   to   describe   the   full   gli   biosynthetic   pathway   using   both   in   vivo   and   in   vitro  
approaches.	    
Figure  2.1.  Domain  architecture  of  GliP  and  DKP  formation  in  question.  (a)  GliP  loads  L-­Phe  
on  T1  and  L-­Ser  on  T2,  which  are  condensed  together  by  the  C1  domain  to  form  T2-­tethered  L-­Phe-­
L-­Ser  (A  =  adenylation,  T  =  thiolation,  C  =  condensation  domain)  (b)  Structure  of  the  final  product  
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   In  2011  our  laboratory  provided  the  most  complete  picture  of  gliotoxin  biosynthesis  
to   date14.   Using   DANS-­based   comparative  metabolomics   of  WT  A.   fumigatus   versus  
knock-­out   of   gliZ   (the   gli   cluster   transcriptional   regulator),   six   previously   unidentified  
gliotoxin  intermediates  and  shunt  metabolites  were  characterized  (red  structures,  Figure  
B1).   These   novel   gli   pathway  metabolites   were   consistent   with   a   biosynthetic   model  
where   tailoring   modifications   occur   to   a   GliP-­tethered   linear   L-­Phe-­L-­Ser   dipeptide  
(Figure   B1).   Our   proposal   for   a   tethered   model   of   gliotoxin   biosynthesis   was   in  
contradiction  with  prior  proposals,  where  the  released  product  of  GliP  was  speculated  to  
be  an  unmodified  2,  rather  than  a  modified  DKP  that  had  already  been  elaborated  by  gli  
cluster  tailoring  enzymes  (Figure  B1)15.  Evidence  for  the  untethered  model  (where  2  is  
the  true  product  of  GliP)  is  based  in  part  on  the  original  in  vitro  characterization  of  GliP,  
which  doesn’t  account  for  the  possibility  of  altered  GliP  activity  when  gli  cluster  tailoring  
enzymes  are  present  and  physically  interacting,  a  situation  that  very  likely  occurs  in  vivo.  
Figure  2.2.  In  vitro  characterization  of  gli  tailoring  enzymes  by  the  Hertweck  group.  GliG  
converts  3  to  4  by  addition  of  two  GSH  groups  at  each  alpha  carbon.  GliK  cleaves  Glu  from  GSH  
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Additional  support  for  the  untethered  model  came  shortly  after  our  lab  published  on  the  
full  gli  pathway  in  2011  when  Hertweck  and  coworkers  published  the  characterization  of  
GliG,  a  Glutathione  S-­Transferase  in  the  gli  cluster16.    
   Deletion   of  GliG   resulted   in   the   accumulation   of  3  and   complete   abrogation   of  
production  of  1  in  A.  fumigatus  (Figure  2.2).  Extracts  from  an  A.  fumigatus  DGliG  mutant  
that  were  treated  with  recombinant  GliG  resulted  in  the  production  of  glutathione  (GSH)  
derivative  4,  which  derived  from  intermediate  3  (Figure  2.2).  This  was  taken  as  evidence  
that   the   substrate   for   both  GliC,   a   cytochrome   p450   hydroxylase   (responsible   for   the  
oxidation  of  2  to  3),  and  GliG  was  indeed  2,  however,  3  could  also  have  resulted  from  an  
oxidation  of  GliP-­tethered  L-­Phe-­L-­Ser  (Figure  B1).  If  this  was  the  case  then  it  would  be  
inconsistent  with  the  next  enzymatic  step  where  GliK  converts  4  to  5,  however,  Hertweck  
and  coworkers  did  not  test  substrate  specificity  to  show  GliG  preferred  the  cyclic  substrate  
4  over  a  linear  dipeptide,  such  as  6  (Figure  2.2).  Hertweck  and  coworkers  later  described  











































Figure  2.3.  Alternative  hypothetical  enzymatic  activity  for  GliK  and  GliJ  peptidases.  GliK  and  
GliJ  dipeptidases  convert  GliP-­tethered  L-­Phe-­L-­Ser-­diGSH  to  GliP-­tethered  L-­Phe-­L-­Ser-­diCys.    
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to  our  original  model  for  1  biogenesis17.  They  showed  that  GliK  and  GliJ  converted  4  to  
cyclo(L-­Phe-­L-­Ser)-­Cys  7,  (Figure  2.2).  Their  characterization  of  the  sulfurization  steps  
did  not  account  for  the  oxidation  steps  prior  to  sulfurization,  as  well  as  substrate  specificity  
of  the  enzymes  required  for  sulfurization.  Considering  GliJ  and  GliK  are  peptidases,  which  
are  known  to  exhibit  high-­levels  of  substrate  promiscuity18,   it  seems  possible  that   they  
could  also  function  in  accordance  with  the  tethered  model  for  gliotoxin  biosynthesis  that  
we  initially  reported.  However,  the  creation  of  a  GliP-­tethered  intermediate,  such  as  8  to  
test  this  hypothesis  is  extremely  difficult  (Figure  2.3).  
   Perhaps,  the  most  unsatisfying  aspect  of  the  untethered  model  for  1  biosynthesis  
is  the  neglect  of  the  C2  and  T3  domains  in  GliP.  If  they  were  truly  unnecessary,  then  it  
seems   unlikely   they   would   have   been   maintained   through   evolution.   The   C2   and   T3  
domains  are  encoded  for  by  large  genomic  sequences  and  1  is  important  for  fungal  fitness  
–  if  they  were  unnecessary,  eventually  a  successful  species  would  arise  where  they  were  
missing.  However,  this  is  not  the  case,  as  GliP  is  highly  conserved  across  many  fungal  
species,  which  points  to  an  important  and  unrealized  function  of  the  C2  and  T3  domains.  
An  indication  for  the  possible  function  of  the  GliP  C2  and  T3  domains  came  in  2012  when  
Tang   and  Walsh   discovered   that   some   terminal   condensation   domains   were   actually  
cyclization   (CT)   domains19.   These   fungal   specific   CT   domains   were   shown   to   be  
necessary  for  the  macrocyclization  of  linear  peptidyl  precursors  produced  by  a  variety  of  
fungal   NRPSs.   They   showed   the   activity   of   the   CT   domain   to   be   dependent   on   the  
conserved  residues  (SHXXXDXXS/T),  and  specifically  the  conserved  histidine.  Tang  and  
Walsh  re-­  annotated  many  NRPSs  involved  in  the  biosynthesis  of  macrocyclic  peptides  
as  having  essential   terminal  CT  domains,   rather   than  simply  C  domains.  They  did  not  
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however,   re-­annotate   the  C2   domain   of  GliP,   despite   the   fact   that   it   too   contains   the  
conserved  sequence  of  the  CT  domain  (Figure  B2)19.  This  is  likely  because  the  C2  is  not  
a  terminal  domain  in  GliP,  whereas,  Tang  and  Walsh  specifically  characterized  a  terminal  
CT  domain  from  the  trimodular  NRPS  TqaA20.  The  homology  of  C2  in  GliP  to  the  published  
CT   domain   strongly   suggested   it   serves   as   an   essential   cyclization   domain   toward   1  
biosynthesis.  Additionally,  the  results  described  in  Chapter  1  of  this  dissertation  provided  
more  support  for  C2  actually  being  CT  and  1  biosynthesis  proceeding  via  a  tethered  model.    
   In  Chapter  1  the  characterization  of  the  has  BGC  is  described.  When  we  initially  
set  out  to  understand  the  has  pathway,  HasD,  the  has  cluster  NRPS,  was  annotated  in  
NCBI   as   another   GliP18.   This   was   because   HasD   and   GliP   share   the   same   domain  
architecture  of  A1-­T1-­C1-­A2-­T2-­C2-­T3.  Despite  sharing  high  homology  for  their  NRPSs,  the  
has  and  gli  clusters  make  completely  different  small  molecule  products,  with  the  exception  
of   both   products   containing   the   structural   feature   of   a   modified   DKP.   In   the   has  
biosynthetic  pathway  deletion  of  HasC,   the  has  O-­methyltransferase   tailoring  enzyme,  
leads  to  the  accumulation  of  compounds  3-­4a/b  from  Chapter  1.  We  hypothesized  3-­4a/b  
from  Chapter  1  resulted  from  a  stalled  biosynthesis  of  a  tethered  dipeptide  attached  to  
HasD,  which  was  cleaved  by  the  has  cluster  encoded  dipeptidase,  HasE,  as  described  in  
Chapter  1.  Fortunately,  another  lab  conducted  the  in  vitro  characterization  of  HasE  and  
showed   it   does   indeed   cleave   linear   dipeptides   and   importantly,   not   cyclic   DKPs,  
evidence  in  favor  of  the  tethered  model  for  the  has  pathway21.  Analogously,  the  gli  cluster  
also  contains  a  dipeptidase,  GliJ,  which  was  previously  shown  to  cleave  glycine  from  5,  
in   the   second   step   of   four   sulfurization   steps   in   the   gli   pathway   (Figure   2.2).   We  
suspected   that   in   addition   to   cleaving   5,   GliJ   activity   would   also   serve   a   function  
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analogous   to   that   of   HasE   and   cleave   linear   L-­Phe-­L-­Ser   in   a   similar   recycling-­type  
mechanism  as  observed  for  HasE  in  the  has  pathway.    
   Here  we  show  that  the  C2  domain  in  GliP  is  actually  a  CT  domain  that  is  essential  
for  gliotoxin  (1)  biosynthesis,  as  predicted  based  on  the  homology  to  other  CT  domains.  
Construction  of  an  A.  fumigatus  point  mutant  for  the  conserved  catalytic  histidine  (GliP-­
H1754A)  predicted   to   be   essential   for   cyclization   activity   resulted   in   complete   loss   of  
gliotoxin  production  and  all  gli-­pathway  metabolites.  In  vitro  reconstitution  of  a  truncated  
GliP-­DC2T3  protein  resulted  in  a  dramatic  decrease  in  rate  of  formation  of  2.  Our  results  
show   that   the   GliP   C2   domain   is   necessary   for   cyclizing   an   unmodified   L-­Phe-­L-­Ser  
substrate   and   that   a  modified  GliP-­T3-­tethered   L-­Phe-­L-­Ser   likely   represents   the   true  
substrate,  which  is  what  occurs  in  vivo.  Further  supporting  the  cyclization  role  of  the  C2  
domain  we  also  show  that  GliJ’s  substrate  specificity  is  not  limited  to  Cys-­Gly  dipeptides  
and  that  it  may  serve  an  additional  recovery-­type  role  by  cleaving  a  stalled  L-­Phe-­L-­Ser  
that  is  still  attached  to  GliP.    
  
In  vivo  truncation  of  GliP  abolished  gliotoxin  production:  In  order  to  determine  the  
biosynthetic  function  of  the  GliP  C2  and  T3  domains  in  vivo  we  first  constructed  truncation  
mutants  in  A.  fumigatus  for  each  of  these  domains  separately,  GliP-­DT3  and  GliP-­DC2T3  
(Appendix  B).  To  assess  the  impact  of  each  truncation  mutant  on  gliotoxin  biosynthesis  
we   subjected   whole   metabolome   extracts   to   a   liquid   chromatography-­high   resolution  
mass   spectrometry   (LC-­HRMS)   comparative  metabolomics   analysis   and   surveyed   for  
gliotoxin   and   two   other   abundant  gli   pathway  metabolites   (1-­2,  9-­10,  Figure   2.4   and  
Figure  B1).  We  were  specifically  interested  in  2,  as  production  of  this  compound  should  
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not  have  been  hindered  by  elimination  of  the  terminal  C2  and  T3  domains  if  the  formation  
was   spontaneous   from   T2,   as   previously   reported.   LC-­HRMS   comparison   of   whole  
metabolome  extracts   from  WT  (Af293),  GliP-­DT3,  and  GliP-­DC2T3  revealed  a  complete  
loss  of  gliotoxin  and  pathway  intermediates  (1-­2,  9-­10)  in  the  GliP-­DC2T3  strain  (Figure  
2.4a-­d).  In  extracts  from  the  GliP-­DT3  mutant  strain  we  were  unable  to  detect  1  and  the  
most  abundant  gli  pathway  metabolites  2  and  9,  however  we  observed  trace  quantities  of  
10  (99.3  %  less  than  Af293,  n=4,  p=0.002),  the  detoxification  product  of  1  (Figure  2.4a-­
d).   These   data   show   that   biosynthesis   of  1   proceeds  without   the   T3   domain   of   GliP,  
however,   only   at   less   than   one   percent   production   compared   to   WT   (Af293).  
   Gliotoxin   (1)   serves  as  a  positive   feedback   loop   for   its  own  production   through  
regulation   of   gli   cluster   expression22.   The   inability   of   the   GliP-­DC2T3  mutant   strain   to  
produce  1  resulted  in  a  complete  loss  of  gli  cluster  expression  (Figure  B3).  Similarly,  the  
reduction  of  gliotoxin  (1)  production  observed  for  the  GliP-­DT3  mutant  strain  resulted  in  
decreased  gli   cluster  expression  but  not  a  complete  abolishment  as  was  seen   for   the  



































































































Figure   2.4.   LC-­HRMS   analysis   of   whole   metabolome   extracts   from   WT   and   mutant   A.  
fumigatus  strains.  (a-­d)  Representative  overlaid  extracted-­ion-­chromatograms  for  1,  2,  9  and  10  
in  Af293  (black  lines),  GliP-­DT3(green  lines),  and  GliP-­DC2T3  (purple  lines).    
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extracts  from  the  GliP-­DC2T3  and  GliP-­DT3  mutant  strains  was  therefore  biased,  since  the  
lack   of   gli   cluster   expression   could   account   for   the   observed  metabolite   profiles.  We  
rescued  gli  cluster  expression  by  growing  cultures  supplemented  with  exogenous  1  (20  
µg/mL  in  GMM)  (Figure  B4).  We  did  not  do  a  quantitative  comparison  to  existing  data22  
for  gli  cluster  rescue,  rather  we  qualitatively  determined  by  northern  blot  that  the  feeding  
of  1  had  brought  back  gli  cluster  expression  to  similar  levels  as  observed  in  the  WT  strain,  
which  should  enable  observation  of  pathway  metabolites.  Additionally,  we  did  not  explore  
effects  of  gliotoxin  feeding  beyond  the  direct  impact  on  gli  cluster  expression,  as  such  an  
exploration  would  be  outside  the  scope  of  this  work.  LC-­HRMS  comparison  of  cultures  
supplemented   with   1   showed   that   despite   rescued   expression,   GliP-­DC2T3   did   not  
produce   any   gli   pathway   metabolites   (Figure   2.5a-­d).   The   GliP-­DT3   strain   however,  
produced  significantly  less  2  (95.7  %  less  than  Af293,  n  =  3,  p  <  0.0001)  and  the  tailored  
metabolite,  9  (96.3  %  less  than  Af293,  n  =  4,  p  =  0.026)  (Figure  2.5a-­b).  These  results  
suggest  that  in  the  absence  of  T3,  low-­level  production  (3-­5  %  of  WT  levels)  of  1  and  other  
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Figure   2.5.   LC-­HRMS   analysis   of   whole   metabolome   extracts   from   WT   and   mutant   A.  
fumigatus  strains  supplemented  with  exogenous  1  during  growth.  (a-­d)  Overlaid  extracted-­
ion-­chromatograms  for  1,  2,  9  and  10  in  Af293  (black  lines),  GliP-­DT3(green  lines),  and  GliP-­DC2T3  
(purple  lines)  
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is   cyclized   by   C2,   albeit   with   extremely   reduced   activity.   This   further   supports   the  
hypothesis  that  T3  is  a  bona  fide  third  peptidyl  carrier  domain  and  serves  as  the  primary  
location  for  linear  substrates  to  be  modified  by  gli  cluster  tailoring  enzymes,  rather  than  a  
remnant  domain  with  no  biosynthetic  function.    
  
Adenylation   activity   of   GliP-­DC2T3   and   GliP-­DT3   A1   and   A2   domains   is   equal   or  
greater  than  GliP-­WT:  One  concern  regarding  the  loss  of  gli  pathway  metabolites  in  the  
GliP-­DC2T3  and  GliP-­DT3  strains  is  that  by  truncating  GliP  we  changed  the  overall  structure  
significantly  enough  to  impede  A  domain  adenylation  activity.  This  would  result  in  L-­Phe  
and  L-­Ser  never  being   loaded  onto  T1  and  T2,  accounting   for   the  observation  of  no  or  
minimal  amounts  of  gli  pathway  metabolites.  To  address  this  concern  we  heterologously  
expressed  and  purified  GliP-­WT,  GliP-­DC2T3  and  GliP-­DT3  from  E.  coli  (Figure  B5  and  
Appendix  B).  We  evaluated  the  adenylation  activity  of  A1  and  A2  for  L-­Phe  and  L-­Ser,  
respectively,  in  all  three  proteins  using  the  standard  ATP-­[32P]pyrophosphate  exchange  
assay23.  The  truncated  proteins,  GliP-­DC2T3  and  GliP-­DT3,  showed  adenylation  activity  
for  L-­Phe  35-­45  fold  and  10-­20  fold  higher  than  water,  respectively,  whereas,  GliP-­WT  
showed  320-­380  fold  higher  adenylation  activity  than  water  (Figure  B6  and  Appendix  
B).  The  decrease  in  adenylation  activity  as  compared  to  water  for  the  truncation  mutants  
could  be  caused  by  higher  levels  of  ATP-­hydrolysis  in  the  shorter  proteins.  Comparison  
of  L-­Phe  to  L-­His  adenylation  activity  of  GliP-­WT,  GliP-­DC2T3,  and  GliP-­DT3  showed  more  
comparable  turn-­over  rates  (GliP-­WT  =  130-­170  fold  increase  for  L-­Phe,  GliP-­DT3  =  50-­
80   fold   increase   for  L-­Phe,  and  GliP-­DC2T3  =  110-­140   fold   increase   for  L-­Phe,  Figure  
B6).  In  agreement  with  the  initial  characterization  of  GliP  by  Balibar  and  Walsh  we  also  
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observed  a  roughly  5-­fold  higher  turn-­over  rate  for  L-­Phe  compared  to  L-­Ser,  which  was  
independent  of   the  version  of  GliP   (Figure  B6).  These   results  suggest   that  A  domain  
activity  is  reduced  but  not  eliminated  by  changes  in  the  terminus  of  GliP.  
  
In   vitro   product   formation   assays   with   GliP-­DC2T3,   GliP-­DT3,   and   GliP-­WT   are  
consistent  with  in  vivo  results:  Next  we  sought  to  characterize  the  product  formation  
of  each  truncated  protein  by  incubating  the  purified  proteins  with  L-­Phe  and  L-­Ser  (see  
Appendix   B   for   experimental   details).   We   monitored   each   reaction   by   LC-­MS   and  
measured  the  rate  of   formation  of  cyclo(L-­Phe-­L-­Ser)  (2),   linear  L-­Phe-­L-­Ser  (12),  and  
looked  for  any  new  products  that  had  not  been  found  in  prior  analyses  of  GliP’s  in  vitro  
activity.  Our  results  for  GliP-­WT  were  consistent  with  the  published  findings,  which  was  a  
slow  formation  of  primarily  2  with  small  quantities  of  hydrolyzed  linear  12  (Figure  2.6a).  
The  GliP-­DT3  protein  had  slightly  reduced  activity  as  measured  by  the  formation  of  2  +  12,  
(93%  of  GliP-­WT,  Figure  2.6b  and  Figure  B7).  Conversely,  GliP-­DC2T3  had  dramatically  
reduced  activity  (33%  of  GliP-­WT,  Figure  B7)  and  the  ratio  of  both  hydrolyzed  12  and  L-­
Phe   captured   13   to   cyclic   2  was   increased   by   2%   (Figure   2.6c).   In   addition   to   the  
previously  detected  products  of  GliP  (2  and  12)  we  also  detected  linear  L-­Phe-­L-­Phe  and  
L-­Phe-­Tris  buffer  adducts  (13  and  14,  respectively,  Figure  2.6b-­d).  The  formation  of  12-­
14   in  each  assay  results  from  insufficient  offloading  of  T2  or  T3  bound  substrates.  This  
effect   is  more   pronounced  with  GliP-­DC2T3   (20-­30%  more  14  observed,  Figure   2.6c)  
because  in  the  absence  of  the  C2  domain,  the  T2  attached  12  is  stalled,  which  increases  
the  amount  of  time  for  T1  attached  L-­Phe  to  be  captured  by  another  L-­Phe  (to  form  13),  
water  (to  form  12),  or  Tris-­buffer  (to  form  14).  
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   In  order   to  determine   if   the  cyclization  activity  of   the  C2  domain  absent   in  GliP-­
DC2T3  could  be  rescued  by  addition  of  free  C2T3  we  expressed  and  purified  standalone  
GliP-­C2T3   from  E.  coli   (Figure  B8  and  Appendix  B).  Addition  of   the  standalone  C2T3  
showed  a  minor  rescue  (4%  increase  from  GliP-­DC2T3  by  itself,  Figure  B7)  in  activity  and  
reversed   the   ratio   of   linear   2   to   12   to   similar   levels   as   seen   in   GliP-­WT,   suggesting  
addition  of   free  C2T3  decreased   the  amount   of   spontaneous  hydrolysis   of  T2   tethered  
substrate  (Figure  2.6d).  The  four  percent  rescue  in  activity  was  not  ideal  to  show  C2  as  
a   standalone   cyclization   domain.   However,   a   couple   of   inherent   problems   with   the  
experiment  likely  impeded  full  activity  rescue,  such  as,  (1)  The  N-­terminal  H6-­tag  on  the  
purified  standalone  C2T3  could  act  as  a  physical  barrier  preventing  it  from  interacting  with  
Figure  2.6.  Product  distribution  for  in  vitro  assays  with  GliP-­WT,  GliP-­DT3  and  GliP-­DC2T3.  
Percentage  for  compounds  produced  in  each  assay  as  2  (black  bar),  12  (orange  bar),  13  (purple  
bar)  and  14  (green  bar)  for  (a)  GliP-­WT,  (b)  GliP-­DT3,  (c)  GliP-­DC2T3,  (d)  GliP-­DC2T3  +  C2T3,  and  
(e)  GliP-­H1754A.    
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GliP-­DC2T3   in  the  correct  orientation  (we  were  unable  to  obtain  soluble  protein  with  C-­
terminal  H6-­tag),  causing  a  decrease  in  reaction  rate;;  (2)  the  cyclization  activity  of  C2  likely  
prefers  substrates  bound  to  T3  and  the  trans-­thiolation  of  T2-­tethered  12  to  T3-­tethered  12  
would  be   reduced  with   two  separate  proteins.   In  order   to  determine   if   the  substrate   is  
indeed  passed  to  T3  via  a  trans-­thiolation,  we  tryptic  digested  the  product  formation  assay  
of   GliP-­WT   and   ran   LC-­HRMS/MS.   We   show   that   T3   is   modified   with   a  
phosphopantetheinyl  arm  using  the  phosphopantetheinyl-­ejection  assay,  but  we  could  not  
capture  a  T3-­tethered  12  (Figure  B9).    
Our  hypothesis  is  that  T3  has  been  maintained  in  GliP  and  related  NRPSs  because  
it’s  a  place  for  the  linear  dipeptide  to  be  received  by  tailoring  enzymes,  which  provides  
both  space  and  time  for  elongation  of  newly  forming  12  on  T2.  This  also  means  that  the  
cyclization  activity  of  C2  should  prefer  a  T3  bound  substrate.  In  order  to  clarify  the  role  of  
T3  in  vitro,  we  heterologously  expressed  and  purified  another  GliP  mutant,  where  the  first  
and  second  thiolation  domains  were  inactivated  by  substitution  of  both  serine  555  and  
1582   to   alanines,   respectively   (GliP-­DT1T2).   Then,   we   synthesized  N-­acetylcystamine  
(SNAC)-­L-­Phe-­L-­Ser  (15)  to  enable  a  trans-­thiolation  reaction  to  create  the  T3-­tethered  
12  (Figure  B10a  and  Appendix  B).  It  is  also  possible  that  15  serves  as  a  substrate  for  
the  C2  domain,  without  first  being  attached  to  T3  (Figure  B10b).  To  distinguish  between  
T3  bound  substrate  (15  post  trans-­thiolation)  and  C2  acting  on  15  itself,  we  conducted  a  
control  experiment  without  Sfp,  meaning  T3  would  have  no  posphopantetheinyl  arm  to  
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capture  15.  Incubation  of  15  with  GliP-­DT1T2,  with  and  without  Sfp,  shows  an  increase  of  
cyclization  activity  of  22  %  more  2  when  Sfp  is  present  (Figure  2.7a  compared  to  Figure  
2.7c).  Since,  15  spontaneously  cyclizes  to  form  2  in  solution,  the  background  cyclization  
rate   is   high,   however,   the   presence   of   T3   significantly   increases   the   amount   of   cyclic  
product  (25%  increase  with  T3  present,  Figure  2.7a  compared  to  Figure  2.7b).    
   In   the   original   publication   by   Tang   and   Walsh   on   the   fungal   CT   domain   they  
described  a  conserved  sequence  that  was  used  to  re-­annotate  C  domains  to  CT  domains  
across   many   fungal   NRPSs.   They   noted   that   within   the   conserved   sequence   the  
cyclization  activity  could  be  pinned  down  to  a  single  catalytic  histidine.  In  the  C2  domain  
of  GliP  that  conserved  catalytic  histidine  is  H1754  (Figure  B2)19.  Before  taking  the  time  
to  create   the  GliP-­H1754A  point  mutant   in  A.   fumigatus  we  quickly   took   the  vector   for  
GliP-­WT  and  used  site-­directed  mutagenesis  to  create  the  construct  for  recombinant  GliP-­
H1754A  point  mutant.  Expression  and  purification  of   the  H6-­tagged  GliP-­H1754A  point  
Figure  2.7.  Percent  cyclization  of  15  to  form  2.  (a)  assay  with  GliP-­DT1T2,  Sfp,  CoA  (b)  assay  
with  GliP-­DT1T2T3  (c)  control  assay  without  Sfp,  (d)  control  assay  with  no  GliP-­DT1T2.  **  =  p<0.01,  
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mutant  was  carried  out  using  previously  described  methods  (Appendix  B).  We  tested  the  
ability  of  GliP-­H1754A  to  form  12  or  2  using  the  same  assay  conditions  described  above.  
The  GliP-­H1754A  point  mutant  had  nearly  identical  product  profiles  to  that  of  the  GliP-­
DC2T3  (Figure  2.6e),  showing  that   in  GliP  the  predicted  conserved  catalytic  histidine  is  
essential   for  C2  cyclization  activity.  Additionally,   this  provided  us  with   the  precedent   to  
create  the  GliP-­H1754A  point  mutant  in  A.  fumigatus  and  evaluate  the  effect  of  this  single  
point  mutation  on  1  biogenesis  in  vivo.  
  
Point   mutation   of   histidine   1754   in   the   C2   domain   of   GliP   abolishes   gliotoxin  
production:  In  order  to  create  the  GliP-­H1754A  point  mutant  strain  of  A.  fumigatus  we  
first  created  a  new  DGliP  strain,  then  via  homologous  recombination  added  back  in  GliP-­
WT  and  GliP-­H1754A  at   the  KU  locus  (see  Appendix  B   for  details),   resulting   in   three  
new  strains,  DGliP,  +GliP-­WT  and  +GliP-­H1754A.  We  grew  each  of  these  three  strains  in  
parallel  in  liquid  media  at  30  °C  for  five  days  and  processed  as  previously  described  (see  
Figure   2.7.   LC-­HRMS   analysis   of   whole   metabolome   extracts   from   WT   and   mutant   A.  
fumigatus  strains.  (a-­d)  Overlaid  extracted-­ion-­chromatograms  for  1,  2,  9  and  10  in  +GliP  (black  
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Appendix  B  for  details).  Following  whole  metabolome  extraction,  we  ran  LC-­HRMS  and  
surveyed   for   the  most   abundant   gliotoxin   pathway  metabolites   (1-­2,  9-­10).  DGliP   and  
+GliP-­H1754A  resulted   in  a  complete   loss  of  all  gli  pathway  metabolites,  whereas,   the  
+GliP-­WT,  despite  being  in  DGliP  background,  showed  a  normal  distribution  of  1-­2  and  
9-­10  (Figure  2.7a-­d),  proving  that  a  GliP  located  at  the  KU  locus  is  still  functional  with  the  
native  gli  cluster.    
     The   lack  of  gliotoxin  production   in   the  +GliP-­H1754A  point  mutant  strain  again  
resulted  in  starkly  decreased  expression  of  gliP  and  gli  cluster  tailoring  genes.  That  the  
loss  of  a  single  histidine  would  result   in  complete  abolishment  of  the  gliotoxin  pathway  
was  rather  surprising,  since  if  the  substrate  for  most  gli  cluster  tailoring  enzymes  is  in  fact  
2  and  derivatives  thereof  (as  has  previously  been  described  by  others12,15,24),  the  loss  of  
the  histidine  1754  should  not  completely  eliminate  gliotoxin  production.  This  alternative  
untethered   model   for   gliotoxin   biosynthesis   in   which   2   is   released   by   spontaneous  
cyclization  from  T2  would  not  be  affected  by  the  elimination  of  a  single  histidine  residue  






























































































Figure   2.8.   LC-­HRMS   analysis   of   whole   metabolome   extracts   from   WT   and   mutant   A.  
fumigatus  strains  supplemented  with  exogenous  1  during  growth.  (a-­d)  Overlaid  extracted-­
ion-­chromatograms  for  1,  2,  9  and  10  in  +GliP  (black  lines),  and  GliP-­H1754A  (blue  lines).  
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hypothesized,  we  expected  to  still  observe  2,  as  this   intermediate   is  produced  in   large  
quantities  by  the  WT  enzyme  (several  mg/L  in  liquid  culture,  Figure  2.4  and  Figure  2.5).  
Upon  feeding  of  exogenous  1  to  +GliP-­H1754A  cultures  to  rescue  gli  cluster  expression,  
we   still   observed   a   complete   loss   of   gli   pathway   metabolites   (Figure   2.8a-­d).   This  
combined   with   our   observations   from   the   GliP-­DC2T3   and   GliP-­DT3   strains   strongly  
support  a  model  for  gliotoxin  biosynthesis  in  which  many  of  the  modification  steps  occur  
while  12  is  tethered  to  the  T3  domain.  
  
A.  fumigatus  DGliP  strain  fed  with  2  does  not  result  in  more  advanced  gli  pathway  
metabolites:   In   our   publication   on   the   gli   pathway   in   2011   we   conducted   a   feeding  
experiment  where  2  was  added  to  liquid  cultures  of  the  A.  fumigatus  DGliP  strain25.  At  the  
time  we  were  unaware  that  in  the  absence  of  gliotoxin,  the  gli  cluster  tailoring  enzymes  
were  not  expressed.  It  was,  however,  shown  that  in  the  DGliP  strain,  exogenous  gliotoxin  
added  to  the  cultures  rescued  gli  cluster  expression  to  WT  levels,  as  described  above22.  
This  means  in  our  initial  feeding  experiment  the  observation  that  2  was  not  processed  by  
gli  cluster  tailoring  enzymes  was  uninformative,  since  they  weren’t  expressed.  To  address  
this  void  in  evidence  we  repeated  the  feeding  experiment,  this  time  however,  in  addition  
to  2  we  also  added  exogenous  1,  as  described  above  (Appendix  B).  Additionally,  instead  
of   feeding   the   full   knock-­out   GliP   strain   (DGliP)   where   no   core   enzyme   is   present  
(disrupting  potential  physical  interactions  between  cluster  tailoring  enyzmes)  we  instead  
fed  the  GliP-­H1754A  point  mutant  strain.  Even  with  WT-­levels  of  gli  cluster  expression  
(as  evidenced  by  the  conversion  of  1  into  10,  Figure  2.9c-­d),  and  all  physical  components  
of   the   gli   cluster   present   (non-­functional   core   enzyme   available   for   essential   non-­
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enzymatic  interactions  with  tailoring  enzymes),  the  supplemented  2  was  not  processed  
to  more  advanced  intermediates  in  the  gli  pathway  (Figure  2.9a-­b).    
One   possible   explanation   for   the   absence   of  more   highly  modified  gli   pathway  
metabolites   in   this   feeding   experiment   is   that  2   did   not   get   in   to   the   cell.   In   order   to  
determine  if  2  was  incorporated  by  the  fungus,  we  filtered  the  mycelia  from  the  culture  
broth  of  a  25  mL  liquid  culture  (see  Appendix  B   for  details),  then  washed  the  mycelia  
twice.   The  washes   and   supernatant  were   extracted   separately   from   the  mycelia,   and  
whole-­metabolome  LC-­HRMS  analysis  of  these  samples  revealed  that  2  was  present  in  
the   mycelia   as   well   as   the   supernatant   (Figure   2.9c-­d).   Therefore,   if   2   was   an  
intermediate  in  the  gli  pathway  and  a  bona  fide  substrate  for  gli  cluster  tailoring  enzymes,  
























































































d +GliP-H1754 - Fed with 2 and 1 - mycelia 
Figure  2.9.  LC-­HRMS  analysis  of  whole  metabolome  extracts  from  GliP-­H1754A  mutant  A.  
fumigatus   strains   supplemented   with   exogenous   1   and   2   during   growth.   (a-­d)   Overlaid  
extracted-­ion-­chromatograms  for  1  (red  lines),  2  (black  lines),  9  (blue  lines)  and  10  (green  lines).  
.  
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Collectively  these  results  strongly  suggest  that  2  is  not  the  substrate  for  at  least  some  of  
gli  cluster  tailoring  enzymes.    
  
GliJ  dipeptidase  cleaves  L-­Phe-­L-­Ser:  The  gli  cluster  dipeptidase,  GliJ,  was  previously  
shown  to  be  responsible  for  converting  cyclo(L-­Phe-­L-­Ser)-­Cys-­Gly  (5)  into  cyclo(L-­Phe-­
L-­Ser)-­Cys  (7),  which  is  then  converted  into  dithiol-­cyclo(L-­Phe-­L-­Ser)  leaving  only  one  
remaining  step   to   form  dithio-­cyclo(L-­Phe-­L-­Ser)  by  GliT17,26.  The   initial  publication  on  
GliJ  did  not  provide  information  on  substrate  specificity  and  the  enzymatic  activity  was  
not  characterized  by  itself,  but  rather  shown  through  a  complex  in  vitro  assay  containing  
two  additional  enzymes,  GliK  and  GliI17.  This  doesn’t   leave  any  doubt  as  to  the  role  of  
GliJ   in   the   anabolism   of  1,   however   as   we   have   previously   seen,   enzymes   in   BGCs  
occasionally  perform  multiple  functions18.  In  order  to  determine  if  GliJ  could  have  a  dual-­
function  in  a  manner  similar  to  HasE  (described  in  Chapter  1),  we  purchased  the  gene  for  
GliJ,   then   expressed   and   purified  H6-­tagged  GliJ   from  E.   coli   (see  Appendix  B).  We  
tested  GliJ  activity  on  a  range  of  dipeptide  substrates  and  monitored  the  hydrolytic  activity  
by  LC-­MS  (Figure  B12).  In  addition  to  cleaving  thiol-­capped  L-­Cys-­L-­Gly,  GliJ  also  readily  
cleaved  L-­Phe-­L-­Ser  and  several  other  dipeptides  (Figure  B12).  Unfortunately,  we  could  
not  compare  GliJ  activity  on  L-­Phe-­L-­Ser  to  5,  as  this  intermediate  would  be  very  difficult  
to  access  synthetically.  The  first  publication  on  GliJ  used  260  L  of  a  DGliK  A.  fumigatus  
strain  to  isolate  4,  which  was  then  processed  by  recombinant  GliK  prior  to  showing  GliJ  
activity  (Figure  2.2)17.  This  would  be  a   time-­intensive  experiment   to  repeat   in  order   to  
show   the   difference   in   turnover   rates   between   L-­Phe-­L-­Ser   and   what   has   been  
hypothesized  to  be  the  true  substrate  for  GliJ,  4.    
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Conclusions:  Our   reentry   into   the   gli   pathway   has   revealed   that   despite   extensive  
speculation12,15-­17,24,   the   cyclization   of   L-­Phe-­L-­Ser   en   route   to   gliotoxin   is   not   a  
spontaneous  event  but  rather  requires  the  cyclization  activity  of  the  C2  domain.  We  also  
provide   evidence   for   the   function   of   the   enigmatic   terminal   thiolation   domain   of  GliP,  
where  it  serves  as  a  location  for  tethered  L-­Phe-­L-­Ser  to  be  modified  by  gli  cluster  tailoring  
enzymes.  The  GliP  C2  domain  and  similar  domains  found  in  other  homologous  NRPSs,  
should  be   re-­annotated  as  CT  domains   from   this  point   forward.   In   the   future   it  will   be  
necessary   to   characterize   the   early   modifications   of   L-­Phe-­L-­Ser   by   other   gli   cluster  
tailoring  enzymes.  In  particular,  in  vitro  reconstitution  of  the  activity  for  the  oxidases  GliC  
and   GliF   would   provide   key   evidence   to   clarify   the   full   mechanism   of   gliotoxin  
biosynthesis.  This  will  be  important  because  gliotoxin  is  representative  of  a  large  class  of  
NRPS-­derived   2,5-­diketopiperazines   that   are   likely   produced   via   similar   biosynthetic  
mechanisms.       
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CHAPTER  3  
  
PLANT-­LIKE  ISOQUINOLINE  ALKALOID  BIOSYNTHESIS    
IN  ASPERGILLUS  FUMIGATUS  
  
Abstract:   Natural   product   discovery   efforts   have   focused   primarily   on   microbial  
biosynthetic   gene   clusters   (BGCs)   containing   large  multi-­modular   PKSs   and   NRPSs;;  
however,  sequencing  of  fungal  genomes  has  revealed  a  vast  number  of  BGCs  containing  
smaller   NRPS-­like   genes   of   unknown   biosynthetic   function.   Using   comparative  
metabolomics,  we  show  that  a  BGC  in  the  human  pathogen  Aspergillus  fumigatus  named  
fsq,  which  contains  an  NRPS-­like  gene  lacking  a  condensation  domain,  produces  several  
novel   isoquinoline   alkaloids,   the   fumisoquins.   These   compounds   derive   from   carbon-­
carbon  bond  formation  between  two  amino  acid-­derived  moieties  followed  by  a  sequence  
that   is   directly   analogous   to   isoquinoline   alkaloid   biosynthesis   in   plants.   Fumisoquin  
biosynthesis   requires   the  N-­methyltransferase   FsqC   and   the   FAD-­dependent   oxidase  
FsqB,   which   represent   functional   analogs   of   coclaurine   N-­methyl   transferase   and  
berberine  bridge  enzyme  in  plants.  Our  results  show  that  BGCs  containing   incomplete  
NRPS   modules   may   reveal   new   biosynthetic   paradigms   and   suggest   that   plant-­like  
isoquinoline  biosynthesis  occurs  in  diverse  fungi.    
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Introduction:  One  major  source  of  medicinally  important  small  molecules  are  microbial  
BGCs  that  encode  polyketide  synthases  (PKSs)  and  nonribosomal  peptide  synthetases  
(NRPSs),   two  classes  of  multi-­functional  mega-­enzymes  that  are  usually  accompanied  
by  sets  of  tailoring  enzymes.  The  recent  surge  in  the  sequencing  of  fungal  genomes  has  
revealed  large  numbers  of  BGCs  that  do  not  appear  to  encode  enzymes  involved  in  the  
production   of   any   known   metabolites   ("orphan   BGCs")   and   thus   may   harbor   new  
biosynthetic  capabilities1-­3.  
In   search   of   new   biosynthetic  mechanisms,   we   focused   on   orphan   BGCs   that  
contain   small   NRPS-­like   genes   that   diverge   from   canonical   NRPSs   in   their   domain  
structure.  Canonical  NRPSs  include,  at  a  minimum,  one  adenylation  domain  that  selects  
and  activates  an  amino  acid  (or  related  building  block),  one  thiolation  domain  for  covalent  
attachment   of   the   activated   amino   acid,   and   a   condensation   domain   that   catalyzes  
formation  of  a  peptide  bond  between  the  tethered  amino  acid  and  another  substrate4-­6.  
However,  sequencing  of  fungal  genomes  has  additionally  revealed  numerous  genes  that  
encode  only  a  subset  of   these  domains1,2.  Such  non-­canonical,  NRPS-­like  genes  may  
feature   adenylation   and   thiolation   domains,   but   lack   condensation   domains,   and   thus  
likely  do  not  function  as  peptide  synthetases7,8.  We  hypothesized  that  analysis  of  BGCs  
including  small  NRPS-­like  genes  encoding  incomplete  modules  would  likely  reveal  novel  
biosynthetic  functions.    
Here  we  show  that  the  fsq  gene  cluster  in  A.  fumigatus,  which  features  an  NRPS-­
like  gene,  fsqF,  produces  a  series  of  novel  isoquinoline  alkaloids,  the  fumisoquins.  We  
then  demonstrate  that  FsqF,  which  lacks  a  canonical  condensation  domain,  is  required  
for   carbon-­carbon   bond   formation   between   L-­serine   and   L-­tyrosine-­derived   building  
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blocks  in  the  fumisoquin  biosynthetic  pathway.  Two  additional  enzymes  encoded  by  the  
fsq   cluster,   the   N-­methyltransferase   FsqC   and   the   FAD-­dependent   oxidase   FsqB,  
catalyze  the  formation  of  the  isoquinoline  ring  system  in  the  fumisoquins  via  a  sequence  
that  we   show   is   directly   analogous   to   the   biosynthesis   of   a   prominent   group   of   plant  
isoquinoline   alkaloids,   one   of   the   largest   families   of   medicinally   important   natural  
products9,10.    
  
FsqF  encodes  an  incomplete  NRPS  module:  Expression  of  many  fungal  orphan  BGCs  
is  under  the  control  of  the  nuclear  protein  LaeA,  a  global  regulator  of  morphogenesis  and  
virulence  factor  in  A.  fumigatus  and  other  pathogenic  fungi11,12.  Among  LaeA-­regulated  
orphan  BGCs  in  the  human  pathogen  A.  fumigatus,  the  fsq  cluster  features  a  small  NRPS-­
like   gene,   fsqF,   which   encodes   an   adenylation,   thiolation,   reductase   and   pyridoxal-­
phosphate  dependent  aminotransferase  domain  (Figure  3.1a).  Notably,  FsqF  lacks  the  
condensation   domain   that   is   essential   for   canonical   peptide   bond   formation,   and  
bioinformatic  analysis  of  the  vicinity  of  fsqF  did  not  reveal  any  genes  that  could  code  for  
a  second  NRPS  or   free-­standing  condensation  domain13.  We  found  that  expression  of  
fsqF  is  regulated  by  the  Zn(II)2Cys6-­type  transcriptional  activator  FsqA  (Figure  3.1a  and  
see  Apendix  C,  Figure  C1).  Zn(II)2Cys6  transcription  factors  are  unique  to  fungi  and  have  
been   shown   to   regulate   many   metabolic   pathways,   e.g.   aflatoxin   biosynthesis   in   A.  
flavus14.  In  addition  to  fsqF,  the  transcription  factor  FsqA  was  found  to  regulate  expression  
of  five  adjacent  genes,  annotated  as  ABC  transporter  (fsqE),  fructosyl  amino  acid  oxidase  
(fsqB),  N-­methyl-­transferase   (fsqC),   phenol   2-­monooxygenase   (fsqG),   and  ATP-­grasp  
enzyme  (fsqD),  defining  the  boundaries  of  the  fsq  cluster  (Figure  C1)13.    
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Identification   of   fsq-­cluster   derived   metabolites:   Overexpression   of   fsqA   was  
associated  with  accumulation  of  a  characteristic  brown  pigment  in  the  surrounding  media  
(Figure  C2),  suggesting  secretion  of  a  colored  metabolite(s).  For  the  identification  of  fsq-­
derived  metabolites  we  employed  2D  NMR-­based  comparative  metabolomics  (differential  
analysis  by  2D-­NMR  spectroscopy,  DANS),  which  facilitates  comprehensive  and  largely  
unbiased  detection  of  new  metabolites  associated  with  gene  cluster  overexpression15,16.  
DANS-­based  comparison  of  whole  metabolome  extracts  from  overexpression  (OE::fsqA)  
and  deletion  (ΔfsqA)  strains  revealed  several  differential  signals,  most  prominently  two  
sets  of  OE-­dependent  doublets  between  4.6  and  5.0  ppm  with  large  coupling  constants  
of  18-­20  Hz  (Figure  3.1b),  suggesting  a  diastereotopic  benzylic  CH2  group  within  a  bi-­  or  
oligocyclic   structure.   The   OE::fsqA-­dependent   metabolites   were   characterized   further  
following  partial  purification  via  reversed-­phase  chromatography,  using  a  standard  suite  
of   2D   NMR   spectra   and   high-­resolution   mass   spectrometry   (HRMS)   (Table   C6-­12).  
These  analyses  revealed  two  novel  tricyclic  isoquinoline  derivatives,  the  pyrido[1,2-­  
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Figure  3.1.  Analysis  of  the  fsq  gene  cluster  and  metabolite  production.  (a)  fsq  gene  cluster  
and  putative  assignments  of  encoded  proteins.  TF:  transcription  factor;;  FAD:  FAD-­binding  domain  
protein;;  MT:  N-­methyltransferase;;  D-­ala:  ATP-­grasp  enzyme  (D-­alanine  ligase);;  Trs:  transporter;;  
NRPS:   nonribosomal   peptide   synthetase   (A   =   adenylation,   T   =   thiolation,   R   =   short-­chain  
dehydrogenase/reductase   domain,   P:   pyridoxal   phosphate   binding   domain);;   MO:   phenol   2-­
monooxygenase.  (b)  Section  of  the  dqfCOSY  spectra  of  OE::fsqA  and  ΔfsqA  metabolite  extracts  
used  for  comparative  metabolomics  (DANS).  (c)  Identified  fsq-­dependent  compounds  fumisoquin  
A  and  B  (1  and  2),  including  stereochemical  assignments  via  NOESY  for  1  (see  Tables  C6  and  
C7),  as  well  as  structure  of  fumisoquin  C  (3),  which  decomposes  to  4  and  5.  (d)  Biosynthesis  of  
structurally  related  isoquinoline  alkaloids  in  plants  via  coclaurine  N-­methyltransferase  (CNMT),  N-­
methylcoclaurine   3’-­monooxygenase   (CYP80B),   3’-­hydroxy-­N-­methyl-­(S)-­coclaurine   4’-­O-­
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b]isoquinolines,  fumisoquin  A  (1,  Figure  3.1c)  and  fumisoquin  B  (2,  Figure  3.1c)  as  major  
metabolites   associated   with   fsq-­overexpression.   Fumisoquin   A   and   B   decompose  
gradually  during  chromatography,  likely  as  a  result  of  the  oxidation-­prone  hydroquinone  
moiety.  We  further  noted  a  deeply  purple  OE-­dependent  metabolite  that  was  not  captured  
by   DANS   because   of   decomposition   during   sample   preparation.   Optimization   of  
extraction  conditions  and  reverse-­phase  fractionation,  followed  by  2D  NMR  spectroscopic  
and  HRMS  analysis  allowed  to  identify  a  third  isoquinoline,  fumisoquin  C  (3,  Figure  3.1c),  
as   the  deeply  purple  colored  metabolite  (Figure  C3  and  Table  C3).  Upon  standing  or  
during  chromatography,  fumisoquin  C  decomposes  into  compounds  4  and  5,  which  are  
more   stable   and  were   isolated   (Figure   3.1c,   and  Figure  C4a).   Treatment   of   partially  
purified   fumisoquin   C   with   (trimethylsilyl)diazomethane   furnished   the   corresponding  
dimethyl   derivative   (Figure   C4b),   which   is   much   less   prone   to   decomposition   and  
provided   additional   NMR   spectroscopic   data   to   confirm   structure   and   relative  
configuration  of  fumisoquin  C  (Supplementary  Note).    
  
A   plant-­analogous   isoquinoline   formation   pathway:   Among   known   fungal   natural  
products,  isoquinoline  alkaloids  are  rare,  and  the  tricyclic  ring  systems  of  the  fumisoquins,  
to   the   best   of   our   knowledge,   are   unprecedented   from   fungi.   However,   the   identified  
dihydroxylated   isoquinolines  are  strikingly   reminiscent  of  a   large  and  diverse   family  of  
plant-­derived  isoquinoline  alkaloids  (pyrido[1,2-­b]isoquinolines,  e.g.  Scoulerine,  6,  Figure  
3.1d),  whose  biosynthetic  pathways  have  been  studied  extensively17-­19.  Plant  pyrido[1,2-­
b]isoquinoline   biosynthesis   proceeds   via  N-­methylation   of   a   tyrosine-­derived   catechol  
precursor,   followed   by   oxidative   cyclization   via   the   FAD-­dependent   berberine   bridge  
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enzyme   (BBE,  Figure   3.1d)17,   a  member   of   a   large   group   of   flavin-­dependent   amine  
oxidases20,21.  The  cyclization   is  believed  to  proceed  via  a   two-­step  process,  beginning  
with  FAD-­dependent  oxidation  of   the  methyl   group   to  an   iminium  species   followed  by  
electrophilic  attack  on  the  deprotonated  phenol17,19.  Because  of  the  manifold    
	  
	  
Figure   3.2.  Comparative  metabolomics   of   fsq   gene   cluster  mutants   by   HPLC-­MS.   (a-­d)  
HPLC-­MS   analysis   of   fsq-­gene   deletion   strains   in   OE::fsqA   background,   shows   ion  
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pharmaceutical   uses   of   plant   isoquinoline   alkaloids,   there   is   considerable   interest   in  
developing   microbial-­based   production   approaches22-­24,   and   yeast-­based   expression  
systems  for  several  groups  of  plant  isoquinoline  alkaloids  have  been  developed,  including  
the  berberines25-­30.  We  noted  that  the  fsq  cluster  features  a  set  of  genes  that  may  encode  
functional  analogs  of  the  berberine  biosynthetic  enzymes,  including  the  putative  phenol  
2-­monooxygenase  FsqG,  N-­methyltransferase  FsqC,  and  FAD-­dependent  oxidase  FsqB.  
Bioinformatic   analysis   revealed   several   orphan   gene   clusters   in   fungi   that   feature  
homologous   sets   of   genes   (Figure   C5).   Moreover,   the   only   other   known   fungal  
isoquinolines  have  been   linked   to  a  gene  cluster   containing  homologs   for   these   three  
genes31.    
   To  investigate  the  biosynthesis  of  the  fumisoquins,  we  created  deletion  strains  in  
the  OE::fsqA  background  for  all  genes  in  the  fsq  cluster,  except  for  fsqD  and  the  putative  
transporter   fsqE,  which  we  were  unable   to  delete,  which  could  be  due   to  a  protective  
function  of   these  proteins  as  has  been   found   in  several  other   fungal  BGCs1.  We   then  
compared  the  metabolomes  of  each  of  these  deletion  strains  with  those  of  OE::fsqA  and  
ΔfsqA   via   DANS   and   HPLC-­MS   (Figure   3.2a-­d).   We   found   that   deletion   of   the   N-­
methyltransferase   FsqC,   phenol   2-­monooxygenase   FsqG,   or   FAD-­dependent   oxidase  
FsqB   in   OE::fsqA   background   led   to   complete   abolishment   of   isoquinoline   alkaloid  
production  and  accumulation  of  a  series  of  benzyl  pyrroles  (7-­8,  Figure  3.2c  and  Figure  
3.3),  including  the  previously  reported  fumipyrrole,  7  (where  the  fsq  cluster  was  referred  
to  as  fmp32),  smaller  amounts  of  which  were  also  produced  in  the  OE::fsqA  control  strain  
(Figure  3.2c).  Comparison  of  the  carbon  skeletons  of  the  pyrroles  (7-­8,  Figure  3.3)  with  
those   of   the   fumisoquins   provided   support   for   the   predicted  N-­methyltransferase   and  
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phenol  2-­monooxygenase  functions  of  FsqC  and  FsqG,  respectively,  and  suggested  that  
the  fumisoquins  form  from  an  open-­chain  precursor  such  as  9  (Figure  3.3),  in  a  manner  
very  similar  to  that  of  plant  benzophenanthridine  alkaloid  biosynthesis18.    
   The   structure   of   the   putative   open-­chain   precursor  9   suggested   that   it  may   be  
derived  from  tyrosine  and  a  dehydroalanine  equivalent  (10,  Figure  3.3),  which  could  be  
produced   from   serine   or   cysteine   via   the   pyridoxal-­phosphate   dependent  
aminotransferase  domain  of  the  NRPS-­like  protein  FsqF10,33.  Growing  the  OE::fsqA  strain  
in  media  supplemented  with  different  stable-­isotope  labeled  amino  acids,  we  found  that  
L-­tyrosine  and  L-­serine  are  incorporated  into  the  fumisoquins  and  pyrroles  (1-­3  and  8)  in  
a  manner  consistent  with  the  biosynthetic  model  shown  in  Figure  3.3,  whereas  L-­cysteine  
is  not  incorporated  (Figure  3.4a,b  and  Figure  C6,  C7b-­d).  Furthermore,  we  showed  that  
the  L-­methionine  methyl  group   is   incorporated   into   the   fumisoquin   ring  systems  at   the  
predicted  position,   in   agreement  with   the   putative   function   of   FsqC  as  an  S-­adenosyl  
methionine-­dependent  N-­methyltransferase  (Figure  3.4c  and  Figure  C8).    
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Figure  3.3.  Model  for  fumisoquin  biosynthesis.  (A  =  adenylation,  T  =  thiolation,  R  =  short-­chain  
dehydrogenase/reductase  domain,  P:  pyridoxal  phosphate  binding  domain),  [Red.]  =  reduction,  
[Ox.]  =  oxidation.  The  proposed  mechanism  for  FsqB-­mediated  isoquinoline  formation  is  based  
on  functional  similarity   to  plant  BBE17-­19,  see  Figure  3.5   for  details.  The  role  of   the  ATP-­grasp  
enzyme  FsqD  in  activating  tyrosine  to  form  19  is  putative.    
  
FsqB  is  a  functional  analog  of  plant  BBE:  To  test  whether  FsqB  catalyzes  isoquinoline  
ring  formation  in  1-­3  and  thus  acts  as  a  functional  ortholog  of  plant  BBE,  we  recombinantly  
produced  polyhistidine-­tagged  FsqB  in  E.  coli  (Figure  C9).  We  then  assayed  its  activity  
on  a  range  of  potential  substrates  that  mimicked  the  tyrosine-­derived  portion  of  putative  
intermediate  9.  Whereas  N-­methyl  dopamine  did  not  react,  we  found  that  FsqB  converts  
N-­methyl  DOPA  11,  prepared  via  a  simple  one-­step  procedure,  directly  into  isoquinoline  
12  (Figure  3.5a  and  Figure  C10,  C12a).  We  first  tested  FsqB  activity  on  11  on  a  small  
scale  suitable  for  LCMS,  which  yielded  near  quantitative  conversion  to  12  within  3–4  h  
(100  mM  phosphate  buffer,  pH  7,  KM  =  142.5  ±  42.9  μM)  (Figure  3.5b  and  Figure  C11).  
Next  we  demonstrated  isoquinoline  formation  from  11  on  a  milligram  scale  by  conducting  
the  reaction   in  an  NMR  tube  using  deuterated  phosphate  buffer   (Figure  3.5c  and  see  
S
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Appendix   C).   Notably,   FsqB-­catalyzed   formation   of   12   proceeds   with   complete  
regioselectivity,   as   the   alternative   cyclization   product,   6,7-­dihydroxy-­1,2,3,4-­
tetrahydroisoquinoline-­3-­carboxylic   acid,   13,   which   does   form   alongside   12   in   a   non-­
enzymatic   reaction   of   DOPA  with   formaldehyde,   was   not   observed   (Figure   C10   and  
Appendix  C).  In  contrast,  we  observed  no  cyclized  products  when  incubating  FsqB  with  
N-­methyl-­L-­tyrosine,  N,N-­dimethyl  DOPA,  or  the  BBE-­substrate  (S)-­reticuline,  suggesting  
that   both   a   catechol  moiety   and   a   secondary   β-­N-­methylamine   are   required   for   FsqB  
activity  (Figure  C12b-­d).    
   Next  we  asked  whether  the  mechanism  of  isoquinoline  formation  as  catalyzed  by  
FsqB  is  directly  analogous  to  that  of  the  extensively  studied  plant  enzyme,  BBE9,17,19,34.  
Fluorescence  analysis  of  recombinant  FsqB  showed  excitation  and  emission  maxima  at  
461  nm  and  530  nm,  respectively  (Figure  C9),  suggesting  FsqB  utilized  a  flavin  cofactor,  
as  predicted35.  Further  proteomic  analysis  of  FsqB  confirmed  the  presence  of  FAD,  which  
was  found  to  be  covalently  bound  to  cysteine-­414  (Figure  C13a  and  Table  C3).  FAD  is  
also  part  of  BBE  where  it  is  bound  to  a  histidine  residue17.  Flavin  reduction  during  catalytic  
cycling  of  BBE   is   recovered  with  molecular  oxygen  generating  hydrogen  peroxide17,  a  
characteristic  that  was  also  observed  with  FsqB  utilizing  an  Amplex  Red  assay  (Figure  
C13b).   Isoquinoline   formation   as   catalyzed   by   BBE   likely   proceeds   via   an   imine  
intermediate  in  a  two-­step  mechanism19.  To  test  whether  isoquinoline  formation  via  FsqB  
also   involves   an   imine   intermediate,   we   incubated   FsqB  with  N-­methyl-­L-­tyrosine  14,  
which  we  hypothesized  may  represent  an  oxidation-­competent  substrate  for  FsqB  but,  as  
shown  above,  does  not  get  cyclized,  in  the  presence  of  the  electrophile  trapping  agent  
dimedone,  15.  This  reaction  produced  the  adduct  16  as  well  as  free  tyrosine,  consistent  
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with  capture  of  an  imine  intermediate,  17,  by  dimedone  or  water  (Figure  3.5d).  Therefore,  
it  appears  that  the  fungal  enzyme  FsqB  catalyzes  isoquinoline  formation  via  a  two-­step  




Figure  3.4.  The  fumisoquins  incorporate  L-­serine,  L-­tyrosine,  and  an  L-­methionine-­derived  
methyl  group.  Shown  are  HPLC-­MS  ion  chromatograms  derived  from  fungal  cultures  grown  with  
(a)  L-­serine  or  L-­[13C3,15N]-­serine,  (b)  L-­tyrosine  or  L-­[2-­13C]-­tyrosine  and  (c)  L-­methionine  or  L-­
[1'-­13C]-­methionine.   In  contrast,  L-­cysteine   is  not   incorporated  (Figure  C6).  See  Figure  C7   for  
mass  spectra.  (*)  denotes  labeled  isotopes.  In  the  case  of  L-­[13C3,15N]-­serine,  loss  of  15N  due  to  
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Carbon-­carbon  bond  formation  requires  FsqF:  Next  we  recombinantly  produced  the  
FsqF  adenylation  domain  to  test  whether  it  activates  L-­tyrosine  or  L-­serine,  as  suggested  
by   the   stable   isotope   labeling   study,   using   the   ATP-­[32P]pyrophosphate   exchange  
activity36.  However,  neither  enantiomer  of  serine  or  tyrosine  showed  any  activity  in  the  in  
vitro  assay  nor  did  any  other  tested  standard  amino  acid  (Figure  C14).  These  results  may  
indicate  that  the  recombinantly  expressed  FsqF  adenylation  domain  was  not  functional  or  
that  the  true  substrate  is  not  a  standard  amino  acid.  Based  on  the  homology  of  the  PLP-­
dependent  domain  in  FsqF  to  other  serine  dehydrogenases13,33,  we  hypothesized  that  L-­
serine  may  first  be  converted  into  dehydroalanine,  which  is  then  activated  and  tethered  
to  the  thiolation  domain  (Figure  3.3).    
   To   further   investigate   the   role   of   the   NRPS-­like   enzyme   FsqF   in   fumisoquin  
biosynthesis,  we  analyzed  the  effect  of   fsqF  deletion  on  the  OE::fsqA  metabolome.  As  
anticipated,   production   of   the   fumisoquins   (1-­3)   as   well   as   the   pyrroles   (7-­8)   was  
completely  abolished   in  OE::fsqA-­ΔfsqF  (Figure  3.2d).  Significantly,  we  also  observed  
production   of   a   single,   brightly   red   shunt   metabolite,   the   anthranilic   acid-­substituted  
isoquinoline  18   (Figure   3.2d   and  Figure   3.3).   Feeding   experiments   of   the  OE::fsqA-­
ΔfsqF  mutant  with  stable-­isotope  labeled  L-­tyrosine  confirmed  that  the  isoquinoline  ring  
system  in  18   is  derived  from  tyrosine,  as  in  the  case  of  the  fumisoquins  (Figure  C15).  
Incubation  of  12,  obtained  in  vitro  from  recombinant  FsqB,  with  anthranilic  acid  (19)  led  
to  formation  of  shunt  metabolite  18,  consistent  with  a  model  in  which  shunt  metabolite  18  
forms   non-­enzymatically   from   12   via   oxidation   to   the   corresponding   o-­quinone,  
subsequent  capture  of  anthranilic  acid,  and  decarboxylation  (Figure  C16).  Compound  12  
was  not  observed  in  any  of  the  analyzed  OE::fsqA-­ΔfsqF  extracts,  likely  as  a  result  of  this  
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compound's   high   susceptibility   to   oxidize   to   the   reactive   o-­quinone,   which   is   rapidly  
captured  by  anthranilic  acid  (Figure  C16).  
   The  identification  of  shunt  metabolite  18  indicates  that  the  NRPS-­like  protein  FsqF  
is   only   required   for   addition   of   a   serine-­derived   dehydroalanine   moiety   to   activated  
tyrosine,  but  is  not  essential  for  the  subsequent  steps  leading  to  isoquinoline  formation,  
and   that   a   different   enzyme,   likely   the   ATP-­grasp   enzyme   FsqD,   is   responsible   for  
activation   of   tyrosine   (Figure   3.3).   The   production   of   shunt   metabolite   7   would   then  
indicate  that  FsqD  is  also  capable  of  activating  phenylalanine;;  however,  phenylalanine-­  
	  
	  
Figure  3.5.  Enzymatic  activity  of  recombinant  FsqB.  (a)  Synthesis  of  N-­methyl-­3',4'-­dihydroxy-­
DL-­phenylalanine  11   (top)  and  regioselective  conversion  of  11   into  12  by  purified  recombinant  
FsqB  (bottom).  The  isomer  13  does  not  form.  (b)  Ion  chromatograms  at  indicated  timepoints  for  
the  FsqB-­catalyzed  in  vitro  conversion  of  11  to  12  (100  mM  phoshate  buffer,  pH  7,  100:1  substrate  
to  enzyme).  (c)  1H  NMR  spectra  of  a  sample  of  11  (1  mM  phosphate  buffer  in  D2O)  prior  to  FsqB  
addition   (top)   and   1   h   post   FsqB   addition   (333:1   substrate   to   enzyme),   showing   selective  
conversion  of  11  into  12  (bottom)  (d)  Ion  chromatograms  showing  formation  of  tyrosine  and  16  
as  a  result  of  capture  of  intermediate  17  by  H2O  or  dimedone,  15  (1.5  μM  FsqB  and  400  μM  N-­
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derived  intermediates  only  lead  to  the  production  of  7,  as  expected  based  on  the  predicted  
function   of   FsqG   as   a   phenol   2-­monooxygenase13   and   given   the   observation   that  
recombinantly  produced  FsqB  requires  a  catechol  as  substrate.  FsqD  has  homology  to  
carboxylate-­amine  ligases  that   furnish  aminoacyl  phosphate  from  ATP  and  amino  acid  
precursors37,38.   In  a   recent  example,   the  FsqD  homolog  PGM1  was  shown   to  activate  
non-­proteinogenic   amino   acids   for   peptide-­bond   formation   in   pheganomycin  
biosynthesis39.   In   contrast,   FsqD   appears   to   activate   tyrosine   (or   phenylalanine)   for  
subsequent  condensation  with  serine-­derived  dehydroalanine  (Figure  3.3),  providing  a  
first  example  for  a  novel  carbon-­carbon  bond  forming  strategy  in  fungi.    
  
Conclusions:   Our   analysis   of   the   fsq   cluster   revealed   a   plant-­like   strategy   for   the  
biosynthesis   of   oligocyclic   alkaloids   in   fungi.   The   biosynthetic   steps   of   phenol-­
hydroxylation,  N-­methylation,  and  oxidative  cyclization  appears  to  be  the  same  in  plants  
and   fungi,   and   thus   the   corresponding   enzymes   can   be   considered   functionally  
equivalent.  Sequence  analysis  does  not  suggest  homology  for  these  proteins,  though  it  
is   notable   that   cyclization   proceeds   via   analogous   two-­step   mechanisms   that   are  
catalyzed  by  FAD-­dependent  oxidases  in  both  fungi  and  plants19,  presenting  a  striking  
case  of  convergent  evolution  of  specialized  metabolic  pathways.  Given  that  analysis  of  
available   fungal   genomes13   revealed   many   co-­occurrences   of   homologs   of   the   N-­
methyltransferase   fsqC  and  FAD-­dependent  oxidase   fsqB   (Figure  C5),   it  seems   likely  
that   fungi   are   capable   of   producing   a   diverse   range   of   yet   undiscovered   isoquinoline  
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alkaloids.  For  example,  in  addition  to  Aspergillus  spp.,  the  genomes  of  plant  pathogenic  
Fusarium  spp.  feature  BGCs  that  include  homologues  for  most  fsq  genes40.    
   Together  with  other  recent  examples7,8,  the  identification  of  the  fumisoquins  shows  
that  analysis  of  gene  clusters  containing  incomplete  NRPS  modules  can  reveal  intriguing  
new   structures   and   biosynthetic   strategies.   It   remains   unclear,   however,   whether   the  
biosynthetic  roles  of  NRPS-­like  enzymes  can  be  predicted,  as  current  examples,  though  
few,  hint  at  considerable  functional  diversity.  For  example,  two  NRPS-­like  enzymes  in  A.  
flavus,  named  LnaA  and  LnaB,  have  been  shown  to  produce  a  series  of  tyrosine-­derived  
piperazines,  pyridines  and  morpholines7,  whereas  an  NRPS-­like  enzyme  from  A.  terreus  
was  shown  to  reduce  products  of  an  accompanying  non-­reducing  PKS8.  The  example  of  
the   fsq  pathway  demonstrates  that  NRPS-­like  enzymes   lacking  condensation  domains  
may  nonetheless  contribute  to  ligating  amino  acids,  albeit  via  formation  of  carbon-­carbon  
bonds.  Characterization  of  BGCs  featuring  small  NRPS-­like  genes  may  thus  reveal  new  
types  of  alliances  of  NRPS-­like  enzymes  with  other  amino  acid-­activating  proteins,  e.g.  
ATP-­grasp  enzymes  such  as  FsqD.    
This  work  supports  a  mining  strategy  of  assessing  fungal  natural  products,  beyond  
not  only  canonical  NRPS  but  also  PKS-­like  genes  and  even  those  fungal  clusters  lacking  
NRPS  or  PKS-­like  domain  genes  all  together.  Recent  examples  have  focused  on  cyclic  
ribosomal  peptides41  but  a  bioinformatic  scan  of   fungal  genomes  and  expression  data  
shows  the  existence  of  yet  more  alternative  biosynthetic  clusters  –   lacking  NRPS-­like,  
PKS-­like   and   canonical   ribosomal   peptides   -­   suggestive   of   unexplored   chemical  
diversity42.  Efforts  to  characterize  such  alternative  clusters  may  yield  even  more  unique  
fungal  chemistry.    
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CHAPTER  4  
  
BIOSYNTHESIS  OF  THE  STRUCTURALLY  UNPRECEDENTED  IMIZOQUINS  IN  THE  
PLANT  PATHOGENIC  FUNGUS  ASPERGILLUS  FLAVUS    
  
Abstract:  Identification  of  fungal  isoquinoline  alkaloids  has  remained  scarce  despite  the  
vast   number   of   these   compounds   that   have   been   characterized   from   plants.   It   was  
recently  shown  that  the  human  pathogen  Aspergillus  fumigatus  biosynthesizes  a  unique  
class  of  fungal  isoquinolines,  called  the  Fumisoquins.  Formation  of  the  isoquinoline  ring  
present  in  the  structure  of  the  Fumisoquins  was  shown  to  occur  via  a  three-­step  enzymatic  
mechanism   directly   analogous   to   the   mechanism   used   by   plants.   While   the   genes  
responsible   for   fungal   isoquinoline   formation   lack   any   homology  with   the   biosynthetic  
genes  in  plants,  they  appear  to  be  conserved  across  diverse  fungi.  Here  we  selected  one  
such  predicted  isoquinoline  producing  cryptic  biosynthetic  gene  cluster  (BGC)  from  the  
plant   pathogenic   fungus  A.   flavus   for   further   characterization,   which   we   call   the   imq  
cluster.  LC-­MS  comparative  metabolomics  followed  by  detailed  2D  NMR  spectroscopic  
analysis   of   overexpression   strains   of   the   transcription   factor   ImqK   revealed   imq-­
dependent  production  of  a  class  of   tripeptide-­derived  alkaloids,   the   imizoquins.  These  
compound   include   the  expected   isoquinoline  moiety   as  part   of   a   tricyclic   imidazo[2,1-­
a]isoquinoline  ring  system,  for  which  there  are  no  other  examples  among  known  natural  
products.  As   in   the  case  of   the   fumisoquins,   the   isoquinoline  portion  of   the   imizoquins  
appears  to  be  derived  from  hydroxylation,  N-­methylation  and  subsequent  cyclization  of  
tyrosine.  This  work  corroborates  the  prediction  that  isoquinoline  biosynthesis  is  conserved  
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across  diverse  fungi  and  highlights  the  plethora  of  remaining  BGCs  that   likely  produce  
novel  compounds  that  are  assembled  around  the  isoquinoline  scaffold.    
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Introduction:   Aspergillus   flavus   is   one   of   the   most   notorious   and   deleterious   plant  
pathogens   in   the  world1.  One  mechanism  by  which  A.   flavus   exhibits   its   high-­level   of  
pathogenicity   towards   plants   is   through   the   production   of   small   molecules   (SMs)   by  
secondary   metabolic   biosynthetic   gene   clusters   (BGCs)2.   The   most   well-­known   SM  
produced  by  A.   flavus   is  Aflatoxin,  a  carcinogenic  polyketide,  which,  conservatively,   is  
responsible   for  millions  of  dollars   in  crop   loss  each  year   in   the  United  States  alone3,4.  
Aflatoxin   production   and   expression   of   its   BGC,   is   positively   affected   by   the   global  
secondary  metabolic  regulator  and  virulence  factor  LaeA5,6.   In  addition  to  the  Aflatoxin  
BGC,  LaeA  also  positively  affects  the  expression  of  other,  yet  to  be  characterized  BGCs.  
Here  we  sought  to  characterize  one  such  LaeA  regulated  cryptic  BGC  from  A.  flavus.    
  
A.   flavus  BGC  regulated  by  LaeA  produces   isoquinolines:   In  our  search   for  other  
LaeA  regulated  and  putative  isoquinoline  producing  gene  clusters  we  identified  an  eleven-­
gene  cluster,  which  we  named  the  imq  cluster  (Figure  4.1a).  The  eleven  cluster  genes  
encode  two  small  proteins  with  no  predicted  function  (imqA  and  imqI)  a  canonical  three-­
module  non-­ribosomal  peptide  synthetase   (NRPS,   imqB),  a  phenol  2-­monooxygenase  
(imqC),   two   transporters   (imqD   and   imqJ),   a   gibberilin   oxidase   (imqE),   an   N-­
methyltransferase   and   an  O-­methyltransferase   (imqF   and   imqG,   respectively),   a   FAD  
dependent  oxidase  (imqH),  and  a  C6  transcription  factor  (imqK)  (Figure  4.1a).  Notably,  
imqC,  imqF,  and  imqH  are  homologs  of  fsqB,  fsqC,  and  fsqG,  which  carry  out  the  three  
enzyme   transformation   of   tyrosine   into   tetrahydroisoquinoline   en   route   to   the  
Fumisoquins7.   In   order   to   facilitate   chemical   characterization   of   the   imq-­associated  
metabolites  we  choose  to  make  an  A.  flavus  overexpression  (OE)  strain  for  the  putative  
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C6  transcription  factor  ImqK.  Often  SM  producing  BGCs  are  regulated  by  C6  transcription  
factors,  enabling  whole  cluster  up-­regulation  by  OE  of  that  single  gene8.  Replacement  of  
the  imqK  promoter  with  the  constitutive  gdpA  promoter  (OE::imqK)  resulted  in  induction  
of  the  other  10  cluster  genes  (Figure  4.1b)  and  yielded  a  purple  pigmented  strain  (Figure  
D1).  Two  cluster  flanking  genes,  (AFLA_064220  and  AFLA_064340)  were  not  regulated  
by  ImqK  and  thus  likely  define  the  boundaries  of  the  cluster  (Figure  4.1b).    
  
Imizoquin  A  and  B  are  the  major  products  of  the  imq  BGC:  To  probe  the  biosynthetic  
function  of  the  imq  cluster  we  employed  liquid  chromatography  –  mass  spectrometry  (LC-­
MS)-­based  comparative  metabolomics9.  We  compared  whole  metabolome  extracts  of  the  
OE::imqK   strain   to  WT  A.   flavus.  Since   the   imq   cluster   is  not  expressed   in  WT  under  
Figure  4.1:  ImqK  controls  imq  cluster  gene  expression  and  metabolite  production.  
(a)   imq  gene  cluster  and  putative  assignments:  Hyp:  hypothetical  protein;;  NRPS:  non-­
ribosomal  peptide  synthetase  (A  =  adenylation,  T  =  thiolation,  C  =  condensation,  TE  =  
thioesterase  domain):  MO:  phenol  2-­monooxygenase;;  Trs:   transporter;;  GOX:  giberillin  
oxidase;;   N-­MT:   N-­methyltransferase;;   O-­MT:   O-­methyltransferase;;   FAD:   FAD-­binding  
domain   protein;;   TF:   transcription   factor.   (b)   northern   blot   analysis   of   imq   cluster   and  
flanking  genes  in  OE::imqK  and  WT  strains.  (c)  LC-­MS  extracted-­ion-­chromatograms  for  
1-­2  from  analysis  of  crude  extracts  from  OE::imqK  and  WT.  (d)  structure  of  Imizoquins  A  
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laboratory   conditions  we  expected   to   observe   complete   differential   production   of   imq-­
associated  metabolites  in  the  OE::imqK  strain  relative  to  WT.  Given  that  liquid  cultures  of  
the  OE::imqK  strain  had  a  purple  pigmentation,  we  utilized  the  visible-­light  detector  during  
our  LC-­MS  analysis  to  search  for  peaks  with  an  absorbance  corresponding  to  a  purple  
pigment  (420  nm).  By  this  method  we  found  two  starkly  differential  components  of   the  
whole  metabolome  of  OE::imqK   compared   to  WT,  with   low-­resolution  mass-­to-­charge  
ratios  of  565.2  and  581.2   (Imizoquin  A,  1  and  B,  2,  Figure  4.1c-­d).  To  determine   the  
structure  of  1-­2  we  grew  large  scale  liquid  cultures  of  OE::imqK  and  conducted  several  
rounds   of   chromatographic   enrichment   (see   Appendix   D   for   details).   Following  
chromatographic  enrichment  and  a  high-­resolution  mass  spectrometric  analysis  (Table  
D1),  a  standard  suite  of  2D-­NMR  spectroscopic  experiments  was  utilized  to  obtain   full  
structural  information  for  1-­2.    
  
The   imizoquins  are  tri-­peptide   imidazo[2,1-­a]isoquinolines:  Analysis  of   the  1H  and  
dqfCOSY   spectra   for   1-­2   revealed   very   similar   spectroscopic   features   for   both  
compounds,  as  expected  because   their  high-­resolution  mass-­to-­charge  ratios  differ  by  
only  a  single  oxygen  (Table  D1  and  Appendix  D  Spectra).  Therefore,  we  will  limit  the  
description  of  our  structural  elucidation  to  1  (Figure  4.2).  The  aromatic  region  of  the  1H  
and  dqfCOSY  spectra   for  1   showed   two  doublets,  H-­19  and  H-­22   (dH   7.50  and  7.12,  
respectively)   that   each   coupled   to   a   triplet,   H-­20   and   H-­21   (dH   6.89   and   6.99,  
respectively),  which  also  coupled  with  each  other.  This  in  addition  to  the  presence  of  a  
singlet,  H-­16  (dH  6.93)  was  strongly  indicative  of  a  substituted  indole  moiety,  such  as  a  
tryptophan.  H-­16  showed  a  long-­range  1H-­1H  coupling  to  a  diastereostopic  methylene,  H-­
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14a/b   (dH   3.05   and   3.12),   which   had   a   13.8   Hz   germinal   coupling   constant   and   one  
additional  1H-­1H  coupling   to  a  methine,  H-­6  (dH  4.20),  entirely  consistent  with   the  beta  
position  of  an  amino  acid.  HMBC  correlations   from  H-­16   to  C-­14  and   the  other   indole  
carbons  C-­18  and  C-­23  unequivocally  confirmed  the  presence  of  a  tryptophan  moiety  in  
the  structure  of  1.  
In  order  to  extend  out  from  the  tryptophan  spin-­system  into  the  rest  of  the  molecule  
we   looked   at   long-­range   1H-­1H   couplings   of   the   alpha   proton   (H-­6)   of   the   tryptophan  
moiety.  In  addition  to  coupling  with  H-­14,  H-­6  also  showed  a  weak  1H-­1H  coupling  with  a  
methine,  H-­8  (dH  5.53)  and  showed  an  HMBC  correlation  to  a  carbonyl  with  a  chemical  
shift  consistent  of  cyclic  amides,  C-­5  (dC  176.44),  suggesting  that  H-­6  and  H-­8  were  part  
of  a  fused  imidazolidine  ring  system.  H-­8  showed  an  addition  long-­range  1H-­1H  coupling  




































1: R = H
2: R = OH
Figure   4.2:  Structure   elucidation   of   1   and   2.   Showing   key   COSY   correlations   (blue  
double-­headed   arrows)   and   key   HMBC   correlations   from   each   proton   to   the   indicated  
carbon  (red  single-­headed  arrows).    
	   64	  
diastereotopic  methylene,   H-­2a/b   (dH   2.67   and   1.54).   H-­2a   and  H-­2b   had   a   germinal  
coupling   constant   of   17.9   Hz,   suggesting   they   were   part   of   a   bi-­cyclic   fused  
heteroaromatic  ring  system,  such  as  tetrahydroisoquinoline7.  HMBC  correlations  from  H-­
2a/b   showed   two   carbonyls,   C-­10   (dC   183.50)   and   C-­13   (dC   184.22),   as   well   as   two  
quaternary  carbons,  C-­1  (dC  134.65)  and  C-­9  (dC  145.92).  H-­8  also  showed  an  HMBC  
correlation  to  C-­1  and  the  broadness  of  the  signal  for  H-­8  meant  this  was  likely  a  three-­
bond   HMBC   correlation   (three-­bond   HMBC   correlations   are   strongest   in   cyclic   spin-­
systems),  which  placed  C-­1  three  bonds  away  from  H-­8.  This  in  addition  to  the  presence  
of  a  methoxy  group,  H3-­32  (dH  3.86),  which  showed  an  HMBC  correlation  to  a  quaternary  
carbon,   C-­12   (dC   139.23)   indicated   the   structure   of   1   contained   a   highly   oxidized  O-­
methoxy  quinone.  The  HMBC  correlation  from  H-­3  to  C-­5  confirmed  the  presence  of  a  
imidazo[2,1-­a]isoquinoline  ring  system  in  1-­2.    
Having  established  the  tri-­cyclic   imidazo[2,1-­a]isoquinoline  ring  system  joined  to  
tryptophan  we  looked  for  connectivity  to  the  last  remaining  portion  of  the  molecule.  The  
HR-­MS  derived  molecular  formula,  C28H30N4O9,  suggested  we  were  missing  a  structural  
feature  with  a  molecular  formula  of  C6H13NO3.  The  missing  formula  corresponded  nicely  
to  hydroxy-­leucine  (in  the  case  of  1)  or  dihydroxy-­leucine  (for  2).  This  in  addition  to  the  
peptidic   nature   of  1-­2   suggested   that   the   last   point   of   connection  would   likely   be   the  
carboxy   group   in   the   three-­position   of   the   isoquinoline   ring   (derived   from   L-­tyrosine  
incorporation).  Indeed,  another  methine,  H-­26  (dH  4.28)  showed  an  HMBC  correlation  to  
the   tyrosine   derived   carbonyl,   C-­24   (dC   171.24).   H-­26   had   a   1H-­1H   coupling   with   a  
methylene,   H-­27a/b   (dH   1.57   and   1.77),   which   had   only   one   other   1H-­1H   coupling   to  
methine,  H-­28  (dH  1.57).  H-­26  and  H-­27a/b  both  showed  an  HMBC  correlation  to  the  last  
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carbonyl  present  in  the  structure  of  1-­2,  C-­31  (dC  175.92),  which  was  not  observed  by  any  
other  protons,  suggesting  it  was  the  free  carboxylic  acid.  This  was  further  confirmed  by  
the  propensity  of  1-­2  to  ionize  in  electrospray  negative  ionization  [M-­H]-­.  In  addition  to  1H-­
1H  coupling  with  H-­27a/b,  H-­28  also  showed  a  1H-­1H  coupling  to  a  terminal  methylene,  
H2-­30   (dH   3.31)   and   a   methyl,   H3-­29   (dH   0.84),   which   collectively,   confirmed   the  
incorporation  of  a  5-­hydroxy-­L-­leucine  in  the  structure  of  1  and  5,5-­dihydroxy-­L-­leucine  in  
the  structure  of  2  (see  Table  D4-­5  for  complete  chemical  shift  table).    
  
Imizoquins   A   and   B   are   structurally   unprecedented   natural   products:   Upon  
completion   of   the   structural   elucidation   of   1-­2   we   searched   Reaxys   and   Scifinder  
databases  to  find  related  compounds  derived  from  natural  sources.  Our  search  revealed  
a  structurally-­related  set  of  isoquinoline  alkaloids  derived  from  A.  oryzae  called  TMC-­2A-­
B  (3-­4,  Figure  4.3),  which  were  identified  in  1997  by  Asai  and  coworkers10.  TMC-­2A-­B  
were  shown  to  be  dipeptidyl  peptidase  IV  inhibitors.  Additionally,  our  search  showed  that  
more   recently,   in   2012,   Imamura   and   coworkers   identified   a   gene   involved   in   the  
biosynthesis  of  3-­4,  which  at  that  time  they  renamed  3  as  Wyk-­111.  The  gene  identified  
by  Imamura  and  coworkers  is  a  part  of  a  BGC  in  A.  oryzae  that  also  possesses  homologs  
to   fsqB,   fsqC,   and   fsqG,   further   confirming   the   conserved   nature   of   isoquinoline  
production   across   a   range   of   fungal   species7.  The   realization   of   the   existence   of  3-­4  
prompted  us  to  revisit  our  LC-­HRMS  analysis  of  whole  metabolome  extracts  from  liquid  
cultures  of  the  OE::imqK  strain.  Somewhat  unsurprisingly,  we  found  that  the  OE::imqK  
strain  also  produces  appreciable  quantities  of  3-­4  (Figure  D2),  suggesting  that  3-­4  are  
intermediates  or  shunt  metabolites  in  the  imq  pathway,  as  they  lack  the  imidazolidine  ring  
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system   present   in   1-­2.   The   structural   distinction   between   1-­2   and   3-­4   is   important  
because   the   simple   isoquinoline   motif   in   3-­4   is   widespread   among   natural   products,  
however,  the  fused  tricyclic  imidazo[2,1-­a]isoquinoline  ring  system  in  1-­2,  to  the  best  of  
our  knowledge  does  not  exist  among  other  known  natural  products.    
  
Imizoquin  A  and  B  could  serve  as  ROS  quenching  metabolites  in  fungi:  When  we  
were  conducting  our  LC-­HRMS  analysis  to  survey  the  OE::imqK  strain  for  the  previously  
identified   isoquinolines   (3-­4)   we   also   identified   other   features   in   the  metabolome   that  
appeared   to   be   imq-­associated   metabolites   based   on   their   high-­resolution   mass-­to-­
charge  ratios  of  583.2046  and  579.1733.  Chromatographic  enrichment  (Appendix  D)  of  
these   new   imq-­associated   features   followed   by   full   2D-­NMR   spectroscopic  
characterization   revealed   they   were   indeed   related   to   1-­2,   and   each   represented   a  
different   oxidation   state   of   the   same   scaffold   (Table  D6-­7   for   NMR   assignments   and  
Figure   4.3:   Structures   of   previously   identified   isoquinolines   (3-­4)   and   novel  
Imizoquins  (4-­5).  Stereochemistry  is  not  defined  for  the  imidazo[2,1-­a]isoquinoline  ring  













































TMC-2A (Wyk-1), 3: R = OH
TMC-2B, 4: R = H
Imizoquin C, 5 Imizoquin D, 6
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Appendix  D  for  NMR  spectra).  In  accordance  with  standard  naming  routines  we  called  
these  compounds  Imizoquin  C  and  Imizoquin  D  (5  and  6,  respectively,  Figure  4.3).  The  
structural  difference  between  2  and  5  is  a  quinone  to  hydroquinone  (2  to  5),  suggesting  
that  1-­2  may  serve  as  a  role  in  fungal  redox  chemistry  (Figure  4.4).  To  test  this  hypothesis  
we  isolated  several  milligrams  of  1  from  OE::imqK  (see  Appendix  D  for  details)  cultures  
and  subjected  the  purified  compound  to  a  total  antioxidant  assay  (TAC,  Figure  D3)12.  In  
the  TAC  assay  1   showed  a   concentration   dependent   increase   in   antioxidant   capacity  
(Figure  D3).  The  amount  of  TAC  exhibited  by  1  was  comparable  to  uric  acid  (a  standard  
measure  of  TAC)   for  concentrations  as   low  as  3  µM,  which   is  consistent  with   isolated  
quantities  of  Imizoquins  A  and  B  (2-­4  mg  /  L  of  liquid  culture).  In  addition  to  Imizoquin  A  
and  B  it  is  likely  the  full  suite  of  imq-­dependent  metabolites  also  have  antioxidant  capacity,  
suggesting  a  possible  biological  function  for  the  imq  cluster  is  to  produce  ROS  quenching  
metabolites13.   This   could   be   in   an   effort   to   provide   resistance   to   the   solar   radiation-­
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Figure   4.4:   Mechanism   showing   how   imizoquins   could   serve   a   role   in   fungal  
redox:  Conversion  of  2  into  5  through  the  reduction  of  the  quinone  to  the  hydroquinone,  
for  example  by  glutathione  and  vice-­versa  oxidation  5  into  2  through  ROS  species  such  
as  H2O2,  converting  the  hydroquinone  back  to  the  quinone.    
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hope  to  explore  the  biological  activity  of  the  imizoquins  more  in  the  future,  however,  the  
existing  data  supports   the   increasingly   realized  essential   role  of  secondary  metabolite  
BGC’s  in  fungal  biology15.    
  
Imq-­dependent  metabolite  profile  reveals  a  model  for  imizoquin  biogenesis:  Once  
we   had   established   the   major   and   minor   products   of   the   imq   custer   and   a   potential  
biological  role  for  these  metabolites  we  sought  to  understand  their  biogenesis.  Since,  part  
of   the   imq   cluster   shares   high-­homology   with   tailoring   genes   in   the   fsq   cluster,   the  
mechanism   for   isoquinoline   formation  en   route   to   the   imizoquins   did   not   need   further  
exploration.  Normally,  to  gain  insights  into  the  role  of  each  individual  gene  (and  therefore  
the  enzyme  encoded)  in  a  BGC  we  would  construct  double-­mutants  with  individual  genes  
deleted  in  the  OE::imqK  background16.  This  however,  seemed  like  an  extensive  task  for  
the  imq  pathway,  since  the  homology  for  many  of  the  tailoring  enzymes  offered  enough  
information  to  provide  an  accurate  putative  function  in  the  biogenesis  of  1-­2.  Furthermore,  
unlike  the  fsq  pathway  (Chapter  3)  the  NRPS,  imqB,  is  a  canonical  three-­module  NRPS  
with  a  terminal  thioesterase  domain  (TE,  Figure  4.1a).  This  indicated  that  the  assembly  







































1: R = H












Figure  4.5:  Potential  model  for  biogenesis  of  1-­2  and  structure  of  shunt  metabolite  7.  
Stereochemistry   is  not  defined   for  7  because  we  currently   lack  spectroscopic  evidence  to  
support  a  specific  configuration.    
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where  C1  and  C2  catalyze  the  formation  of  two  peptide  bonds,  first  between  T1-­tethered  
L-­Trp  and  T2-­tethered  L-­Tyr,  then  T2-­tethered  L-­Trp-­L-­Tyr  dipeptide  is  captured  by  L-­Leu  
on  T3.  Lastly,  the  T3-­tethered  tripeptide  (L-­Trp-­L-­Tyr-­L-­Leu)  is  offloaded  from  the  NRPS  
by  the  TE  domain  and  subsequently  modified  by  imq  tailoring  enzymes  (Figure  4.5a).  If  
this  model  was  accurate,  the  substrate  for  each  of  the   imq  tailoring  enzymes  would  be  
the   tripeptide,   NH2-­L-­Trp-­L-­Tyr-­L-­Leu-­OH.   Evidence   to   the   contrary   of   this   simple  
prediction   for   imq   biogenesis   came   upon   the   discovery   of   another   imq-­associated  
metabolite  (7,  Figure  4.5b  and  see  Appendix  D  for  HR-­MS  and  NMR  assignments)  
   There  are  a  few  possibilities  that  come  to  mind  for  an   imq  biosynthetic  pathway  
that  is  consistent  with  the  formation  of  7.  One,  an  early  termination  event  where  the  amino  



















































3: R = OH














Figure  4.6:  Possible  mechanisms  explaining  the  existence  of  7  in  OE::imqK  strains.  
(a)  L-­Tyr  and  L-­Trp  spontaneously  release  from  T2  of  ImqB  forming  cyclo(L-­Tyr-­L-­Trp),  which  
is  then  modified  by  imq  cluster  tailoring  enzymes  to  form  7.  (b)  Compound  3-­4  are  produced  
as   speculated   in   Figure   4.5,   then   upon   standing   undergo   spontaneous   cyclization   and  
oxidation  ([Ox.])  to  form  7.    
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is  then  acted  upon  by  the   imq  cluster  tailoring  enzymes  (Figure  4.6a).  Two,  the  L-­Trp-­
derived   amino   group   in   3-­4   cyclizes   intramolecularly   and   releases   hydroxy-­L-­Leu   or  
dihydroxy-­L-­Leu,  then  further  oxidation  of  the  isoquinoline  ring  results  in  formation  of  7  
(Figure  4.6b).  This  possibility  seems  the  least  likely,  since  we  didn’t  observe  formation  of  
7  in  isolated  samples  of  3-­4  (spectra,  Appendix  D)  and  cleavage  of  the  L-­Leu  amide  bond  
is  unfavorable.  Lastly,  and  perhaps  most   likely,   the  modifications   to   form   the  oxidized  
isoquinoline   portion   of   1-­2   occur   while   the   dipeptide   is   tethered   to   ImqB,   which  
occasionally   prematurely   cyclizes   off   the  T2   domain   of   ImqB,   resulting   in   appreciable  
quantities  of  7  (Figure  4.7).  This  is  a  preferred  model  over  the  one  shown  in  Figure  4.6a  
because  it  doesn’t  require  extreme  substrate  promiscuity  for  the  imq  tailoring  enzymes.  If  
cyclo(L-­Tyr-­L-­Trp)   was   modified   in   addition   to   linear   L-­Trp-­L-­Tyr-­L-­Leu,   as   would   be  
suggested  by  the  model  in  Figure  4.6a,  then  each  tailoring  enzyme  would  need  to  accept  
two   different   substrates   with   dramatically   different   size   and   shape.   Collectively,   our  
characterization  of  the  fsq  pathway  (where  the  tailoring  modification  occur  on  a  tethered  
dipeptide)  in  addition  to  the  observation  of  7  lead  to  an  fsq-­analogous  model  for  the  imq  
pathway  where  1-­2  biogenesis  occurs  via  isoquinoline  formation  on  a  T2-­tethered  L-­Trp-­
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L-­Tyr  prior  to  the  formation  of  the  tripeptide  (Figure  4.7).  Following  action  of  ImqC,  ImqF,  
and   ImqG,   the   isoquinoline   dipeptide   is  moved   from   the  T2   domain   of   ImqB  and  T3-­
tethered  L-­Leu   is  condensed   in  via   the  C2  domain,   resulting   in   the  near  complete  1-­2  
(Figure   4.7).   Lastly,   ImqD,   the   gibberilin   oxidase,   either   partially   (resulting   in   2)   or  
completely  hydroxylates  the  four  position  of  the  L-­Leu  moiety,  resulting  in  1  (Figure  4.7).    
  
Conclusions:  Our   characterization   of   the   imq   BGC   in   A.   flavus   represents   another  
confirmed  example  of  conserved  isoquinoline  production  in  diverse  fungi.  The  biological  
function  of  the  imizoquins  remains  in  question,  however,  our  characterization  of  several  
different   imq   dependent  metabolites  with   varied  extent  of   oxidation   indicates  a   role   in  

































































































Figure  4.7:  Model   for   imq   biosynthesis.   L-­tryptophan,   L-­tyrosine,   and  L-­leucine  are  
loaded  onto   ImqB   thiolation  (T)  domains  via   their   respective  adenylation   (A)  domains.  
Then   ImqF   (N-­methyltransferse,   pink),   ImqC   (phenol   2-­monooxygenase,   purple),   and  
ImqG  (O-­methyltransferase,  yellow)  act  on  the  T2-­bound  L-­Tyr.  Following  N-­methylation  
and  hydroxylation   ImqH  (FAD  dependent  oxidase,  blue)  catalyzes   the   formation  of   the  
isoquinoline   ring.   Then   C2   condenses   L-­Leu   into   the  modified   T2-­tethered   dipeptide,  
which  subsequently  is  hydroxylated  by  ImqE  (giberillin  oxidase,  turquoise)  to  form  3  and  
4.  Alternatively,  the  modified  T2-­tethered  dipeptide  can  prematurely  cyclize  off  (red  arrow)  
to   form   7.   Lastly,   prior   to   L-­leu   condensation   another   oxidation   precedes   the   L-­Leu  
capture,  allowing  the  formation  of  1  and  2.    
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redox  chemistry.  Further  supporting  this  hypothesis   is  the  total  antioxidant  capacity  for  
the  purified  compounds.    It  should  be  noted  that  the  identification  of  many  of  the  oxidation-­
sensitive   imq   cluster  metabolites  was  greatly   facilitated  by   the  use  of   2D  NMR-­based  
metabolomics,  highlighting  the  utility  of  this  method  for  comprehensive  analysis  of  new  
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CHAPTER  5  
  
BIOSYNTHESIS  OF  THE  FUMIZINONES:  SECONDARY  PRODUCTS    
OF  THE  FSQ  CLUSTER  IN  ASPERGILLUS  FUMIGATUS  
  
Abstract:  Microbial  biosynthetic  gene  clusters  (BGCs)  containing  non-­ribosomal  peptide  
synthetases   (NRPSs)   typically   produce   a   single   class   of   small-­molecules   (SMs)   with  
limited   structural   diversity   within   the   context   of   the   cluster   products.   The   outcome   of  
microbial  NRPS-­based  BGCs  can  therefore  be  summarized  as  one  or  two  major  products  
(the  most  highly-­modified  SM)  and  often  an  array  of  associated  intermediates  that  follow  
the  same  enzymatic  entourage.  Here  we  show  that  the  previously  characterized  fsq  BGC  
in   Aspergillus   fumigatus   unexpectedly   has   a   secondary   set   of   SM   products,   the  
fumizinones,   which   result   from   divergent   enzymatic   activity   of   the   cluster   NRPS-­like  
enzyme   (FsqF)   and   ATP-­grasp   enzyme   (FsqD).   The   fumizinones   represent   a   novel  
addition  to  the  limited  number  of  pyrazinone  natural  products  identified  to  date.  Stable-­
isotope  incorporation  suggests  that  fumizinone  biogenesis  proceeds  via  a  unique  carbon-­
carbon   bond   forming   reaction   between   two   L-­serine   derived   precursors.   This   work  
represents  the  first  example  of  a  single  BGC  producing  two  different  structurally  unrelated  
SMs  and  adds  to  the  mounting  evidence  that  NRPS-­like  enzymes  are  a  rich  and  untapped  
source  of  new  natural  products.    
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Introduction:  Historically,   small-­molecule   (SM)  production   from  microbial   biosynthetic  
gene   clusters   (BGCs)   has   been,   perhaps,   the   richest   source   of   important   natural  
products1.  Many  of  these  medicinally  important  compounds  derive  from  BGCs  harboring  
large   canonical   non-­ribosomal   peptide   synthetases   (NRPSs)   or   polyketide   synthases  
(PKSs),   the  megasynth(et)ases1,2.   In  particular,   large  canonical  NRPSs  are  defined  as  
having  multiple  modules  which  are  each   composed  of   at   a  minimum,  an  adenylation,  
thiolation,  and  condensation  domain.  Frequently,  other  domains  with  varied  enzymatic  
activity,  such  as  methyl  transferase  or  oxidase/reductase  domains  are  found  within  one  
or  more  modules2.  Megasynthetase-­based  SM  biosynthesis  proceeds  via  an  assembly  
line  style  of  loading  (adenylation),  tethering  (thiolation),  and  elongation  (condensation),  of  
amino   acids.   Termination   of   the   assembly   line   occurs   with   a   variety   of   mechanisms  
(enzymatic  and/or  non-­enzymatic),  where  either  the  unmodified,  or  modified  peptide  (via  
tailoring  domains  or  cluster  enzymes)  is  released  from  the  N-­terminus  of  the  NRPS3.    
The  assembly  line  nature  of  canonical  NRPSs  provides  a  basis  for  semi-­accurate  
prediction   of   the   amino   acids   and  modifications   that  will   occur   during   the   biogenesis,  
making  them  tempting  targets  for  natural  products  chemists4.  Additionally,  early  discovery  
efforts   from   BGC’s   harboring   megasynth(et)ases   were   rewarded   with   therapeutic  
compounds,  such  as  Vancomycin  and  Erythromycin5,6.  Accordingly,  the  vast  majority  of  
characterized  NRPSs  are  multi-­module  versions  with  peptidyl  SM  products  consisting  of  
several  amino  acids  (or  derivatives  thereof)7.  Unfortunately,  continued  efforts  to  capture  
new   and   important   bioactivity   from   megasynthetase-­derived   SMs   have   not   been  
rewarded  as  expected  from  the  early  successes  in  the  field,  although  exceptions  exist,  
such  as  Teixobactin8.    
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Recently,  a  related  class  of  enzymes  called  NRPS-­like  enzymes  have  emerged  as  
a  source  of  SMs  with  overall  structural  novelty  and  potentially  useful  bioactivity.  NRPS-­
like  synthetases  differ  from  their  larger  counter-­parts  primarily  in  that  they  lack  complete  
modules9,10.   In   fact,   all   NRPS-­like   enzymes   consist   of   less   than   one   module,   which  
importantly,  never  contains  a  condensation  domain.  The  dearth  of  condensation  domains  
among  NRPS-­like  enzymes   is  what  makes   them   interesting   targets   for  new  molecular  
assemblies.  The  absence  of  a  condensation  domain  significantly  hinders  one’s  ability  to  
predict  the  bonds  formed  between  two  amino  acids,  which  ultimately  leaves  an  immense  
number  of  possible  structural  outcomes,  even  if  the  substrates  are  constricted  to  solely  
standard   amino   acids   (which  may   not   always   be   the   case)11.  While   relatively   little   is  
currently  known  about  the  biosynthetic  potential  of  BGCs  containing  NRPS-­like  enzymes,  
evidence   from   early   publications   suggest   their   potential   for   biosynthesizing   complex  
architectures  far  exceeds  that  of  their  larger  counter-­parts9,10.  Moreover,  because  NRPS-­
like  (and  PKS-­like)  enzymes  are  small  in  comparison  to  the  canonical  enzymes  they  have  
often  been  overlooked  computationally,  resulting  in  a  significant  underestimation  of  their  
true   numbers   among   microbial   genomes12.   Here   we   sought   to   highlight   the   utility   of  
NRPS-­like  enzymes  by  characterizing  an  additional  biosynthetic  function  of  the  NRPS-­
like  enzyme  at  the  core  of  the  previously  characterized  fsq  BGC  in  the  human  pathogen  
Aspergillus  fumigatus.    
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The  fumizinones  are  secondary  products  of  the  fsq  cluster:	  Recently  we  published  
the  characterization  of  the  Fumisoquins,  a  novel  class  of  isoquinoline  alkaloids  derived  
from   the   fsq   BGC9.   This   was   accomplished   in   no   small   part   through   the   usage   of  
differential   analysis   by   2D-­NMR   spectroscopy   (DANS)   combined   with   liquid  
chromatography   –   high-­resolution  mass   spectrometry   (LC-­HRMS)-­based   comparative  
metabolomics   of   overexpression   (OE)   and   knock-­out   (D)   strains   of   the   cluster  
transcriptional  regulator,  fsqA  (Figure  E1)13.  While  the  Fumisoquins  certainly  represent  
the  major  products  of  the  fsq  cluster,  upon  further  analysis  of  our  comparison  of  whole-­
metabolome  extracts  of  the  OE::fsqA  vs.  DfsqA  strains  we  found  two  additional  features  
that  were  consistently  produced  in  an  FsqA  dependent  manner  (1-­2,  Figure  5.1a).  The  
high-­resolution   mass-­to-­charge   ratio   of   these   differential   features   (1-­2,   Figure   5.1a)  
suggested  they  were  not  intermediates  or  shunt  metabolites  in  the  previously  established  
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Figure  5.1:  FsqA  dependent  metabolite  production  and  structure  of  fumizinones.  
(a)  LC-­HRMS  extracted-­ion-­chromatograms   for  1-­2   in  whole-­metabolome  extracts  of  
OE::fsqA  (red  lines)  and  DfsqA  (black  lines).  (b)  structure  of  the  1-­2.  
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containing   two  nitrogens,  whereas,  all  Fumisoquins  of   similar   size  only  posessed  one  
nitrogen.  To  confirm  that  1-­2  were  in  fact  structurally  unrelated  to  the  other  fsq-­associated  
metabolites  (Fumisoquins  and  their  intermediates,  Chapter  3)  we  grew  large  scale  liquid  
cultures  of  OE::fsqA  and  conducted  several  rounds  of  chromatographic  enrichment  (see  
Appendix  E  for  details).  Following  chromatographic  enrichment,  a  standard  suite  of  2D-­
NMR  spectroscopic  experiments  was  utilized  to  obtain  full  structural  information  for  1-­2.  
(Figure  5.1b).    
  
The   fumizinones   are   a   novel  members   of   the   small   class   of   pyrazinone   natural  
products:   The   peak   intensity   for   1-­2   in   our   LC-­HRMS   analysis   suggested   isolating  
quantities   sufficient   for  NMR  analysis  would   be   rather   straightforward.  However,   after  
several   rounds   of   isolation   from   8   L   of   liquid   culture   of   the   OE::fsqA   strain   we   only  
obtained  sub-­milligram  quantities  of  1-­2.  Fortunately,  we  isolated  enough  1  to  obtain  high-­
quality   2D   NMR   spectra,   affording   us   the   ability   to   conduct   a   full   spectroscopic  
characterization  (Figure  5.2,  see  Table  E4  for  complete  chemical  shift  assignments  and  
Appendix  E  for  spectra).  Our  entry  into  the  spin-­system  of  1  was  from  the  aliphatic  region,  















Figure  5.2:  Structure  elucidation  of  1.  Showing  key  COSY  correlations  (blue  double-­
headed  arrows)  and  key  HMBC  correlation  from  each  proton  to  the  indicated  carbon  (red  
single-­headed  arrows).    
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showed  a  7  Hz  1H-­1H  coupling  with  a  methine,  H-­11  (dH  2.20).  From  H-­11  the  spin  system  
did  not  extend  much  further,  as  H-­11  had  only  one  other  coupling  to  a  methylene  H-­10a/b  
(dH  2.60  and  2.60).  The  carbon  chemical  shift  of  position  ten  (dC  42.37)  suggested  the  
presence  of  an  alpha  heteroatom  or  aromatic  spin-­system.  HMBC  correlations  from  H-­
10a/b  to  C-­9  (dC  159.09)  and  C-­1  (dC  156.46)  confirmed  the  presence  of  the  suspected  
adjacent  heteroaromatic  spin-­system.    
   In   order   to   connect   the   isopropyl-­based   spin-­system   to   the   remainder   of   the  
molecule  we  next   looked  at   the  aromatic   region  of   the  1H  NMR  spectra.  The  aromatic  
region  only  contained  one  singlet,  H-­7  (dH  7.46),  which  showed  a  strong  HMBC  correlation  
to  C-­9  and  a  weaker  correlation  to  C-­1.  H-­7  showed  one  additional  HMBC  correlation  to  
an   aromatic   carbon,  C-­6   (dC   144.37),  which   collectively   suggested  H-­7  was   part   of   a  
heteroaromatic   six-­membered   ring   system,   such   as   a   pyrazinone.   The   dqfCOSY  
spectrum  of  1  revealed  that,  despite  being  a  singlet  in  the  1H  NMR  spectrum,  H-­7  showed  
a  long-­range  1H-­1H  coupling  to  a  methine  H-­5  (dH  5.15),  which  appeared  to  be  attached  
to  an  oxygen-­bearing  carbon,  C-­5  (dC  72.43).  H-­5  showed  an  HMBC  correlation  back  to  
C-­6  and  C-­7,  solidifying  its  position  three  bonds  away  from  H-­7.  H-­5  also  showed  strong  
1H-­1H   coupling   with   a   diastereotopic   methylene   H-­4a/b   (dH   2.22   and   dH   2.72).   The  
germinal  1H  coupling  constant  of  H-­4a  and  H-­4b  (13.5  Hz)  suggested  that  they  were  part  
of   a   five-­membered   ring.   In   addition   to   coupling   with   H-­5,   H-­4a/b   also   had   a   1H-­1H  
coupling  with  another  methine,  H-­3  (dH  4.83),  which  showed  strong  HMBC  correlations  to  
two  carbonyls,  C-­1  and  C-­14   (dC  176.02).  This  connected   the   two  hemispheres  of   the  
molecule   and   confirmed   that   the   structure   of   1   was   composed   of   a   fused   isobutyl-­
dihydropyrrolo-­pyrazinone  (Figure  5.2)14.    
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Stable-­isotope  amino  acid  labeling  provides  insights  into  fumizinone  biogenesis:  
Once  we  had  established  the  structure  of  1-­2,  we  sought  to  understand  how  they  could  
be   biosynthesized   in   a   manner   consistent   with   the   Fumisoquins.   We   started   by  
conducting  a  stable-­isotope  amino  acid   labeling  experiment   to  determine  which  amino  
acids   are   incorporated   in  1-­2.   First,   we   tested   L-­Leucine   because   that   was   the  most  
probable  candidate  for  the  origin  of  the  isobutyl  moiety  present  in  the  structure  1-­2.  LC-­
MS  analysis  of  whole-­metabolome  extracts  from  cultures  of  OE::fsqA  strain  fed  with  L-­
Leucine  and  L-­[1-­13C]-­Leucine  revealed  that,  as  expected,  L-­Leucine  is  incorporated  in  1-­
2  (Figure  E2).  It  was  rather  straightforward  to  anticipate  the  incorporation  of  L-­Leucine  in  
1-­2  based  on  their  structures,  however,  the  remainder  of  the  structure  does  not  represent  
an   obvious   amino   acid.   A   natural   starting   point   was   to   test   L-­Serine   and   L-­Cysteine  
because  we  had  previously  established   that   the  Fumisoquins,  which  were  supposedly  
derived  from  the  same  BGC  incorporated  L-­Serine  based  substrates  into  their  structures.  
	   82	  
In  order  to  test  for  for  the  incorporation  of  L-­Cysteine  and  L-­Serine  we  utilized  LC-­HRMS  
analysis   of   OE::fsqA   cultures   fed   with   L-­Cysteine   or   L-­Serine   (controls)   or   L-­[3,3-­d2]-­
Cysteine/Serine  (Figure  5.3a-­b).  Interestingly,  we  observed  that  not  only  is  one  L-­Serine  
incorporated  into  1-­2  but  a  second  L-­Serine  is  also  incorporated  (Figure  5.3a).  Similar  to  
our  analysis  of   the  amino  acid   incorporation   in   the  Fumisoquins  we  also   found   that  L-­
Cysteine  was  not   incorporated   in  1-­2   (Figure  5.3b).  LC-­HRMS  analysis  was  pivotal   in  




















































































































































































Figure  5.3:  Stable-­isotope   incorporation   into  1-­2.   (a)   L-­Serine   or   L-­[3,3-­d2]-­Serine   are  
incorporated  into  1-­2  with  the  resulting  deuteration  shown  in  red.  Below  are  extracted-­ion-­
chromatograms  for  the  indicated  high-­resolution  mass-­to-­charge  from  the  control  or  labelling  
experiment.   (b)   L-­Serine   or   L-­[3,3-­d2]-­Serine   are   incorporated   into   1-­2   with   the   resulting  
deuteration  shown   in   red.  Below  are  extracted-­ion-­chromatograms   for   the   indicated  high-­
resolution  mass-­to-­charge  from  the  control  or  labelling  experiment.  
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abundance   carbon   13   species,   which   overlap   in   a   low-­resolution   mass   spectrometry  
experiment.    
   The   results  of   the   stable-­isotope   labeling  experiments  allowed  us   to  propose  a  
tentative  model  for  the  biogenesis  of  1-­2  (Figure  5.4a-­f).  Analogous  to  the  Fumisoquins,  
one  of  the  early  steps  in  the  fumizinone  pathway  is  a  carbon-­carbon  bond  forming  reaction  
catalyzed  by  FsqF.  However,   between   two  L-­Serine  derived  dehydroalanine’s   (DHAs)  
rather  than  one  dehydroalanine  and  an  activated  tyrosine  (Figure  5.4a-­b).  Following  the  
FsqF  mediated  dimerization  of  dehydroalanine,  FsqD  provides  an  activated  L-­Leucine,  
which  forms  a  peptide  bond  with  the  free  amino  group  of  the  DHA  dimer  (Figure  5.4c-­d).  
Following   peptide-­bond   formation   an   intramolecular   cyclizes   furnishes   the   pyrazinone  
moiety  (Figure  5.4e).  Lastly,  the  L-­Serine  derived  ketone  is  reduced  to  the  corresponding  
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Figure  5.4:  Tentative  model  for  fumizinone  biogenesis.  (a)  L-­Serine  is  dehydrated  by  
the  PLP-­dependent  domain  in  FsqF  and  tethered  to  the  T  domain.  (b)  another  L-­Serine  
is   dehydrated   by   the   PLP-­domain   and   (c)   subsequently   undergoes   a   claisen  
condensation  with  the  T-­bound  dehydroalanine.  (d)  The  PLP-­bound  adduct  adds  to  an  
activated  L-­Leucine  (perhaps  by  FsqD),  which  then  (d)  cyclizes  intramolecularly  to  form  
the  pyrazinone  ring.  (e)  one  reductive  equivalent  reduces  the  ketone  to  hydroxy  and  then  
(f)  the  pyrazinone  amide  cyclizes,  releasing  1-­2  from  the  PLP  domain.  A  =  adenylation,  T  
=  thiolation,  R  =  reductase  and  P  =  PLP-­dependent  domain.    
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amide  bites  into  the  PLP-­imine  to  release  1-­2.  This  model  for  fumizinone  biogenesis  is  in  
contrast  to  our  proposal  for  the  Fumisoquin  pathway  where  FsqD  serves  to  activate  L-­
Tyrosine,  which  means  FsqD  exhibits  substrate  promiscuity  to  the  extent  of  accepting  L-­
Tyrosine  and  L-­Leucine.  One  of  the  only  other  ATP-­grasp  enzymes  characterized  also  
showed   high-­substrate   promiscuity,   giving   some   credence   to   this   hypothesis15.   The  
corresponding   fumizinone   derivatives   where   instead   of   L-­Leucine,   L-­Tyrosine   was  
incorporated  were  not  found  in  our  LC-­HRMS  survey.  Perhaps  they  were  too  unstable,  or  
simply  don’t  fit  in  the  active  site  of  FsqF  after  the  dimerization  of  DHA.    
  
Conclusions:   To   the   best   of   our   knowledge   the   fumizinones   represent   the   first  
pyrazinones   isolated   from   A.   fumigatus   and   add   to   the   interesting   biosynthetic  
transformations   afforded   by   the   under-­appreciated   class   of   NRPS-­like   enzymes.   Our  
observation   that   two   L-­Serine’s   and   L-­Leucine   are   incorporated   into   the   fumizinones  
provided  some  insight  into  their  biosynthetic  pathway,  however,  work  remains  to  clarify  
the  correct  biogenesis.  In  particular,  in  vitro  reconstitution  of  the  enzymes  involved,  FsqF  
and  FsqD  will  be  critical   to  determine   if   they   function   in  a  manner  consistent  with  our  
proposed  model.  Lastly,  the  fumizinones  are  intriguing  from  the  stand-­point  of  a  unique  
BGC  where  two  distinct  biosynthetic  outcomes  are  possible.  Perhaps  regulation  of   the  
two  divergent  pathways  is  a  strategy  employed  by  A.  fumigatus  in  the  wild.    
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CHAPTER  6  
  
CONCLUSIONS  AND  OUTLOOK  
  
Filamentous  fungi  as  a  source  of  new  chemistry:  While  having  long  been  known  as  
prominent  producers  of  small-­molecules,  filamentous  fungi’s  ability  to  perform  a  diverse  
range  of  chemical  transformations  has  been  largely  under  appreciated.  As  evidenced  by  
Chapters   3   and   5,   noncanonical   NRPS-­like   enzymes   have   the   potential   to   produce  
completely   unexpected   molecular   architectures.   In   aspergillus   species   alone   there  
remains  a  significant  number  of  uncharacterized  BGCs  that  include  genes  encoding  for  
putative  NRPS-­like  enzymes.   It   is   likely   that   future  explorations  of   these  orphan  gene  
clusters   will   be   rewarded   with   yet   more   interesting   biosynthetic   mechanisms   and  
potentially  useful  compounds.  Further,  based  on  genomic  sequencing  data,  NRPS-­like  
enzymes   represent   only   a   small   portion  of   the  unexplored  enzymology   in   filamentous  
fungi.    
  
DANS-­  and  LC-­MS-­based  comparative  metabolomics:  A  continued  effort  to  advance  
DANS-­  and  LC-­MS-­based  comparative  metabolomics  is  critical  to  the  success  of  the  field  
of  chemical  biology.  To  date,  no  other  method  has  been  as  efficient  at  comprehensively  
annotating  metabolic   pathways   in  microorganisms   and   animals.  As   evidenced   by   this  
dissertation,   DANS-­based   comparative   metabolomics   is   uniquely   suited   toward   the  
identification   of   unstable  molecules,  which   represent   a   particularly   important   group   of  
metabolites.  Moreover,   the   combination   of   genetic   engineering   and  DANS  provides   a  
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direct  feedback  loop  to  understand  the  biological  context  of  the  regulation  involved  in  the  
anabolism  or  catabolism  of  metabolic  pathways.  This  dissertation  provides  a  basis  for  the  
reality   of   completely   annotating   the   microbial   metabolome   through   the   systematic  
analysis  of  each  putative  BGC.   It  will  however,  be  necessary   to   improve  DANS-­based  
comparative  metabolomics  to  eliminate  the  necessity  for  extensive  human  interpretation  
by   creating   software   packages   capable   of   automatically   distinguishing   differential  
features  in  2D-­NMR  spectra.    
  
The  metabolome  at  large:  The  most  profound  take  away  from  this  dissertation  is  that  
despite   years   of   sustained   isolation   and   characterization   efforts   by   natural   products  
chemists  the  microbial  metabolome  remains  almost  completely  unknown.  It  is  especially  
surprising  considering  that  the  organisms  studied  in  this  dissertation  are  among  the  most  
well-­studied  microbial   species.  An  extension  of   this  observation   is   that  not  only   is   the  
microbial  metabolome  not  well  understood  but  all  metabolomes  are  not  well  understood,  
especially   our   own.   Comprehensive   annotation   of   the   human   metabolome   has   the  
potential   to  be  as   influential  as   the  human  genome  project  and   there   is  no  doubt   that  




































Figure! A2.! Phenotypes( of(has(mutants.! Strains(were( point2inoculated( and( grown( on(
minimal( medium( (1.8( µM( Fe2+)( for( 3( days( at( 37( °C.( 1:( WT( (cea1721),( 2:( OE::hasA(
(TJW109.3),( 3:( OE::hasA∆hasD( (TWY25.5)( ,( 4:( OE::hasA∆hasE( (TWY26.1),( 5:(
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Figure! A5.! The(HAS( gene( cluster( is( conserved( in( a( variety( of( fungal( species.( a)(A.*
fumigatus( cea10]( b)( A.* terreus( NIH2624]( c)( Neosartorya* fischeri( NRRL181]( d)(




HPLC2MS.( (Chromatograms( of(mouse( lung( extracts(were( integrated( using(MassLynx(
software.(See(methods( for( details.(Decreased( levels(of( gliotoxin( in(OE::hasA* infected(

























Figure! A7.( Triacetylfusarinine( C( (TAFC)( production( as( measured( using( HPLC2MS.(
TAFC(peaks( in( the(MS( chromatograms(were( integrated( using(MassLynx( software( for(
each(sample.(Strains(were(cultured(as(described(in(methods.(Increased(levels(of(TAFC(


































Gene! cloning,! plasmid! construction,! and! genetic! manipulations.! The( plasmids(
utilized(in(this(work(are(listed(in(Supplementary(Table(1.(The(oligonucleotide(sequences(
for(PCR(primers(are(given(in(Supplementary(Table(2.(PCR(amplification(was(carried(out(
on(a(C1000TM(Thermal(Cycler( from(Bio2Rad( (Hercules,(CA).(For(creation(of( the(hasA(
overexpression( (OE)( strain( at( its( native( locus,( the( OE( cassette( was( constructed( by(
using(single(and(double(joint(PCR(procedures.2(Single(joint(PCR(reactions(were(set(up(
for(fusion(of(the(maker(gene(A.(parasiticus*pyrG(which(was(amplified(from(pJMP9.1(and(
A.* nidulans( glyceraldehyde232phosphate( dehydrogenase( gene( (gpdA)( promoter( (1.5(
kb),( which( was( amplified( from( pWY25.16.3( Then,( the( 1.03( kb( fragment( upstream( of(
hasA* and( 1.1( kb( fragment( containing( hasA( ORF( downstream( were( amplified( from(




confirmed(with( endonuclease(digestion,( and(purified( for( fungal( transformation.(Except(
for(the(first(round(PCR(with(Pfu(Ultra(II(DNA(Polymerases((Agilent,(Santa(Clara,(CA),(all(
PCR( steps( were( performed( by( using(an( Expand( long( template( PCR( system( (Roche,(
Indianapolis,( IN)( according( to( the(manufacturer's( instructions.( Cea1722( (auxotroph(A.*
fumigatus(∆nkuB,*pyrGS)(was(used(for(host(strain(for(transformation.(
For( the( creation( of( deletion( mutants( in(OE::hasA( TJW109.3( background,( a( deletion(
cassette( of( each( cluster( gene( (hasB( to(hasH)( was( constructed( by( using( double( joint(
PCR( with( hygromycin* B( (hph)( replacement( of( target( genes.( ( The( hph( gene( was(
amplified( by( using( plasmid( pUCH228( as( template.( Five( µg( of( the( double2joint( PCR(
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cassette( were( used( to( delete( each( has( cluster( gene( by( using* TJW109.3(
(A.ppyrG::gpdA(p)::* hasA,* ∆nkuB,* pyrG1)( as( the( recipient( host.( After( transformation,(
transformants( were( grown( on( minimal( media( plates( with( 100( µg( mL21( hygromycin( B(
(GOLDBIO,(St.(Louis,(MO)(for(screening.(To(create(strains(for(the(pathogenicity(assay,(
we( reconstructed(OE::hasA( (TWY22.2)( and(OE::hasA∆hasD( (TWY24.121)(mutants( in(
A.*fumigatus(293((Af293.6)(background(to(avoid(any(influence(of(∆nkuB(in(pathogenicity(
(all(A.*fumigatus(cea10(strains(contained(∆nkuB).(The(creation(of(OE::hasA(was(carried(
out( using( ectopic( integration( of( the( plasmid( pWY47.2.( The( plasmid( pWY47.2( was(
constructed(as(follows.(Firstly,(the(open(reading(frame(of(hasA(was(amplified(by(using(
designated(primers(WB(OETF1_for(and(WB(OETF1_rev.(Secondly,(plasmid(pJMP10.1(
(A.* nidulans( gpdA(p)( and( A.* fumigatus( argB( in( pBS( SK2)( was( used( as( template( for(
insertion( of( hasA( via( quick2change( method.4( The( plasmid( was( then( confirmed( by(
sequencing.( Ten( µg( of( plasmid( pWY47.2( were( used( for( overexpression( of( hasA( by(
using*Af293.6((A.*fumigatus*pyrG1,*argB1)(as(the(recipient(host.(The(disruption(mutant(
of( hasD( was( created( by( the( replacement( of( A.* parasiticus( pyrG( with( TWY22.2( as(
recipient(host.(The(prototrophic(strain(of(OE::hasA(was(created(by(transforming(plasmid(
pSA2.4( to( TWY22.2.( Overexpression( and( deletion( strains( were( verified( by( PCR( and(
Southern(blot(analysis.(Three(confirmed(strains( for(each(mutant(were(stored(at( 280(C(
with(33(%(glycerol(for(future(uses.(
Nucleic! acid! analysis.! Plasmid( preparation,( digestion( with( restriction( enzyme,( gel(
electrophoresis,( blotting,( hybridization,( and( probe( preparation( were( performed( by(








For( the( determination( of( boundaries( of( the(has( gene( cluster,( the( fragments( from(has(
gene(members(used(as(probes(were(amplified(individually(from(cea1721(genomic(DNA(
with( appropriate( primers( (Supplementary( Table( 2).( ( WT( (cea1721)( and( OE::hasA(
(TJW109.3)(mutants( were( used( for( this( experiment.( For( assessment( of( fumitremogin(






Fermentation! and! metabolome! extraction.! A.( fumigatus* strains( were( inoculated(
(1.0!106(spores/mL)(into(1(L(GMM(in(a(2(L(flask(at(25(°C(with(shaking(at(250(rpm.((After(












Analytical! methods! and! equipment! overview.! (a)( NMR( Spectroscopy:( NMR(
spectroscopic(instrumentation:(a(Varian(INOVA(600(MHz(NMR(spectrometer((600(MHz(
1H( reference( frequency,( 151( MHz( for( 13C)( equipped( with( an( HCN( indirect2detection(
probe.(Non2gradient(phase2cycled(dqfCOSY(spectra(were(acquired(using(the(following(




(Shigemi)( were( used( for( sample( amounts( smaller( than( 1( mg.( ( NMR( spectra( were(
processed(and(baseline(corrected(using(Varian(VNMR(and(MestreLabs(MestReC(and(
MNOVA(software(packages.((b)(Mass(spectrometry:(High2resolution(mass(spectrometry(
was( performed( on( a( Waters( nanoACQUITY( UPLC( system( equipped( with( a( Waters(
Acquity(UPLC(HSS(C218(column((2.1(x(100(mm,(1.8(μm(particle(diameter)(connected(to(
a(Xevo(G2(QTof(Mass(Spectrometer(operated(in(electrospray(positive((ESI+)(ionization(
mode.( Low2resolution( mass( spectrometer( was( performed( on( an( HPLC2MS( system(
equipped( with( a( diode( array( detector( and( connected( to( a( Quattro( II( spectrometer(
(Micromass/Waters)( operated( in( positive( electrospray( ionization( (ESI+)( mode.( Data(
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4,! 5a/b,! 688.! !Compounds(were( purified( via( semi2preparative(HPLC( using( a( Supelco(
Discovery(HS(C218(column((25(cm(x(10(mm,(5(μm(particle(diameter)(a(1:12mixture(of(





evaporated( to(dryness(and( then(dissolved( in(502300(μL(of(methanol(and(analyzed( for(



































L-trp, R = H
3, R = prenyl (
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$
Conversion! of! compound! 3! and! L8trp! into! R/S8MTPA! derivatives! for! NMR!
spectroscopic!analysis.! !To(a(solution(of(an(isolated(sample(of(compound(3!(4.0(mg,(
0.0147(mmol)( in(3:2( toluene/MeOH((0.75(mL)(was(added( (trimethylsilyl)diazomethane(
(15( μL,( 0.0294( mmol)( as( a( 2.0( M( diethyl( ether( solution.( After( stirring( at( room(
temperature(for(45(min,( the(mixture(was(dried(by(rotary(evaporation.(The(residue(was(
dissolved( in( dichloromethane( (1.0(mL),( split( into( two( vials( (0.5(mL( each)( and( treated(
separately( with( triethylamine( (10.3( μL,( 0.0735( mmol)( and( (+)2( or( (2)2α2methoxy2α2
(trifluoromethyl)phenylacetyl(chloride((11(μL,(0.0588(mmol).(After(stirring(for(2(h(at(room(




Iron! removal! from! HAS! and! formation! of! compound! 9.! Adapted( procedure( from(
Yamamato( and( co2workers.7( Isolated( HAS( or( OE::hasA* extract( (110( mg)( was(
suspended( in(acetone(and(any( insoluble(materials(were(filtered(off.(To(the(filtrate(was(
added(0.2(M(NaOH((0.75(mL)(dropwise(with(stirring,(the(resulting(brown(precipitate(was(
filtered(off,( and( the(acetone(was( removed( from( the( filtrate(by( rotary(evaporation.(The(
aqueous( residue( was( neutralized( by( the( addition( of( 0.2( M( HCl( (0.75( mL),( and( the(







g( were( immunosuppressed( via( administration( of( cyclophosphamide( by( separate(
subcutaneous(injections,(one(at(4(days((200(mg(kg21(of(body(weight)(and(the(other(at(1(
day( (200( mg( kg21)( before( infection.( The( second( treatment( includes( administration( of(





Murine! lung! tissue! extraction! and! HPLC8MS! analysis.! Lung( tissue( samples( from(
infected(mice(with(all(three(fungal(strains(were(extracted(and(subsequently(analyzed(by(
HPLC2MS( as( follows.( (a)( Extraction:( mice( lungs( were( lyophilized,( placed( in( 125( mL(
Erlenmeyer( flasks,(and(extracted(with(75(mL(of(10%(methanol( in(ethyl(acetate( in( the(
presence( of( ~2( g( of( pre2washed( chromatography( grade( sand( for( 10( h.( The( resulting(
pulverized( lung( material( was( filtered( over( pre2washed( cotton( and( dried( by( rotary(
evaporation.( (b)( HPLC2MS( Analysis:( the( crude( mice( lung( extracts( were( analyzed( by(
HPLC2MS(using(a(1:1(mixture(of(methanol:acetonitrile((organic(phase)(and(0.1(%(acetic(
acid( in( water( (aqueous( phase)( as( solvents( at( a( flow( rate( of( 1.0( mL/min.( A( solvent(
gradient( scheme( was( used( starting( at( 5%( organic( for( 3( min,( followed( by( a( linear(
increase( to( 100%( organic( over( 35( min,( holding( at( 100%( organic( for( 15( min,( then(
decreasing(back(to(5%(organic(for(1(min(and(holding(at(5%(organic(for(the(final(6(min.(
The(Quattro(II(mass(spectrometer(was(operated(in(single(ion(recording((SIR)(mode(for(




Detection!of!gliotoxin! in!mice! lung!samples.! !Lung(tissue(extracts(described(in(the(
previous(section(were(analyzed(by(HPLC2MS(using(the(same(chromatographic(method(










































































TF2(Nor_for( ( GTTTGTCGGATCTCAGGG(( hasF(northern(probe(
TF2(Nor_rev( CTTGCCAATCCCGGGAAG(
P450(Nor_for( ( CTCATTTGGCGTCAGTTCAC(( hasH(northern(probe(
P450(Nor_rev( GATAACGGACCCCAAAGACG(
MT(Nor_for( ( CTACATCAACTCAGACTCCC(( hasC(northern(probe(
MT(Nor_rev( CAGAGCTTTTCTACAACACC(
 106 










































































































































Nor_ftmA_for( ( GTTGACGGAACATTCGGCTG( ftmA(northern(probe(
Nor_ftmA_rev( GCATTCACGCTTCTGGATCC(

















































































































1! 1129.3751! [M!+!Na]+! C60H60FeN9NaO9! 1129.3761! 46.87!
2! 1135.4259! [M!+!Na]+! C60H66FeN9NaO9! 1135.4231! 48.82!
3! 273.1605! [M!+!H]+! C16H21N2O2! 273.1603! 24.17!
4a! 271.1451! [M!+!H]+! C16H19N2O2! 271.1447! 24.01!
4b! 271.1452! [M!+!H]+! C16H19N2O2! 271.1447! 23.15!
5a! 372.1691! [M!+!Na]+! C21H23N3NaO2! 372.1688! 29.20!
5b! 402.1787! [M!+!Na]+! C22H25N3NaO3! 402.1294! 28.56!
6! 306.1224! [M!+!Na]+! C16H17N3NaO2! 306.1218! 19.79!
7! 348.1694! [M!+!Na]+! C19H23N3NaO2! 348.1688! 26.90!
8! 364.1620! [M!+!Na]+! C19H23N3NaO3! 364.1637! 27.56!




















Position& δc& Proton& δH(JHH[Hz])& HMBC&
1! ! 1$NH! ! !
2! 125.05! 2$H! 7.20!! 3,!3a,!7a!
3! 109.87! ! ! !
3a! 128.38! ! ! !
4! 117.09! 4$H! 7.54!(J5$H!=!8)! 6,!7a!
5! 120.29! 5$H! 6.99!(J4$H,!6$H!=!8)! 3a,!7!
6! 121.79! 6$H! 6.92!(J5$H!=!8)! 4,!7a,!11!
7! 125.79! ! ! !
7a! 137.03! ! ! !
8! 28.21! 8$Ha! 3.52!(J8$Hb!=!15,!J9$H!=!5)! 2,!3,!3a,!9!
! ! 8$Hb! 3.15!(J8$Ha!=!15,!J9$H!=!9)! 2,!3,!9!
9! 56.54! 9$H! 3.85!(J8$Ha!=!5,!J8$Hb!=!9)! 3,!8,!10!
10! 174.30! ! ! !
11! 30.21! 11$CH2! 3.55!(J12$H!=!7)! 6,!7,!7a,!12,!13!
12! 123.21! 12$H! 5.43!(J11$H!=!7,!J14a/b$CH3!<!1)! !
13! 133.67! ! ! !
14a! 25.88! 14a$CH3! 1.76! 12,!13,!14b!





























Position& δc& Proton& δH(JHH[Hz])& HMBC&
1! ! 1$NH! ! !
2! 125.13! 2$H! 7.24! 3,!3a,!7a!
3! 109.59! ! ! !
3a! 129.12! ! ! !
4! 118.43! 4$H! 7.62!(J5$H!=!8)! 3,!6,!7a!
5! 120.34! 5$H! 7.07!(J4$H,!6$H!=!8)! 3a,!7!
6! 119.40! 6$H! 7.35!(J5$H!=!8)! 4,!7a,!11!
7! 122.40! ! ! !
7a! 136.23! ! ! !
8! 28.21! 8$Ha! 3.52!(J8$Hb!=!15,!J9$H!=!5)! 2,!3,!3a,!9,10!
! ! 8$Hb! 3.15!(J8$Ha!=!15,!J9$H!=!9)! 2,!3,!3a,!9,!10!
9! 56.54! 9$H! 3.85!(J8$Ha!=!5,!J8$Hb!=!9)! 3,!8,!10!
10! 174.30! ! ! !
11! 124.93! 11$H! 6.99!(J12$H!=!15)! 13!
12! 132.87! 12$H! 7.04!(J11$H!=!15)! 7,!13!
13! 143.60! ! ! !
14! 117.12! 14$H! 5.16!(J14$H’!=!4)! 12,!15!
! ! 14$H’! 5.08!(J14$H!=!4)! 12,!15!






























Position& δc& Proton& δH(JHH[Hz])& HMBC&
1! ! 1$NH! ! !
2! 125.16! 2$H! 7.20! 3,!3a,!7a!
3! 109.59! ! ! !
3a! 128.07! ! ! !
4! 118.53! 4$H! 7.62!(J5$H!=!8)! 6,!7a!
5! 119.70! 5$H! 7.01!(J4$H,!6$H!=!8)! 3a,!7!
6! 123.19! 6$H! 7.05!(J5$H!=!8)! 4,!7a,!11!
7! 122.87! ! ! !
7a! 135.97! ! ! !
8! 28.40! 8$Ha! 3.52!(J8$Hb!=!15,!J9$H!=!5)! 2,!3,!3a,!9,10!
! ! 8$Hb! 3.15!(J8$Ha!=!15,!J9$H!=!9)! 2,!3,!3a,!9,!10!
9! 56.54! 9$H! 3.85!(J8$Ha!=!5,!J8$Hb!=!9)! 3,!8,!10!
10! 174.30! ! ! !
11! 126.04! 11$H! 6.65!(J12$H!=!12)! 7,!13!
12! 134.73! 12$H! 6.40!(J11$H!=!12)! 7,!13,!14,!15!
13! 143.60! ! ! !
14! 118.12! 14$H! 4.95!(J14$H’!=!4)! 12,!15!
! ! 14$H’! 5.02!(J14$H!=!4)! 12,!15!



















Chemical! shifts!were! referenced! to! δ(CHCl3)! =! 7.26!ppm! 1H,! 1H$J$coupling! constants!
were! determined! from! the! acquired! 1H! or! dqfCOSY! spectra.! Carbon! chemical! shifts!































































Position& δc& Proton& δH(JHH[Hz])& HMBC&
1! ! 1$NH! 8.30! !
2! 123.82! 2$H! 7.31! 3,!3a,!7a!
3! 110.61! ! ! !
3a! 127.76! ! ! !
4! 118.72! 4$H! 7.75!(J5$H!=!8)! 3,!6,!7a!
5! 119.84! 5$H! 7.12!(J4$H,!6$H!=!8)! 3a,!7!
6! 120.33! 6$H! 7.26!(J5$H!=!8)! 4,!7a,!17!
7! 121.32! ! ! !
7a! 133.58! ! ! !
8! 20.00! 8$CH2! 4.36! 2,!3,!3a,!9,!10!
9! 127.39! ! ! !
10! 149.80! ! ! !
11! ! ! ! !
12! 134.39! ! ! !
13! 146.74! ! ! !
14! ! ! ! !
15! 18.38! 15$CH3! 2.42! 12,!13!
16! 54.17! 16$OCH3! 3.99! 10!
17! 124.57! 17$H! 6.73!(J18$H!=!16)! 6,!7a,!19!
18! 132.64! 18$H! 6.91!(J17$H!=!16)! 7,!19,!20,!21!
19! 141.82! ! ! !
20! 18.53! 20$CH3! 2.01! 19,!21!
21! 117.35! 21$H! 5.09! 18,!19,!20!
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Figure!B3.!gliI#gene( expression( in(WT(Af293)(GliP.!C2T3( and(GliP.!T3( A.( fumigatus(












GliP.!C2T3(A.( fumigatus(strains.(107(spores/ml(were( inoculated( in(50ml( liquid(glucose(
minimal(medium(and(incubated(for(24hr(at(30(oC,(225rpm(and(additional(24hr(at(25oC,(
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Figure!B12.!GliJ( dipeptidase(activity( exhibits( loose( substrate( specificity.( (a8e)( In# vitro(
assay(with(recombinant(GliJ(and(the(indicated(dipeptides(showing(LC.MS(analysis(with(



















































































































































































































































Two( plasmids( were( then( generated,( one( which( included( a( full( length( copy( of( gliP#
(pBTP12),(and(one(that(contained(a(H1754A(copy(of(gliP#(pBTP13),(both(targeted(to(the(
akuA(locus.(The(pBTP12(plasmid(was(assembled(by(amplifying(akuA(flanks((KU5’.F(&(
KU5’.R,(and(KU3’.F(&(KU(3’.R),(gliP( (gliP.F(&(gliP.R),(and(A.# fumigatus(argB( as( the(
selectable(marker((AFU(argB(fwd(&(AFU(argB(rev).(These(PCR(fragments(were(combined(
with(digested(pJMP218(to(act(as(the(plasmid(backbone(in(a(yeast(transformation(to(allow(
for(homologous( recombination( to(assemble( the( fragments( into(a( full(plasmid.(pBTP13(
was(assembled(using(the(same(fragments(and(method,(expect(the(H1754A(substitution(
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was( introduced( by( using( primers( containing( the( mutation( and( amplifying( gliP( in( two(
separate( PCR( reactions( (gliP.F( &( gliP.H1754A.R,( and( gliP.H1754A.F( &( gliP.R).(
TBTP12.02(was(then(transformed(with(pBTP12(and(pBTP13(to(generate(TBTP99(and(
TBTP100(respectively,(which(were(confirmed(by(Southern(blot(analysis.(TBTP12.02(was(
taken( to( prototrophy( by( amplifying( argB( (AFU( argB( fwd( &AFU( argB( rev2)( from( A.#
fumigatus(and(selecting(prototrophic(transformants(generating(TBTP94.(
(
Nucleic! acid! analysis.! Plasmid( preparation,( digestion( with( restriction( enzyme,( gel(
electrophoresis,( blotting,( hybridization,( and( probe( preparation( were( performed( by(
standard(methods6.(Aspergillus#DNA(for(diagnostic(PCR(was(isolated(using(the(previously(





Lysis( Reagent( according( to( the( manufacturer’s( instructions( (5( Prime,( Hamburg,(
Germany).((







(a)( Preparation( for( LC.HRMS(Analysis:( Crude( extracts(were( suspended( in( 1.5(mL( of(
extraction(solvent(and(centrifuged( to( remove( insoluble(materials,( and( the(supernatant(
was(subjected(to(LC.HRMS(analysis.(
(
Analytical! methods! and! equipment! overview.! (a)( NMR( Spectroscopy:( NMR(
spectroscopic(instrumentation:(a(Varian(INOVA(600(MHz(NMR(spectrometer((600(MHz(
1H(reference(frequency,(151(MHz(for(13C)(equipped(with(an(HCN(indirect.detection(probe.(
Non.gradient( phase.cycled( dqfCOSY( spectra( were( acquired( using( the( following(




(Shigemi)( were( used( for( sample( amounts( smaller( than( 1( mg.( ( NMR( spectra( were(
processed(and(baseline(corrected(using(Varian(VNMR(and(MestreLabs(MestReC(and(
MNOVA(software(packages.((b)(Mass(spectrometry:(High.resolution(mass(spectrometry(
was( performed( on( a( Waters( nanoACQUITY( UPLC( system( equipped( with( a( Waters(
Acquity(UPLC(HSS(C.18(column((2.1(x(100(mm,(1.8(μm(particle(diameter)(connected(to(
a(Xevo(G2(QTof(Mass(Spectrometer(operated(in(electrospray(positive((ESI+)(ionization(
mode.( Low.resolution( mass( spectrometer( was( performed( on( an( HPLC.MS( system(
equipped( with( a( diode( array( detector( and( connected( to( a( Quattro( II( spectrometer(
(Micromass/Waters)( operated( in( positive( electrospray( ionization( (ESI+)( mode.( Data(
acquisition(and(processing(for(the(HPLC.MS(was(controlled(by(Water(MassLynx(software.(
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1( 263.1030( [M.S2+H]+( C13H15N2O4+( 263.1032( 5.00(
2( 235.1080( [M(+(H]+( C12H15N2O3+( 235.1082( 2.30(
9( 279.0801( [M.SCH3+H]+( C13H16N2O3S+( 279.0803( 3.84(











No.! δc! Proton! δH(JHH[Hz])! HMBC!
1( 129.28( 1.H( 7.24((J1,2(=(7.5)( 3(
2( 127.68( 2.H2( 7.21((J2,1(=(7.5)((J2,3(=(7.4)( 2,4(
3( 128.92( 3.H2( 7.25((J3,2(=(7.4)((J3,5(=(1.0)( 1,3,5(
4( 133.65( ( ( (
5( 36.87( 5.Ha( 2.98((J5a,5b(=(14.0)((J5a,6(=(8.2)((J5a,3(=(1.0)( 3,4,6,7(
5.Hb( 3.28((J5b,5a(=(14.0)((J5b,6(=(5.5)((J5a,3(=(1.0)( 3,4,6,7(
6( 54.39( 6.H( 4.26((J6,5a(=(8.2)((J6,5a(=(5.5)( 4,5,7(
7( 168.86( ( ( (
8( ( 8.NH( (( (
9( 61.54( 9.H( 4.55((J9,10a(=(4.0)((J9,10b(=(4.5)( 7,10,11(
10( 61.70( 10.Ha( 3.75((J10a,10b(=(11.8)((J10a,9(=(4.0)( 9,11(
10.Hb( 3.84((J10b,10a(=(11.8)((J10b,9(=(4.5)( 9,11(
11( 198.19( ( ( (
12( ( ( ( (
13( 28.44( 13.H2( 2.90((J13,14(=(12.0)( 11,14(
14( 38.48( 15.H2( 3.27((J14,13(=(12.0)( 13,16(
15( ( 15.NH( ( (
16( 172.01( ( ( (




























































































2.' Gao,' X.' et# al.' Cyclization' of' fungal' nonribosomal' peptides' by' a' terminal'
condensation?like'domain.'Nat#Chem#Biol'1–8,'(2012).''
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Figure' C6.( Mass' spectra' of' FSQ' cluster' metabolites' with' and' without' heavy' atom'
incorporation.'(a)(L,serine,(L,tyrosine,(and(L,methionine(are(incorporated(into(the(fumisoquins.(
(b)( (Mass(spectrum(of(2(with(L,serine(incorporated((left)(and(mass(spectrum(of(2'with'L,[13C3,(
15N],serine( incorporated( (right).( Increased( M+1( and( M+2( peaks( likely( result( from(
amination/deamination(and(use(of(abundant(labeled(serine(for(methionine(production.((c)(Mass(
spectrum(of(2(with(L,tyrosine(incorporated((left)(and(mass(spectrum(of(2'with'L,[2,13C],tyrosine(
incorporated( (right).( (d)( Mass( spectrum( of( 2( with( L,methionine( incorporated( (left)( and( MS,
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of( 4( obtained( from( fumisoquin( C( (3)( isolated( from( a( fungal( culture( grown( with( L,[1’,13C],
methionine( (top)( and( 1H,13C(decoupled( 1H(NMR(spectrum(of( the( same(sample(of(4( (bottom),(
showing(selective(incorporation(of(the(methionine(methyl(group.(In(the(decoupled(spectrum,(the(
intensity( of( the( signal( of( the( proton( attached( to( the( labeled( carbon( does( not( increase(






Figure' C8.(Purification' and' spectra' of' FsqB.'SDS,polyacrylamide( gel( of( the( polyhistidine,
tagged( FsqB( (left),( and( UV,Vis( absorption( and( fluorescence( spectra( (right)( of( FsqB.( Spectra(
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Figure' C9.( Reaction( of( DL,DOPA( with( formaldehyde( followed( by( addition( of( sodium(
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Figure' C11.(Substrate' specificity' of' FsqB.( (a)( Ion( chromatograms( for(N,methyl( dopamine(
(m/z(=(166.1)(and(cyclic(product((m/z(=(164.1),(showing(no(product(formation(after(151(min.(((b)(
FsqB(does(not(catalyze(the(cyclization(of(N,methyl,L,tyrosine.(Ion(chromatograms(for(N,methyl,
L,tyrosine( (m/z( =( 194.1)( and( cyclic( product( (m/z( =( 192.1)( obtained( after( 151( min( show( no(
product( formation.( (c)( FsqB( does( not( catalyze( the( cyclization( of( N,N,dimethyl( DOPA.( Ion(
chromatograms(for(N,N,dimethyl(DOPA((m/z(=(224.1)(and(putative(cyclic(product((m/z(=(222.1)(
obtained( after( 200( min( show( no( product( formation.( Validating( FsqB( preference( toward(
secondary( β,N,methylamine( substrates.( (d)( FsqB( does( not( catalyze( the( cyclization( of( (S),






























































































































































covalently( bound( FAD.( Amino( acid( sequence( and( location( of( FAD( attachment( were( inferred(
from(indicated(b?*(green)(and(y?type((red)( ion(series(and(diagnostic(FAD(fragmentation((blue).(




























showing( the( purity( of( the( FsqF( adenylation( domain( (left),( and( ATP,[32P]pyrophosphate(
exchange(assay(results((right)(for(amino(acids(selected(based(on(results(from(the(stable,isotope(
labeling( experiments( (see(Figure' 3.4aRc( and(Figure' C5( and(Methods(below).( The(exchange(
assay(shows(none(or(minimal( (in( the(case(of(L,cysteine)(activation( for(all( tested(amino(acids.(





































Figure' C14.' LRtyrosine' is' incorporated' into' shunt' metabolite' 18.' Ion( chromatograms(
extracted( from(HPLC,MS(analysis(of(extracts( from(OE::fsqA,ΔfsqF( fed(with(L,tyrosine(or(L,[2,













1 mM, pH 7 




































































































































































































































































Figure' C16.(Synteny' analysis' of' fsq& cluster' in' indicated' Aspergillus& and& Neosartorya&







Figure'C4.'Southern(analysis(confirmation(of(all(mutants(used( in( this(study.(Mutant( (number)(
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when( appropriate,( were( supplemented( with( 0.56( g/L( uracil,( 1.26( g/L( uridine,( 1.0( g/L(
arginine(and(maintained(as(glycerol(stocks(at(,80(ºC.(Escherichia*coli*strain(DH5α(was(
propagated(in(LB(medium(with(appropriate(antibiotics(for(plasmid(DNA.'
Gene' cloning,' plasmid' construction,' and' genetic' manipulations.' The( plasmids(
utilized( in( this( study( are( listed( in(Table' C4.( The( oligonucleotide( sequences( for( PCR(
primers( are( given( in( Table' C5.( PCR( amplification( was( carried( out( on( a( C1000TM(
Thermal( Cycler( (Bio,Rad).( For( creation( of( the( fsqA( overexpression( (OE)( strain(
(TJES1.18)(the(OE(cassette(was(constructed(by(amplifying(the(fsqA(open(reading(frame(
(ORF)( from( Af293( genomic( DNA( using( primers( Afu6g03430_NcoI_For( and(
Afu6g03430_NotI_Rev,( which( introduced( a( 5’( NcoI( restriction( site( and( a( 3’( NotI(
restriction( site.( This( PCR( product( was( purified( with( a( QIAquick( gel( extraction( kit(
(Qiagen),(quantified,(and(digested(with(the(appropriate(restriction(enzymes(before(being(
cloned(into(pJMP8.122,(resulting(in(plasmid(pJES(1.2.(Subsequently,(A.*fumigatus(argB*
was( transferred( from(pJMP4.13(by(digesting(with(EcoRI(and( introduced( into(pJES1.2,(
resulting( in( plasmid( pJES2.7( (A.* fumigatus* argB::gpdA(p)::fsqA).( All( PCR( steps(were(
carried(out(with(Pfu(Ultra(II(DNA(Polymerases((Agilent)(and(all(digestion(reactions(were(
carried( out( with( NEB( enzymes( (New( England( BioLabs).( Correctness( of( the( inserted(
DNA(was(then(confirmed(by(sequencing.*




respectively.( These( three( amplified( PCR( products( were( purified( with( a( QIAquick( gel(
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extraction( kit,( quantified,( and( fused( using( standard( double,joint(PCR(procedures.( The(
final( PCR( product( was( amplified( with( the( bottom( primer( pairs,( gene_5’F_flank( and(
_3’R_flank,( confirmed( with( endonuclease( digestion,( and( purified( for( fungal(
transformation.( The( first( two( rounds( of( PCR( were( done( with( Pfu( Ultra( II( DNA(
Polymerases((Agilent),(and(the(final(PCR(step(used(Expand(long(template(PCR(system(
(Roche)( according( to( the( manufacturer's( instructions.( Af293.6( (double( auxotroph( A.*
fumigatus,*pyrG?,*argB?)(was(used( to(make( the(OE::fsqA,*pyrG?(auxotroph,(TJES1.18.(
This(strain(was(used(as(the(recipient(host(strain(for(subsequent(deletions(of(fsq(genes(
as( well( as( the( ectopic( complementation( of( pyrG1( with( plasmid( pJMP9.1( (containing(
A.ppyrG)( resulting( in(prototrophic(strain(TJES3.1( (OE::fsqA,*A.ppyrG).(Similarly(∆fsqA*
auxotrophic* strains( (TJES2.20)( were( made( by( transforming( Af293.6( with( deletion(
cassettes( and( complemented( with( ectopically( integrated( pJMP4( to( make( ∆fsqA(
prototroph(TJES8.2.(




cassette( were( used( to( delete( each( fsq( cluster( gene( by( using* TJES1.18(
(A.fargB::gpdA(p)::* fsqA,* pyrG1)( as( the( recipient( host.( After( transformation,(
transformants(were(grown(on(minimal(media(plates(without(supplements(for(screening.(
All( strains( were( verified( by( PCR( and( Southern( blot( analysis( (Figure' C17).( Multiple(







3’( XhoI( restriction( sites,( respectively.( These( products( were( gel( purified( and( digested(
with(the(appropriate(enzymes(before(being(cloned(into(pET30,a(+)((EMD(Biosciences)(
to( create( an( expression( plasmid( with( a( 6xHis( tagged( fsqF( adenylation( domain.( The(
plasmid(was( introduced( into( chemically( competent(E.coli*DH5α,( selected( on( LB( agar(
with(Kanamycin(and(confirmed(by(sequencing.(Subsequently,(they(were(extracted(from(
DH5α(cells(and(used(to(transform(expression(host(E.coli(BL21.(Protein(purification(was(
carried( out( as( described5.( All( reactions( were( carried( out( in( triplicate.( Reaction(
parameters( for( the(ATP,[32P]pyrophosphate(exchange(assay(were:( total(assay(volume(
of(100(µL(at(25°C(in(100(mM(phosphate(buffer,(5(mM(MgCl2,(125(nM(EDTA,(5(mM(ATP,(
100( nM( purified( FsqF( adenylation( domain,( 0.1( µM( [32P]pyrophosphate( (50( Ci/mmol),(
and( 1( mM( amino( acid( substrate.( The( reaction( proceeded( for( 30( min( before( it( was(
stopped((1(%((w/v)(activated(charcoal,(4.5(%((w/v)( tetrasodium(pyrophosphate,(3.5(%(
(v/v)( perchloric( acid)( and( further( processed( as( described6.( Pyrophosphate( exchange(
was(quantified(on(a(scintillation(counter((PerkinElmer(TriCarb(2910TR).((
The(expression(vector(for(fsqB((fructosyl(amino(acid(oxidase)(was(constructed(using(the(










6000(G( for( 20(min( yielding( 10.6( g( of(wet(weight( pellet( and( stored( at( ,80( °C.(Protein(
purification(was(carried(out(at(4(°C(by(resuspending(the(pellet(in(lysis(buffer(containing(
100(mM(phosphate(buffer(pH(7.8,(10(mM(imidazole,(10(%((v/v)(glycerol,(1(mM(PMSF,(
0.1( mg/mL( lysozyme,( 0.1( mg/mL( Benzonase( (EMD( Millipore)( and( sonicated.( All(









in( the( dark.( Reaction( products( were( identified( on( a( Thermo( Scientific,Dionex(
Ultimate3000(UHPLC(system(equipped(with(a(diode(array(detector(and(connected(to(a(
Thermo( Scientific( Q( Exactive( Orbitrap( operated( in( electrospray( negative( (ESI,)(
ionization(mode.( (UV,Vis(absorbance(spectra(were(obtained(on(a(Cary(5000(UV,Vis,
NIR( spectrophotometer,( and( fluorescence( emission( was( obtained( on( a( HORIBA(
Nanolog(Spectrofluorometer.(
FsqB' SteadyRstate' kinetic' analysis' and' imine' capture.( Steady,state( kinetics(were(
carried( out( at( 25( °C( in( 100(mM( phosphate( buffer( pH( 7.0( with( 100( nM( FsqB( at( final(
volumes(of(500(or(1000(μL(at(various( initial(concentrations(of(N,methyl,3,4,dihydroxy,
DL,phenylalanine( (11).( Imine(capture(was(carried(out(at(25( °C( in(100(mM(phosphate(
buffer(pH(7.0(with(1.5(μM(FsqB,(400(μM(N,methyl,L,tyrosine((14),(and(1(mM(dimedone(
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(15)( (Sigma( Aldrich)( with( <0.5%( (v/v)(methanol( for( dimedone( solubility.( Both( kinetics(
and( imine( capture( were( monitored( with( low,resolution( HPLC,MS( performed( on( an(
Agilent(1100(series(HPLC(system(equipped(with(a(diode(array(detector(and(connected(
to( a( Quattro( II( mass( spectrometer( (Micromass/Waters)( operated( in( electrospray(
negative(ionization((ESI,)(mode(for(kinetic(analysis(and(positive(electrospray(ionization(
(ESI+)(mode( for( imine( capture.( Kinetic( data( analysis(was( performed( using(GraphPad(
Prism(version(6.00(for(Windows((GraphPad(Software).((





HRP)(was( added( and( incubated( at( 25( °C( in( the( dark( for( 10(minutes.(Readings(were(
performed(on(a(BioTek(Synergy(2(96,well( plate( reader(using(a(500±27(nm(excitation(
filter( and( a( 615±15( nm( emission( filter( and( normalized( to( 0( and( 100( μM( hydrogen(
peroxide(standards.(All(conditions(were(performed(in(triplicate.(
FsqB'trypsinization'analysis.'80(μg(of(recombinant(FsqB(was(buffer(exchanged(into(
55( μL( of( 50( mM( ammonium( bicarbonate.( 3( μL( of( 0.33( μg/μL( of( sequencing( grade(
porcine(trypsin((Promega)(was(added(to(FsqB(and(incubated(at(37(°C(for(12(h.(5(μL(50(
mM(TCEP(was(added(and(the(mixture(was(further(incubated(at(37(°C(for(10(min.(The(
solution( was( cooled( to( 25( °C( and( 5( uL( of( 100( mM( iodoacetamide( was( added( and(
incubated(at(25(°C(in(the(dark(for(1(h.(Formic(acid(was(added(to(1(%((v/v),(and(peptides(
were( prepared( with( 100( μL( Pierce( C18( Tips( (Thermo( Scientific)( per( manufacturers(
protocol( utilizing( 100( μL( elution( solution.( Peptides(were( identified( via(UHPLC,MS/MS(
using(a(Thermo(Scientific(Dionex(Ultimate(3000(UHPLC(system(equipped(with(a(diode(
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array( detector( and( connected( to( a(Thermo(Scientific(Q(Exactive(Orbitrap( operated( in(
positive(electrospray((ESI+)(ionization(mode.(
Nucleic' acid' analysis.' Preparation( of( plasmids,( restriction( enzyme( digestions,( gel(
electrophoresis,( blotting,( probe( preparation( and( hybridization( were( carried( out( by(
standard( protocols.( Aspergillus( DNA( was( extracted( using( a( previously( described(
method7.(Sequence(data(were(analyzed(using(the(LASERGENE(software(package(from(
DNASTAR.(








hybridized( with( designated( DNA( fragments.( All( experiments( were( performed( in(
duplicate.( Detection( of( signals( was( carried( out( with( a( Storm( 860( phosphoimager(
(Molecular(Dynamics).(
Fermentation'and'metabolome'extraction'for'comparative'metabolomics'by'DANS'
and' HPLCRUVRMS.'Preparation( for(NMR(spectroscopic( analysis:(A.( fumigatus*strains(
were(inoculated((1.0"106(spores(mL,1)(into(1(L(GMM1(in(a(2(L(Erlenmeyer(flask(at(37(°C(
with(shaking(at(220(rpm.(After(4(days,(liquid(fungal(cultures(including(fungal(tissue(and(









Preparation( for( HPLC,MS( analysis:( A.( fumigatus* strains( were( inoculated( (1.0"106(
spores(mL,1)(into(50(mL(GMM1(in(a(125(mL(Erlenmeyer(flask(at(37(°C(with(shaking(at(
220( rpm.( After( 4( days,( liquid( fungal( cultures( including( fungal( tissue( and(media( were(






A.( fumigatus* strains( were( inoculated( (1.0"106( spores( mL,1)( into( 1( L( GMM1( in( a( 2( L(
Erlenmeyer(flask(at(37(°C(with(shaking(at(220(rpm.(After(3.5(days,(liquid(fungal(cultures(
including( fungal( tissue( and( media( were( frozen( using( a( dry( ice( acetone( bath,( and(
lyophilized.(The(lyophilized(residues(were(extracted(with(500(mL(of(MeOH(for(1(h(with(
vigorous(stirring.(Extracts(were(filtered(over(cotton(and(evaporated(on(Celite,545((Acros(
Organics)( to( dryness.( The( dry( Celite( was( then( loaded( into( a( 25( gram( solid( phase(
cartridge( (Isco)( and( subjected( to( large,scale( reverse( phase( chromatography( (see(
Chromatographic(enrichment(section(below( for(details).(Compounds(4'and(5'are(also(
minor(components(of(the(culture(media.'
Analytical' methods' and' equipment' overview.' (a)( NMR( spectroscopy:( NMR(
spectroscopic(instrumentation:(a(Varian(INOVA(600(MHz(NMR(spectrometer((600(MHz(
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1H( reference( frequency,( 151( MHz( for( 13C)( equipped( with( an( HCN( indirect,detection(
probe( or( a(Bruker(AvanceIII( HD( (800(MHz( 1H( reference( frequency,( 201(MHz( for( 13C)(
equipped( with( a( 5( mm( CPTCL( 1H,13C/15N( cryo( probe.( Non,gradient( phase,cycled(
dqfCOSY(spectra(were(acquired(using(the(following(parameters:(0.6(s(acquisition(time,(
400,600( complex( increments,( 8,( 16( or( 32( scans( per( increment.( Non,gradient( HSQC,(
HMQC,( and( HMBC( spectra( were( acquired( with( these( parameters:( 0.25( s( acquisition(
time,( 200,500( increments,( 8,64( scans( per( increment.( 1H,( 13C,HMBC( spectra( were(
optimized( for( JH,C( =( 6( Hz.( HSQC( spectra( were( acquired( with( or( without( decoupling.(
Susceptibility,matched( NMR( tubes( (Shigemi)( were( used( for( sample( amounts( smaller(
than( 1( mg.( NMR( spectra( were( processed( and( baseline( corrected( using( MestreLabs(
MNOVA( software( packages.( (b)( Mass( spectrometry:( high,resolution( UHPLC,MS( was(
performed(on(a(Thermo(Scientific,Dionex(Ultimate3000(UHPLC(system(equipped(with(a(
diode(array(detector(and(connected(to(a(Thermo(Scientific(Q(Exactive(Orbitrap(operated(
in( electrospray( positive( (ESI+)( or( electrospray( negative( (ESI,)( ionization( mode.( Low,
resolution(HPLC,MS(was(performed(on(an(Agilent(1100(series(HPLC(system(equipped(
with( a( diode( array( detector( and( connected( to( a( Quattro( II( mass( spectrometer(
(Micromass/Waters)(operated(in(ESI+(or(ESI,(mode.(Data(acquisition(and(processing(for(
the(LC,HRMS(was(controlled(by(Thermo(Scientific(Xcalibur(software.(Data(acquisition(
and( processing( for( the( HPLC,MS( was( controlled( by( Waters( MassLynx( software.( (c)(
Chromatography:( flash( chromatography( was( performed( using( a( Teledyne( ISCO(
CombiFlash(system.(For(semi,preparative(HPLC(Agilent(Zorbax(Eclipse(XDB,C18(or(,
C8( columns( (25( cm(x(10(mm,(5(μm(particle( diameter)(were(used.(An(Agilent(Zorbax(
RRHD(Eclipse(XDB,C18(column((2.1(x(100(mm,(1.8(µm(particle(diameter)(was(used(in(
the(LC,HRMS(A.* fumigatus*mutant(profiling(analysis.(An(Agilent(Zorbax(Eclipse(XDB,




Methanol(extracts(derived( from(1,2(L(of(A.* fumigatus(cultures(were( fractionated(using(
large,scale(reverse,phase(flash(chromatography(on(a(Teledyne(ISCO(CombiFlash(with(




vials( at( ,20( °C.(Fractions( containing( compounds(1,(3,( dimethyl,3,(7R8,(11R13,' and(18(
were( further( purified( via( semi,preparative( HPLC( using( an( Agilent( XDB( C,18( or( C,8(
column((25(cm(x(10(mm,(5(μm(particle(diameter)(acetonitrile((organic(phase)(and(0.1(%(
acetic(acid(in(water((aqueous(phase)(as(solvents(at(a(flow(rate(of(3.6(mL/min.(A(solvent(
gradient( scheme( was( used,( starting( at( 5( %( organic( for( 3( min,( followed( by( a( linear(




were(purchased( from(Cambridge( Isotopes( Inc.(Each(amino(acid( (labeled(or(unlabeled(
control)(was(added(to(50(mL((2(mM)(of(GMM1(media(in(125(mL(Erlenmeyer(flasks.(Each(
flask( was( inoculated( with( OE::fsqA( or( OE::fsqA, fsqF! (1.0! x! 106! spores! mL/1)! and!
grown!for!4!days!at!37!°C!with!shaking!at!220!rpm.!After!4!days,!liquid!fungal!cultures!
including! fungal! tissue! and! media! were! frozen! using! a! dry! ice! acetone! bath! and!
lyophilized.!The! lyophilized!residues!were!extracted!with!MeOH!(25!mL)!for!1.5!h!with!
vigorous!stirring.!Extracts!were!filtered!over!cotton,!evaporated!to!dryness,!and!stored!in!






partially! purified! fumisoquin! C! (3)! in! 3:2! toluene/MeOH! (2! mL)! was! added!
(trimethylsilyl)diazomethane! (Sigma/Aldrich)! (20! L,! 0.04! mmol)! as! a! 2.0! M! diethyl!
ether!solution.!After!stirring!at!room!temperature!for!30!min,!the!mixture!was!quenched!
with! glacial! acetic! acid! (10! L)! and! dried! by! rotary! evaporation.! The! mixture! was!
resuspended!in!MeOH!(100! L)!and!dimethyl/3!was!purified!by!semi/preparative!HPLC!
(see!section!"chromatographic!enrichment"!above!for!details).!!!
Synthesis) of) FsqB) substrates.) All! reagents! were! purchased! and! used! as! is! from!
Sigma/Aldrich.!All!solvents!were!purchased!and!used!as! is! from!Fischer!Scientific.!N/
methyl/3,4/dihydroxy/DL/phenylalanine! (11).! A! 100! mL! Schlenk! flask! under! argon! at!




quenched! by! addition! of! glacial! acetic! acid! (10!mL).! The! solvents! were! removed! by!
rotary!evaporation,!and!the!product!isolated!by!reverse/phase!HPLC.!See!below!for!full!


















1! 281.1137! [M+H]+! C13H17N2O5+! 281.1132! 0.74! ~1–5!mg!
2! 359.0557! ![M/H]/! C13H15N2O8S/! 359.0555! 0.81! ~1–5!mg!
3! 289.0471! [M/H]/! C13H9N2O6/! 289.0466! 4.31! ~10–50!mg!
4! 241.0255! [M/H]/! C12H5N2O4/! 241.0255! 4.38! !
5! 227.0462! [M/H]/! C12H7N2O3/! 227.0462! 6.58! !
7! 200.0727! [M/H]/! C12H10NO2/! 200.0717! 7.46! ~0.5–2!mg!
8! 216.0676! [M/H]/! C12H10NO3/! 216.0666! 5.98! ~0.5–2!mg!
11! 210.0772! [M/H]/! C10H12NO4/! 210.0772! 1.71! !
12! 208.0615! [M/H]/! C10H10NO4/! 208.0165! 1.38! !
18! 293.0565! [M/H]/! C16H9N2O4/! 293.0568! 5.46! ~1–5!mg!
21! 343.0941! [M/H]/! C17H15N2O6/! 343.0936! 4.31! !


















































Peptide) observed) expected) z) Δ)
MGSSHHHHHHSSGLVPR! 590.2879! 633.9679! 3! /131.0400!
GSHMSIPNSFIIVGSGVFGLSLAYALSLDDRFADKKIILVDR! 1075.2218! 1075.2200! 3! 0.0254!
WNFEPPNATGSVHNPAAANADTSR! 842.0560! 842.0509! 3! /0.0066!
DYPHGPYASLALEAMK! 881.9266! 881.9198! 2! /0.0010!
FGENNR! 736.3424! 736.3373! 1! 0.0051!
LLFSGEGSSLTTPPK! 767.4106! 767.4043! 2! /0.0020!
ALETVNYIK! 1050.5813! 1050.5757! 1! /0.0017!
AYAISCELTPGGR! 697.8393! 697.8330! 2! /0.0020!
DAVQVLDSLDEVR! 1458.7411! 1458.7362! 1! /0.0024!
FLGNTPSHPPHLPVNK! 457.2478! 457.2409! 4! /0.0015!
GYVSNDCGWADAGASIEWLR! 1113.9964! 1113.9900! 2! /0.0018!
VECVVGEVESLVYSDDQR! 1041.9851! 1041.9788! 2! /0.0020!
VLTAELTVIAAGAR! 462.2763! 462.2695! 3! /0.0014!
SSHILGIPK! 951.5615! 951.5549! 1! /0.0007!
LCDVYSEFVAYIQLTK! 974.9887! 974.9826! 2! /0.0023!
EEADELR! 431.2024! 431.1938! 2! 0.0027!
QWPILVNCHR! 661.8428! 661.8357! 2! /0.0003!
GVFAVGPDHDNCLK! 764.8631! 764.8570! 2! /0.0024!
FGHFSYSGIVDVLR! 798.9108! 798.9048! 2! /0.0026!
EASIQVPTRPDGWEAQQK! 1020.5093! 1020.5036! 2! /0.0032!
YWSDPR! 412.1909! 412.1903! 2! 0.0012!
FAFGGEVK! 854.4397! 854.4334! 1! /0.0009!
VSALGDVDDYENPAAQR! 910.4254! 910.4192! 2! /0.0022!
LFLLELLGPTGLQGVDTLGLDQSDNLLNNIANRPFTR! 1346.7254! 1346.7195! 3! /0.0042!
KCWYNDTPALDFVVDYHPSYGK! 1134.4530! 892.7407! 3! 725.1369!
TLFVATGGCDHAFK! 762.3686! 762.3620! 2! /0.0013!
FLPIIGEK! 916.5490! 916.5429! 1! /0.0012!
TLALILR! 799.5390! 799.5327! 1! /0.0009!
GDSAVSLPAGVEPSLEELSELWR! 1221.1133! 1221.1061! 2! /0.0002!
FPVELLQDN! 1074.5451! 1074.5393! 1! /0.0015!
! ! ! ! !






































































































































































































































































Table)C6.!1H (800 MHz) and 13C (200 MHz) NMR spectroscopic data for fumisoquin A, 1, 
in methanol-d4.!
Chemical!shifts!were!referenced!to!δ(CHD2OD)!=!3.31!ppm!and!δ(13CHD2OD)!=!49.0!ppm.13C!
















No.) δc) Proton) δH)(JHH[Hz])) HMBC) NOESY)
1! 128.03! ! ! ! !
2! 70.99! 2/H! 4.94!(J2,3!=!1.9)! 1,!3,!4,!7,!10,!11,!14! 3,!4,!14!
3! 60.44! 3/H! 3.73!(J3,2!=!1.9,!J3,4!=!8.7)! 1,!7! 2,!4,!5b!
4! 67.19! 4/H! 4.65!(J4,3!=!8.7,!J4,5a!=!7.6,!!
J4,5b!<!1)!
5! 2,!5a,!5b!
5! 33.67! 5/Ha! 2.46!(J5a,4!=!7.6,!J5a,5b!=!13.0,!
J5a,6!=!5.7)!
3,!4,!6,!7! 4,!6,!5b!
! ! 5/Hb! 2.06!(J5b,4!<!1,!J5b,5a!=!13.0,!!
J5b,6!=!12.4)!
3,!4,!6,!7! 3,!4,!5a!
6! 47.88! 6/H! 4.29!(J6,5a!=!5.7,!J6,5b!=!12.4)! 5,!7! 5a!
7! 169.75! ! ! ! !
8! ! ! ! ! !
9! 42.35! 9/Ha! 4.66!(J9Ha,9Hb!=!18.0)! 1,!2,!3,!6,!7,!10,!11,!12,!13! !
! ! 9/Hb! 4.78!(J9Hb,9Ha!=!18.0)! 1,!2,!3,!6,!7,!10,!11,!12,!13! 3!
10! 119.92! ! ! ! !
11! 142.82! ! ! ! !
12! 146.06! ! ! ! !
13! 114.23! 13/H! 6.73!(J13,14!=!8.0)! 1,!10,!11,!12! 14!






















No.) δc) Proton) δH)(JHH[Hz])) HMBCa) ROESY)
1! 134.03! ! ! ! !
2! 70.75! 2/H! 4.98!(J2,3!=!2.0)! 1,!3,!10! 4,!14!
3! 60.19! 3/H! 3.71!(J3,2!=!2.0,!J3,4!=!9.2)! ! 5a!
4! 67.30! 4/H! 4.62!(J4,3!=!9.2,!J4,5a!=!6.9,!J4,5b!=!7.9)! 6! 2!
5! 34.69! 5/Ha! 1.94!(J5a,4!=!6.9,!J5a,5b!=!13.0,!J5a,6!=!11.5)! 4,!6,!7! 3!
! ! 5/Hb! 2.43!(J5b,4!=!7.9,!J5b,5a!=!13.0,!J5b,6!=!5.8)! 4,!6,!7! !
6! 47.88! 6/H! 4.02!(J6,5a!=11.5,!J6,Hb!=!5.8)! 5,!7! !
7! 171.61! ! ! ! !
8! ! ! ! ! !
9! 42.26! 9/Ha! 4.63!(J9Ha,9Hb!=!18.5)! 3! !
! ! 9/Hb! 4.81!(J9Hb,9Ha!=!18.5)! 10,!11! !
10! 121.61! ! ! ! !
11! 147.05! ! ! ! !
12! 140.92! ! ! ! !
13! 122.08! 13/H! 7.23!(J13,14!=!8.1)! 1,!11,!12w! !


























No.) δc) Proton) δH)(JHH[Hz])) HMBC) NOESY)
1! 115.62! ! ! ! !
2! 138.33! ! ! ! !
3! ! 3/NH! 9.46!(J3,4!=!1.5)! 1,!4,!5,!6,!8! 4!
4! 53.27! 4/H! 3.73!(J4,3!=!1.5,!J4,6a!=9.6,!J4,6b!=!5.4)! 2,!5,!6,!7! 3,!7!
5! 173.40! ! ! ! !
6! 32.31! 6/Ha! 1.69!(J6a,4!=12,!J6a,6b!=!12.8,!J6a,7!=!9.5)! 4,!5,!7,!8! !
6/Hb! 2.38!(J6b,4!=12,!J6a,6b!=!12.8,!J6b,7!=!5.3)! 4,!5,!7,!8! !
7! 66.85! 7/H! 4.57!(J7,6a!=!9.5,!J7,6b!=!5.3)! 2,!4,!6,!8! 4!
8! 152.69! ! ! ! !
9! ! ! ! ! !
10! 130.73! 10/H! 7.98! 1,!8,!11,!12,!13,!
15!
!
11! 124.93! ! ! ! !
12! 188.04! ! ! ! !
13a! 184.60! ! ! ! !
14! 107.92! 14/H! 5.24! 1,!12,!13,!15! !






ppm.13C! chemical! shifts! were! determined! via! HMBC! and! HSQC! spectra.! 1H,! 1H/J/coupling!
















No.) δc) Proton) δH)(JHH[Hz])) HMBCa)
1! 127.41! ! ! !
2! 134.33! ! ! !
3! ! 3/NH! 13.71!(J3,4!=!6.6,!J3,5!=!1.7)! !
4! 140.30! 4/H! 8.06!(J4,3!=!6.6,!J4,5!=!7.3)!! 2,!5,!6!
5! 111.88! 5/H! 6.24!(J5,4!=!7.3,!J5,3!=!1.7)! 4,!7!
6! 175.28! ! ! !
7! 144.61! ! ! !
8! ! ! ! !
9! 141.85! 9/H! 8.91! 1,!2w,!7,!10,!11w,!
12w!
10! 125.00! ! ! !
11! 185.04! ! ! !
12! 180.67! ! ! !
13b! 108.10! 13/H! 5.45! 1,!2w,!11,!12w,!14w!























No.) δc) Proton) δH)(JHH[Hz])) HMBCa) NOESY)
1! 108.19! ! ! ! !
2! 142.74! ! ! ! !
3! ! ! ! ! !
4! 146.12! 4/H! 8.87!(J4,5!=!4.7)!! 2,!5,!6! 5,!14/OH!
5! 121.77! 5/H! 7.75!(J5,4!=!4.7,!J5,6!=!8.3)! 4,!7! 4,!6!
6! 136.97! 6/H! 8.48!(J6,5!=!8.3)!! 2,!4! 5!
7! 136.52! ! ! ! !
8! ! ! ! ! !
9! 149.94! 9/H! 9.52! 1,!2w,!7,!10,!11,!14w! !
10! 118.41! ! ! ! !
11! 133.63! ! ! ! !
12! 146.74! ! ! ! !
13! 106.91! 13/H! 6.97! 1,!2w,!11,!12,!14! !
14! 150.40! ! ! ! !






























No.) δc) Proton) δH)(JHH[Hz])) HMBCa) ROESY)
1! 112.56! ! ! ! !
2! 138.34! ! ! ! !
3! ! 3/NH! 9.22!(J3,4!=!3.8)! 1,2,4,6,8! 4!
4! 49.12! 4/H! 4.49!(J4,3!=!3.8,!J4,6a!=!6.3)!
(J4,6b!=!12.2)!
2,5,6,7,8! 3,!6a,!6b,!7!
5! 172.07! ! ! ! !






7! 65.09! 7/H! 4.69!(J7,6a!=!3.6,!J7,6b!=!9.0)! ! 4,!6a,!6b,!
7OH!
7!! ! 7/OH! 5.61!(J7OH,7!=!4.2)! 2,4,8! 7!
8! 153.51! ! ! ! !
9! ! ! ! ! !
10! 132.52! 10/H! 8.31! 1,2w,8,11,12,13,15! !
11! 123.43! ! ! ! !
12! 179.63! ! ! ! !
13! 159.07! ! ! ! !
14! 111.20! 14/H! 6.32! 1,2,12,13,15! 17!
15! 187.38! ! ! ! !
16! 51.58! 16/H3! 3.63! 5! 4!




















No.) δc) Proton) δH)(JHH[Hz])) HMBC)
1! ! ! ! !
2! 129.62! 2/H! 7.03!(J2,3!=!8.5)! 1,!3,!4,!7!
3! 130.63! 3/H! 6.70!(J3,2!=!8.5)! 1,!4,!5!
4! 155.91! ! ! !
5! 130.63! 5/H! 6.70!(J5,6!=!8.5)! 1,!4,!5!
6! 129.62! 6/H! 7.03!(J6,5!=!8.5)! 1,!3,!4,!7!
7! 33.04! 7/H2! 3.83! 2,!3,!5,!6,!8,!9!
8! 138.30! ! ! !
9! 108.30! 9/H! 5.80!(J9,10!=!3.5)! 7,!8,!10,!11,!13!
10! 116.12! 10/H! 6.62!(J10,9!=!3.5)! 8,!9,!11,!13!
11! 122.63! ! ! !
12! ! 12/NH! ! !





Chemical! shifts! were! referenced! to! δ(HOD)! =! 2.79! ppm! and! δ(13CH3OD)! =! 49.0! ppm.13C!
chemical! shifts! were! determined! via! an! HMBC! and! HSQC! spectrum.! 1H,! 1H/J/coupling!














No.) δc) Proton) δH)(JHH[Hz])) HMBC)
1! 127.21! ! ! !
2! 117.10! 2/H! 6.84!(J2,6!=!1.8)! 4,!6,!7!
3! 144.36! ! ! !
4! 143.63! ! ! !
5! 116.49! 5/H! 6.92!(J5,6!=!8.0)! 1,!3!
6! 121.86! 6/H! 6.76!(J6,5!=!8.0,!J6,2!=!1.8)! 2,!4,!5,!7!
7! 35.06! 7/H2! 3.14!(J7,8!=!6.0)! 1,!2,!6,!8,!9!
8! 64.71! 8/H! 3.82!(J8,7!=!6.0)! 1,!7,!9,!10!
9! 173.12! ! ! !





Chemical! shifts! were! referenced! to! δ(HOD)! =! 2.79! ppm! and! δ(13CH3OD)! =! 49.0! ppm.13C!
chemical! shifts! were! determined! via! an! HMBC! and! HSQC! spectrum.! 1H,! 1H/J/coupling!












No.) δc) Proton) δH)(JHH[Hz])) HMBC)
1! 124.11! ! ! !
2! 28.50! 2/Ha! 3.08!(J2a,2b!=!16.0,!J2a,3!=!11.5)! 1,!3,!6,!10,!11!
! ! 2/Hb! 3.32!(J2b,2a!=!16.0,!J2b,3!=!5.0)! 1,!3,!6,!10,!11!
3! 56.25! 3/H! 3.98!(J3,2a!=!11.5,!J3,2b!=!5.0)! 1,!2,!5,!11!
4! ! 4/NH! ! !
5! 40.60! 5/Ha! 4.25!(J5a,5b!=!16.0)! 1,!3,!6,!7!
! ! 5/Hb! 4.54!(J5b,5a!=!16.0)! 1,!3,!6,!7!
6! 116.69! ! ! !
7! 140.97! ! ! !
8! 142.61! ! ! !
9! 116.49! 9/H! 6.93!(J9,10!=!8.4)! 1,!7!
10! 121.86! 10/H! 6.80!(J10,9!=!8.4)! 2,!6,!8!





Chemical! shifts! were! referenced! to! δ(CHD2SOCD3)! =! 2.50! ppm! and! δ(13CHD2SOCD3)! =!


















No.) δc) Proton) δH)(JHH[Hz])) HMBCa) NOESY)
1! 140.40! ! ! ! !
2! 117.23! 2/H! 8.05!(J2,3!=!5.2)! 3,!6,!7,!10! !
3! 154.59! 3/H! 9.02!(J3,2!=!5.2)! 1,!2,!5! !
4! ! ! ! ! !
5! 148.00! 5/H! 9.08!(J5,2!=!2.3)! 1,!3,!6,!7! !
6! 125.13! ! ! ! !
7! 181.43! ! ! ! !
8! 175.31! ! ! ! !
9! 102.40! 9/H! 6.45! 1,!7,!8,!10w! 13!
10! 149.45! ! ! ! !
11! ! 11/NH! ! ! !
12! 142.36! ! ! ! !
13! 120.03! 13/H! 7.48!(J13,14!=!8.5)! 15,!17! 9!
14! 130.23! 14/H! 7.45!(J14,13!=!8.5,!J14,15!=!7.5)! 12,!16! !
15! 122.68! 15/H! 7.11!(J15,14!=!7.5,!J15,16!=!7.5)! 13,!17! !
16! 131.10! 16/H! 8.01!(J16,15!=!7.5)! 12,!14,!18! !
17! 126.86! ! ! ! !





































































































































































































































































































































































































































































































































































































































6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in 1mM Phosphate buffer at pH 7, 1H NMR spectrum 













































































coli,strain(DH5α(was(propagated( in( LB(medium(with( appropriate( antibiotics( for(
plasmid(DNA.(
Gene! cloning,! plasmid! construction,! and! genetic! manipulations.! The(





ku70( gene, was( amplified( from( genomic( DNA( of( A.( flavus( NRRL3357( using,
designated( primers,( respectively.( These( three( amplified( PCR( products( were(
purified(with(a(QIAquick(gel(extraction(kit((Qiagen,(Valencia,(CA),(quantified,(and(
fused(using(standard(double( joint(PCR(procedures.(The( final(PCR(product(was(
amplified( with( the( bottom( primer( pairs,( Fku70IF( and( Fku70IR,( confirmed( with(
endonuclease( digestion,( and( purified( for( fungal( transformation.( The( first( two(
rounds(of(PCR(were(done(with(Pfu(Ultra(II(DNA(Polymerases((Agilent,(Santa(Clara,(
CA),( and( the( final(PCR(step(used(Expand( long( template(PCR(system( (Roche,(









with(a(QIAquick(gel( extraction( kit.( These( fragments(were( fused(using( standard(
singleQjoint( reaction( procedures( and( amplified( with( the( bottom( primer( pairs(
AFLA_pyrGrecyc_5’F( and( AFLA_pyrGrecyc_3’R,( confirmed( with( endonuclease(
digestion(prior( to( transformation.(Five(µg(of( the(doubleQjoint(PCR(cassette(was(







joint( PCR( procedures4.( Briefly,( A.( parasiticus, pyrG, (A.ppyrG)( and( A., nidulans,
(p)gpdA( was( amplified( from( pJMP9.1( Then,( an( approximately( 1( kb( fragment(
upstream(and(downstream(of(the(imqA(gene,was(amplified(from(genomic(DNA(of(
A.( flavus( NRRL3357( using, designated( primers.( These( three( amplified( PCR(
products(were(purified(with(a(QIAquick(gel(extraction(kit((Qiagen,(Valencia,(CA),(
quantified,(and(fused(using(standard(double(joint(PCR(procedures.(The(final(PCR(
product( was( amplified( with( the( bottom( primer( pairs,(AFLA_OE064330_5'F( and(
 247 






with(A.,parasiticus(pyrG( (A.ppyrG)( for( replacement(of( imqA.(The(A.ppyrG(gene(
was(amplified(from(the(plasmid(pJMP9.1(as(template.(Five(µg(of(the(doubleQjoint(
PCR(cassette(was(used(to(delete(imqA(by(again(using,TJES19.1(as(the(recipient(











250( rpm(at( 25( °C.(After( 48( h,( the(mycelium(was( collected( and( total(RNA(was(













Analytical! methods! and! equipment! overview.! (a)( NMR( spectroscopy:( NMR(






per( increment.( 1H,( 13CQHMBC( spectra( were( optimized( for( JH,C( =( 6( Hz.( HSQC(
spectra(were(acquired(with(or(without(decoupling.(NMR(spectra(were(processed(
and(baseline(corrected(using(MestreLabs(MNOVA(software(packages.((b)(Mass(




or( electrospray( negative( (ESIQ)( ionization( mode.( LowQresolution( LCQMS( was(
performed(on(an(Agilent(1100(series(HPLC(system(equipped(with(a(diode(array(
detector(and(connected( to(a(Quattro( II(mass(spectrometer( (Micromass/Waters)(
operated(in(ESI+(or(ESIQ(mode.(Data(acquisition(and(processing(for(the(LCQHRMS(
was( controlled( by( Thermo( Scientific( Xcalibur( software.( Data( acquisition( and(



































1( 565.1942( [MQH]Q( C28H29N4O9Q( 565.1940( 5.79(
2( 581.1889( [MQH]Q( C28H29N4O10Q( 581.1889( 5.25(
3( 569.2253( [MQH]Q( C28H33N4O9Q( 569.2253( 4.97(
4( 553.2304( [MQH]Q( C28H33N4O8Q( 553.2304( 5.22(
6( 553.2048( [MQH]Q( C28H31N4O10Q( 553.2046( 4.48(














































































































































































































































































No.! δc! Proton! δH(JHH[Hz])! HMBC! NOESY!
1( 134.65( ( ( ( (
2( 23.62( 2QHa( 2.67(J2a,2b(=(17.9)((J2a,3(=(1.5)((J2a,8(=(5.2)( 1,3,9,13,23( (
2QHb( 1.54(J2b,2a(=(17.9)((J2b,3(=(7.5)((J2b,8(=(5.1)( 1,3,9,10w,23( 8(
3( 50.64( 3QH( 4.90(J3,2a(=(1.5)((J3,2b(=(7.5)( 1,2,5,8,23( (
4( ( ( ( ( (
5( 176.44( ( ( ( (
6( 61.21( 6QH( 4.20(J6,14a(=(6.0)((J6,14b(=(4.1)((J6,8(=(5.2)( 5,8,14,15( 8(
7( ( 7QNH( ( ( (
8( 66.84( 8QH( 5.53(J8,2a(=(5.2)((J8,2b(=(5.1)((J8,6(=(5.2)( 1( 2b,6(
9( 138.24( ( ( ( (
10( 183.50( ( ( ( (
11( 139.23( ( ( ( (
12( 145.92( ( ( ( (
13( 184.22( ( ( ( (
14( 30.01( 14QHa( 3.05(J14a,14b(=(13.8)((J14a,6(=(6.0)( 5,6,15,16( 19,21(
14QHb( 3.12(J14b,14a(=(13.8)((J14b,6(=(4.1)( 5,6,15,16(




16( 125.27( 16QH( 6.93( 14,15,18,23( 14a/b(
17( ( 17QNH( ( ( (
18( 137.66( ( ( ( (
19( 112.41( 19QH( 7.12(J19,20(=(7.6)( 21,23( (
20( 122.37( 20QH( 6.99(J20,19(=(7.6)((J20,21(=(5.8)( 18,22( (
21( 119.99( 21QH( 6.89(J21,20(=(5.8)((J21,22(=(7.8)( 19,23( (
22( 120.53( 22QH( 7.50(J22,21(=(7.8)( 18,20( 14a/b(
23( 129.47( ( ( ( (
24( 171.24( ( ( ( (
25( ( 25QNH( ( ( (
26( 52.23( 26QH( 4.28(J26,27a(=(5.2)((J26,27b(=(10.5)( 24,27,28,31( 27a/b,28,29,
30(
27( 35.89( 27QHa( 1.57(J27a,27b(=(17.3)((J27a,26(=(5.2)((J27a,28(=(10.5)( 26,28,29,30( 26,28,29,30(
27QHb( 1.77(J27b,27a(=(17.3)((J27b,26(=(5.2)((J27b,28(=(10.5)( 26,28,29,30,31(
28( 33.87( 28QH( 1.57(J28,29(=(6.1)((J28,30(=(6.7)( 27,29,30( 26,27a/b,29,
30(
29( 68.18( 29QH2( 3.31(J29,28(=(6.1)(( 27,28,30( 26,27a/b,28,
30(
30( 16.02( 30QH3( 0.84(J30,28(=(6.7)( 27,28,29( 26,27a/b,28,(
29(
31( 175.92( ( ( ( (






1HQJQcoupling( constants( were( determined( from( the( acquired( 1H( or( dqfCOSY( spectra.(
HMBC(correlations(are(from(the(proton(s)(stated(to(the(indicated(13C(atom. 
 
No.! δc! Proton! δH(JHH[Hz])! HMBC!
1( 134.20( ( ( (
2( 23.08( 2QHa( 2.70((J2a,2b(=(17.9)(( 1,3,9,13,23(
2QHb( 1.56((J2b,2a(=(17.9)((J2b,3(=(7.6)(( 1,3,9,10w,23(
3( 50.41( 3QH( 4.91((J3,2b(=(7.6)( 1,2,5,8,23(
4( ( ( ( (
5( 175.98( ( ( (
6( 60.86( 6QH( 4.22((J6,14a(=(4.4)((J6,14b(=(4.4)(( 5,8,14,15(
7( ( 7QNH( ( (
8( 66.43( 8QH( 5.54(( 1(
9( 138.02( ( ( (
10( 184.24( ( ( (
11( 147.69( ( ( (
12( 147.14*( ( ( (
13( 182.83( ( ( (
14( 29.67( 14QHa( 3.08((J14a,14b(=(14.7)((J14a,6(=(4.4)( 5,6,15,16(
14QHb( 3.13((J14b,14a(=(14.7)((J14b,6(=(4.4)( 5,6,15,16(






































16( 124.94( 16QH( 6.94( 14,15,18,23(
17( ( 17QNH( ( (
18( 137.34( ( ( (
19( 112.09( 19QH( 7.14((J19,20(=(8.2)( 21,23(
20( 122.10( 20QH( 7.03((J20,19(=(8.2)((J20,21(=(5.8)( 18,22(
21( 119.71( 21QH( 6.91((J21,20(=(7.5)((J21,22(=(7.5)( 19,23(
22( 120.20( 22QH( 7.51((J22,21(=(7.5)( 15,18,20(
23( 134.20( ( ( (
24( 170.43( ( ( (
25( ( 25QNH( ( (
26( 52.92( 26QH( 4.29((J26,27a(=(4.5)((J26,27b(=(9.7)( 24,27,28,31(
27( 31.40( 27QHa( 1.67((J27a,27b(=(16.5)((J27a,26(=(4.5)((J27a,28(=(9.7)( 26,28,29,30(
27QHb( 1.82((J27b,27a(=(16.5)((J27b,26(=(4.5)((J27b,28(=(9.7)( 26,28,29,30,31(
28( 41.12( 28QH( 1.58(( 26,27,29,30(
29( 63.76( 29QHa( 3.51( 27,28,30(
29QHb( 3.55( 27,28,30(
30( 62.32( 30QHa( 3.51( 27,28,29(
30QHb( 3.55( 27,28,29(
31( 176.35( ( ( (






1HQJQcoupling( constants( were( determined( from( the( acquired( 1H( or( dqfCOSY( spectra.(
HMBC(correlations(are(from(the(proton(s)(stated(to(the(indicated(13C(atom. 
 
No.! δc! Proton! δH(JHH[Hz])! HMBC!
1( 116.22( ( ( (
2( 24.65( 2QHa( 3.04(( 1,3,9,12,13,23(
2QHb( 3.14(( 1,3,9,12,13,23(
3( 53.06( 3QH( 4.64( 1,2,5,8,23(
4( ( ( ( (
5( 175.81( ( ( (
6( 60.72( 6QH( 4.24( 5,8,14,15(
7( ( 7QNH( ( (
8( 68.95( 8QH( 5.84( 1,5,6,9,10(
9( 112.45( ( ( (
10( 142.19( ( ( (
11( 138.96( ( ( (
12( 140.23( ( ( (
13( 136.39( ( ( (
14( 28.73( 14QHa( 2.81( 5(
14QHb( 3.30( 5(





































16( 124.30( 16QH( 7.19( 14,15,18,23(
17( ( 17QNH( ( (
18( 137.87( ( ( (
19( 111.84( 19QH( 7.34(( 21,23(
20( 122.09( 20QH( 7.10(( 18,22(
21( 119.37( 21QH( 7.01(( 19,23(
22( 118.90( 22QH( 7.58(( 15,18,20(
23( 128.07( ( ( (
24( 171.72( ( ( (
25( ( 25QNH( ( (
26( 52.88( 26QH( 4.44(( 24,27,28,31(
27( 31.48( 27QHa( 1.71(( 26,28,29,30(
27QHb( 1.84(( 26,28,29,30,31(
28( 40.92( 28QH( 1.61( 26,27,29,30(
29( 62.32( 29QHa( 3.53( 27,28,30(
29QHb( 3.60( 27,28,30(
30( 63.73( 30QHa( 3.53( 27,28,29(
30QHb( 3.60( 27,28,29(
31( 176.54( ( ( (







1HQJQcoupling( constants( were( determined( from( the( acquired( 1H( or( dqfCOSY( spectra.(
HMBC(correlations(are(from(the(proton(s)(stated(to(the(indicated(13C(atom. 
 
No.! δc! Proton! δH(JHH[Hz])! HMBC!
1( 115.87( ( ( (
2( 25.63( 2QHa( 3.22((J2a,2b(=(16.7)((J2a,3(=(8.0)( 1,3,8w,9,10,12,13,24(
2QHb( 3.67((J2b,2a(=(16.7)((J2b,3(=(3.0)(( 1,3,8w,9,10,12,13,24(
3( 51.83( 3QH( 4.98((J3,2a(=(8.0)((J3,2b(=(3.0)( 1,2,5,8,24(
4( ( ( ( (
5( 169.54( ( ( (
6( 100.35( ( ( (
7( ( 7QN( ( (
8( 156.07( ( (( 1(
9( 100.38( ( ( (
10( 148.27( ( ( (
11( 135.15( ( ( (
12( 145.89( ( ( (
13( 137.26( ( ( (





































15( 112.68( ( ( (
16( 131.85( 16QH( 8.22((J16,14(=(1.0)( 15,18,23(
17( ( 17QNH( ( (
18( 137.20( ( ( (
19( 112.82( 19QH( 7.47((J19,20(=(7.9)(( 21,23(
20( 123.83( 20QH( 7.25((J20,19(=(7.9)((J20,21(=(6.2)( 18,22(
21( 122.04( 21QH( 7.23((J21,20(=(6.2)((J21,22(=(7.8)( 19,23(
22( 119.31( 22QH( 7.92((J22,21(=(7.8)( 15,18,20(
23( 128.48( ( ( (
24( 171.23( ( ( (
25( ( 25QNH( ( (
26( 52.25( 26QH( 4.43((J26,27a(=(10.0)((J26,27b(=(5.0)( 24,27,28,31(
27( 31.34( 27QHa( 1.73((J27a,27b(=(18.0)((J27a,26(=(10.0)(( 26,28,29,30,31(
27QHb( 1.92((J27b,27a(=(18.0)((J27b,26(=(5.0)(( 26,28,29,30,31(
28( 40.82( 28QH( 1.74( 26,27,29,30(
29( 62.22( 29QHa( 3.57( 27,28,30(
29QHb( 3.61( 27,28,30(
30( 63.68( 30QHa( 3.57( 27,28,29(
30QHb( 3.61( 27,28,29(
31( 175.71( ( ( (







1HQJQcoupling( constants( were( determined( from( the( acquired( 1H( or( dqfCOSY( spectra.(
HMBC(correlations(are(from(the(proton(s)(stated(to(the(indicated(13C(atom. 
 
No.! δc! Proton! δH(JHH[Hz])! HMBC!
1( 134.85( ( ( (
2( 26.31( 2QHa( 0.05((J2a,2b(=(18.5)((J2a,3(=(11.7)( 1,3,4,10,11,14(
2QHb( 2.28((J2b,2a(=(18.5)((J2b,3(=(5.0)(( 1,3,4,10,11,14(
3( 54.57( 3QH( 3.82((J3,2a(=(11.7)((J3,2b(=(5.0)( 1,2,4,7,9(
4( 168.39( ( ( (
5( ( 5QNH( ( (
6( 56.53( 6QH( 4.33((J6,16a(=(3.5)((J6,16b(=(3.5)((J6,3(=(1.0)( 4,7,15(
7( 166.43( ( ( (
8( ( ( (( (
9( 39.03( 9QHa( 3.31((J9a,9b(=(18.2)( 1,3,10,11,14(
9QHb( 5.03((J9b,9a(=(18.2)( 1,3,10,11,14(
10( 135.77( ( ( (
11( 182.57( ( ( (
12( 139.18( ( ( (
13( 137.21( ( ( (
14( 183.45( ( ( (
15( 60.43( 15QH3( 3.88( 12(
16( 31.85( 16QHa( 3.01((J16a,16b(=(14.7)((J16a,6(=(3.5)( 6,7,17,18,25(
16QHb( 3.57((J16b,16a(=(14.7)((J16b,6(=(3.5)( 6,7,17,18,25(
17( 108.74( ( ( (
18( 126.20( 18QH( 7.04( 16,17,20,25(




















20( 137.21( ( (( (
21( 112.62( 21QH( 7.04((J20,21(=(7.5)( 23,25(
22( 122.59( 22QH( 6.88((J22,21(=(7.5)((J22,23(=(7.5)( 20,24(
23( 119.53( 23QH( 6.71((J23,22(=(7.5)((J23,24(=(7.8)( 21,25(
24( 119.85( 24QH( 7.39((J24,23(=(7.8)( 17,20,22(














































































































































































































































































































































































































































































































































































































Figure' E1.' Northern( blot( analysis( of( WT( (Af293)( left,( !fsqA( middle,( and( OE::fsqA,& right.(

















































































Figure' E2.( LVLeucine( is( incorporated( into( the( fumizinones.( (a)( Feeding( experiments( with( LV
Leucine(or(LV[1V13C]VLeucine(result( in(a(distribution(of( isotopes( for(1.( (b)(LCVMS(extractedVionV
chromatograms( from( whole( metabolome( analysis( of( OE::fsqA( fed( with( unlabeled( control,( LV
Leucine.((c)(LCVMS(extractedVionVchromatograms(from(whole(metabolome(analysis(of(OE::fsqA(







Figure' E3.'Southern(analysis(confirmation(of(all(mutants(used( in( this(study.(Mutant( (number)(
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Gene' cloning,' plasmid' construction,' and' genetic' manipulations.' The( plasmids(
utilized( in( this( study( are( listed( in(Table' E2.( The( oligonucleotide( sequences( for( PCR(
primers( are( given( in( Table' E3.( PCR( amplification( was( carried( out( on( a( C1000TM(
Thermal( Cycler( (BioVRad).( For( creation( of( the( fsqA( overexpression( (OE)( strain(
(TJES1.18)(the(OE(cassette(was(constructed(by(amplifying(the(fsqA(open(reading(frame(
(ORF)( from( Af293( genomic( DNA( using( primers( Afu6g03430_NcoI_For( and(
Afu6g03430_NotI_Rev,( which( introduced( a( 5’( NcoI( restriction( site( and( a( 3’( NotI(
restriction( site.( This( PCR( product( was( purified( with( a( QIAquick( gel( extraction( kit(
(Qiagen),(quantified,(and(digested(with(the(appropriate(restriction(enzymes(before(being(
cloned(into(pJMP8.122,(resulting(in(plasmid(pJES(1.2.(Subsequently,(A.&fumigatus(argB&
was( transferred( from(pJMP4.13(by(digesting(with(EcoRI(and( introduced( into(pJES1.2,(
resulting( in( plasmid( pJES2.7( (A.& fumigatus& argB::gpdA(p)::fsqA).( All( PCR( steps(were(
carried(out(with(Pfu(Ultra(II(DNA(Polymerases((Agilent)(and(all(digestion(reactions(were(
carried( out( with( NEB( enzymes( (New( England( BioLabs).( Correctness( of( the( inserted(
DNA(was(then(confirmed(by(sequencing.&





respectively.( These( three( amplified( PCR( products( were( purified( with( a( QIAquick( gel(
extraction( kit,( quantified,( and( fused( using( standard( doubleVjoint(PCR(procedures.( The(
final( PCR( product( was( amplified( with( the( bottom( primer( pairs,( gene_5’F_flank( and(
_3’R_flank,( confirmed( with( endonuclease( digestion,( and( purified( for( fungal(
transformation.( The( first( two( rounds( of( PCR( were( done( with( Pfu( Ultra( II( DNA(
Polymerases((Agilent),(and(the(final(PCR(step(used(Expand(long(template(PCR(system(
(Roche)( according( to( the( manufacturer's( instructions.( Af293.6( (double( auxotroph( A.&
fumigatus,&pyrGB,&argBB)(was(used( to(make( the(OE::fsqA,&pyrGB(auxotroph,(TJES1.18.(
This(strain(was(used(as(the(recipient(host(strain(for(subsequent(deletions(of(fsq(genes(
as( well( as( the( ectopic( complementation( of( pyrG1( with( plasmid( pJMP9.1( (containing(
A.ppyrG)( resulting( in(prototrophic(strain(TJES3.1( (OE::fsqA,&A.ppyrG).(Similarly(∆fsqA&
auxotrophic& strains( (TJES2.20)( were( made( by( transforming( Af293.6( with( deletion(
cassettes( and( complemented( with( ectopically( integrated( pJMP4( to( make( ∆fsqA(
prototroph(TJES8.2.(




cassette( were( used( to( delete( each( fsq( cluster( gene( by( using& TJES1.18(
(A.fargB::gpdA(p)::& fsqA,& pyrG1)( as( the( recipient( host.( After( transformation,(
transformants(were(grown(on(minimal(media(plates(without(supplements(for(screening.(
All( strains( were( verified( by( PCR( and( Southern( blot( analysis( (Figure' E3).( Multiple(
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confirmed(strains( for(each(mutant(were(stored(at( V80( °C(with(33(%(glycerol( for( future(
use.(
Nucleic' acid' analysis.' Preparation( of( plasmids,( restriction( enzyme( digestions,( gel(
electrophoresis,( blotting,( probe( preparation( and( hybridization( were( carried( out( by(
standard( protocols.( Aspergillus( DNA( was( extracted( using( a( previously( described(
method7.(Sequence(data(were(analyzed(using(the(LASERGENE(software(package(from(
DNASTAR.(








hybridized( with( designated( DNA( fragments.( All( experiments( were( performed( in(
duplicate.( Detection( of( signals( was( carried( out( with( a( Storm( 860( phosphoimager(
(Molecular(Dynamics).(
Fermentation' and'metabolome' extraction' for' comparative'metabolomics'by'LCE
MS.( Preparation( for( LCVMS( analysis:( A.( fumigatus& strains( were( inoculated( (1.0"106(
spores(mLV1)(into(50(mL(GMM1(in(a(125(mL(Erlenmeyer(flask(at(37(°C(with(shaking(at(
220( rpm.( After( 4( days,( liquid( fungal( cultures( including( fungal( tissue( and(media( were(
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A.( fumigatus& strains( were( inoculated( (1.0"106( spores( mLV1)( into( 1( L( GMM1( in( a( 2( L(
Erlenmeyer(flask(at(37(°C(with(shaking(at(220(rpm.(After(3.5(days,(liquid(fungal(cultures(
including( fungal( tissue( and( media( were( frozen( using( a( dry( ice( acetone( bath,( and(
lyophilized.(The(lyophilized(residues(were(extracted(with(500(mL(of(MeOH(for(1(h(with(
vigorous(stirring.(Extracts(were(filtered(over(cotton(and(evaporated(on(CeliteV545((Acros(
Organics)( to( dryness.( The( dry( Celite( was( then( loaded( into( a( 25( gram( solid( phase(
cartridge( (Isco)( and( subjected( to( largeVscale( reverse( phase( chromatography( (see(
Chromatographic(enrichment(section(below(for(details).'
Analytical' methods' and' equipment' overview.' (a)( NMR( spectroscopy:( NMR(
spectroscopic(instrumentation:(a(Bruker(AvanceIII(HD((800(MHz(1H(reference(frequency,(
201(MHz( for( 13C)(equipped(with(a(5(mm(CPTCL( 1HV13C/15N(cryo(probe.(NonVgradient(
phaseVcycled( dqfCOSY( spectra( were( acquired( using( the( following( parameters:( 0.6( s(
acquisition( time,(400V600(complex( increments,(8,(16(or(32(scans(per( increment.(NonV
gradient(HSQC,(HMQC,(and(HMBC(spectra(were(acquired(with(these(parameters:(0.25(
s( acquisition( time,( 200V500( increments,( 8V64( scans( per( increment.( 1H,( 13CVHMBC(
spectra(were(optimized( for( JH,C(=(6(Hz.(HSQC(spectra(were(acquired(with(or(without(
decoupling.( NMR( spectra( were( processed( and( baseline( corrected( using( MestreLabs(
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MNOVA( software( packages.( (b)( Mass( spectrometry:( highVresolution( LCVMS( was(
performed(on(a(Thermo(ScientificVDionex(Ultimate3000(UHPLC(system(equipped(with(a(
diode(array(detector(and(connected(to(a(Thermo(Scientific(Q(Exactive(Orbitrap(operated(
in( electrospray( positive( (ESI+)( or( electrospray( negative( (ESIV)( ionization( mode.( Data(
acquisition( and( processing( for( the( LCVHRMS( was( controlled( by( Thermo( Scientific(
Xcalibur( software.( (c)(Chromatography:( flash( chromatography(was( performed(using( a(
Teledyne(ISCO(CombiFlash(system.(For(semiVpreparative(HPLC(Agilent(Zorbax(Eclipse(
XDBVC18( or( VC8( columns( (25( cm( x( 10( mm,( 5( μm( particle( diameter)( were( used.( An(
Agilent( Zorbax( RRHD( Eclipse( XDBVC18( column( (2.1( x( 100( mm,( 1.8( µm( particle(
diameter)(was(used(in(the(LCVHRMS(A.&fumigatus&mutant(profiling(analysis.((
Chromatographic'enrichment'of'compounds'1E2.'Methanol(extracts(derived(from(1V2(
L( of( A.& fumigatus( cultures( were( fractionated( using( largeVscale( reverseVphase( flash(
chromatography(on(a(Teledyne(ISCO(CombiFlash(with(a(Teledyne(C18(gold((100(gram)(
column(with(acetonitrile((organic(phase)(and(0.1(%(acetic(acid(in(water((aqueous(phase)(
as( solvents( at( a( flow( rate( of( 60( mL/min.( A( linear( ramp( from( 0(%( organic( to( 100(%(
organic( over( 30( min( was( used( and( fractions( containing( compounds( of( interest( were(
collected,( evaporated( to( dryness,( and( stored( in( 8(mL(glass( vials( at( V20( °C.(Fractions(






























1( 251.1049( [MVH]V( C12H15N2O4V( 251.1037( 4.36(







































































































































































































































































Chemical( shifts( were( referenced( to( δ(CHD2OD)( =( 3.31( ppm( and( δ(13CHD2OD3)( =(
49.00.13C(chemical(shifts(were(determined(via(HMBC,(HSQC(and(direct(observation(13C(
spectra.(1H,(1HVJVcoupling(constants(were(determined(from(the(acquired(1H(or(dqfCOSY(





No.' δc' Proton' δH(JHH[Hz])' HMBC' NOESY'
1( 156.46( ( ( ( (
2( ( ( ( ( (
3( 64.95( 3VH( 4.83((J3,4a(=(3.8)((J3,4b(=(8.5)( 1,4,5,6,14( 4(
4( 37.50( 4VHa( 2.22((J4a,4b(=(13.5)((J4a,3(=(3.8)((J4a,5(=(4.0)( 3,5,6,14( 3,5(
4VHb( 2.72((J4b,4a(=(13.5)((J4b,3(=(8.5)((J4b,5(=(7.9)( 3,5,6,14( 3,5(
5( 72.43( 5VH( 5.15((J5,4a(=(4.0)((J5,4b(=(7.9)((J5,7(=(1.0)( 3,7( 4,7(
6( 144.39( ( ( ( (
7( 119.55( 7VH( 7.46((J7,5(=(1.0)( 1w,5,6,9( 5(
8( ( ( ( ( (
9( 159.09( ( ( ( (
10( 42.37( 10VHa( 2.60((J10a,10b(=(13.8)((J10a,11(=(7.8)( 1,9,11,12,13( 11(
( 10VHb( 2.68((J10b,10a(=(13.8)((J10b,11(=(6.4)( 1,9,11,12,13( 11(
11( 27.77( 11VH( 2.20((J11,10a(=(7.8)((J11,10b(=(6.4)((J11,12/13(=(7.0)( 9,10,12,13( 10(
12( 22.67( 12VH3( 0.93((J12,11(=(7.0)( 10,11,13( (
13( 22.67( 13VH3( 0.93((J13,11(=(7.0)( 10,11,12( (

























No.' δc' Proton' δH(JHH[Hz])' HMBC'
1( 157.01( ( ( (
2( ( ( ( (
3( ( 3VH( 4.98(Broad)( (
4( 28.33( 4VHa( 2.34((J4a,4b(=(15.6)((J4a,3(=(13.0)((J4a,5b(=(6.7)( (
4VHb( 2.48((J4a,4b(=(15.6)((J4a,5(=(11.0)( (
5( 28.99( 5VHa( 3.08((J5a,5b(=(17.0)((J5a,4b(=(8.5)(( (
5VHb( 3.18((J5b,5a(=(17.0)((J5b,4a(=(6.7)((J5b,4b(=(11.0)( (
6( 143.76( ( ( (
7( 118.99( 7VH( 7.29(( 6,9(
8( ( ( ( (
9( 156.46( ( ( (
10( 42.23( 10VHa( 2.15((J10a,10b(=(14.0)((J10a,11(=(7.3)(( 9,11,12,13(
10VHb( 2.65((J10b,10a(=(14.0)((J10b,11(=(6.9)( 9,11,12,13(
11( 27.84( 11VH( 2.15((J11,10a(=(7.3)((J11,10b(=(6.9)((J11,12/13(=(6.5)( 10,12,13(
12( 22.66( 12VH3( 0.93((J12,11(=(6.5)( 10,11,13(
13( 22.73( 13VH3( 0.93((J13,11(=(6.5)( 10,11,12(
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